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Introduction 

1Introduction 11
1.1 BaCkgROunD
The discovery of the link between lung cancer, chronic obstructive pulmonary 
disease and tobacco: a brief history
While the 1964 Report of the US Surgeon General1 is often regarded as a turning 
point in the recognition that cigarette smoking causes several cancers and chronic 
obstructive pulmonary disease (COPD), the evidence took time to build and was much 
disputed along the way. Before the twentieth century, lung cancer was a rare disease2 
(around 1 death per 100 000).3 In 1900, an increase in lung cancer mortality was noted 
by vital statisticians.1 The possible association between lung cancer and tar — highly 
used in road construction and known to cause skin cancer in mice — was presented in 
1926 by De Vries, a Dutch pathologist, at the first World Congress on Cancer Control, 
in New York. He had observed increases in the proportion of lung cancer deaths in his 
autopsies, from 1% in 1901 to 10% in 1925.4 
Lung cancer was not yet a concern, and cigarettes were not suspected, probably 
because most men of higher socioeconomic status smoked, including doctors and 
scientists. In 1929, in Germany, and 2 years later in the Netherlands – based on 
autopsies — it was declared plausible that smoking caused lung cancer. The first 
case-control study was published in 1939 by Müller from the Cologne Hospital.5 He 
showed that lung cancer patients were far more likely to have smoked compared 
with cancer-free controls. Around that time, increases in lung cancer incidence and 
mortality became more conspicuous, with around 10 men out of 100 000 dying from 
lung cancer in the US (Figure 1).6 In this country, it corresponded to less than 3 000 
deaths per year, with women contributing very little.1 
This was only the dawn of massive cigarette smoking in the US, made possible by the 
invention of the cigarette rolling machine in the 1880s (Figure 2), pushed by advertis-
ing and what would become modern marketing.
Likewise, in England and Wales, there was a fifteenfold increase in the number of 
deaths from lung cancer between 1922 and 1947.3 This led Hill and Doll to conduct a 
study on 1,732 cancer patients and 743 controls on exposure to smoking, car and fuel 
fumes, and occupational exposure. They concluded that smoking was an important 
factor in the cause of carcinoma of the lung.3 In 1948, Wassink, a Dutch surgical 
oncologist, linked smoking and cancer based on smoking patterns of patients with 
lung cancer versus those with skin cancer.7 Notwithstanding those alarming news, 
smoking remained almost universal in industrialized countries, at least among men. 
In the Netherlands, 90% of men8 and 30% of women9 smoked in 1958. One year 
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earlier, at the urge of the US general Surgeon General, a study group on smoking and 
health, composed of members of the American Cancer Society, the American Heart 
Association, the National Cancer Institute, and the National Heart Institute, concluded, 
based on 16 studies from 5 countries that:10
- Lung cancer occurs five to fifteen times more frequently among smokers than 
nonsmokers;
- One of every ten men who smoked more than two packs of cigarettes a day died 
of lung cancer;
- Smoking cessation reduces the risk of lung cancer occurrence.
At that point, the tobacco industry was already toiling to create and maintain doubt 
over the causal relationship between cigarette smoking and lung cancer.10 In 1959, the 
Cancer Prevention Study I (CPS I) recruited one million people in the US to examine 
the association of tobacco use with cancer and other causes of death.11 By virtue of 
its large sample size, CPS I offered solid quantification of some mortality risks — 
including lung cancer and COPD — in relation to smoking.11 In the meantime, the 
extraordinary rise in lung cancer deaths remained unabated: 18 000 deaths in 1950, 
27 000 deaths in 1955, reaching 41 000 deaths in 1962, in the US.1 Similarly, rapid 
increases in deaths from chronic bronchitis and emphysema were observed in the 
US: from 2 300 in 1945 to 15 000 in 1962.1 The Surgeon General’s report,1 released 
in 1964, was the decisive milestone in the ever growing evidence that smoking was 
causally related to several diseases, including lung cancer and chronic bronchitis (a 
term then used for the disease now generally referred to as COPD). That year, 68% of 
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Figure 2 | Trends in cigarette consumption and male lung cancer rates, 1920–2005. The number of cigarettes 
consumed per adult (males are used as the appropriate denominator for cigarette smoking as few females currently 
smoke in Asia) and the age-standardized lung cancer rates over time by country. The widespread automation of cigarette 
production in the early twentieth century turned cigarettes into a global commodity94. Lung cancer was a rare disease 
before the Second World War, and the large increase in lung cancer rates lagged behind consumption by three or more 
decades. The mean consumptions in Chinese men were 1, 4 and 10 cigarettes per day in 1952, 1972 and 1992, respectively, 
which were similar to the increases in cigarette consumption that were reported 40 years earlier in the United States 
(US)34,49. Chin  has reported a marked increase in cigarette production since 2000. Increases in exposure to smoking at
very young ages, combined with prolonged exposure, would be likely to increase the age-specific death rates in the future 
in China, Indonesia and other countries.
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Figure 1. Trends in cigarette consumption and male lung cancer rates, 1920–2005.
Source:6 
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the male and 32% of the female US population was smoking cigarettes, adding up to 
nearly 70 million people.1
Since then, the list of diseases linked to smoking – although continuously contested12 
– has expanded to include nearly all organs (Figure 3). In the latest report released in 
2014,13 fifty years after the first Surgeon General’s report, 12 cancers were confirmed 
to be linked to cigarette smoking: oropharynx, larynx, esophageal, lung, stomach, 
liver, pancreas, kidney and ureter, cervix uteri, urinary bladder and acute myeloid 
leukemia. In 2004, the International Agency for Research on Cancer (IARC) had estab-
lished a few more smoking-related cancers:14 oral cavity, nasopharynx, hypopharynx, 
nasal cavity, paranasal sinuses and ovary. 
Figure 2. Cigarette rolling machine. Circa 1880. Louisiana State University Rural life 
museum. Baton Rouge, Louisiana, USA.
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Water-pipes, a common way of smoking tobacco in North Africa and Southwest Asia, 
and increasingly popular in the US, expose to the same toxicants and carcinogens as 
cigarette — plus high levels of carbon monoxide and polycyclic aromatic hydrocarbons 
from the burning charcoal.15 Cigars and pipes cause cancer as well.16 Secondhand 
tobacco smoke induces lung cancer14 and other smoking-related diseases commonly 
diagnosed among smokers. In total, 15% of lung cancer cases among individuals who 
have never smoked in the UK in 2010 were due to exposure to secondhand smoke.17 
Finally, smokeless tobacco causes cancer of the oral cavity, esophagus, and pancreas.14 
However, the chapter on the list of diseases triggered by tobacco, whether smoked 
or smokeless, might not be closed yet. Indeed, new evidence shows that even more 
cancers18 and more diseases19 could be caused by cigarette smoking. Also, the mecha-
nistic link between lung cancer and COPD is being further investigated.20 
In the next chapters, the burden of smoking-related cancers and COPD at the turn of 
the twenty-first century, and their relationship with smoking will be examined. Given 
the gender differences in smoking prevalence, both burdens will be studied by sex. 
Surgeon General’s Report
4 Chapter 1
Figure 1.1A The health consequences causally linked to smoking
Source: USDHHS 2004, 2006, 2012.
Note: Each condition presented in bold text and followed by an asterisk (*) is a new disease that has been causally linked to smoking 
in this report.
Organization of the Report
This report is divided into three sections. Sectio  1 
“Historical perspective, overview, and conclusions” pro-
vides an overall summary of the report and its conclu-
sions. It also provides a summary of the history of this 
series of reports, moving from their origins in 1964 to the 
present, contrasting what we knew in 1964 with what we 
know now in 2014. Section 2 “The Health Consequences 
of Active and Passive Smoking: The Evidence in 2014” 
provides a direct link to the 1964 report, which addressed 
the health effects of active smoking only. The first chapter 
in this section gives a 50-year perspective on the identi-
fication of the health consequences of active smoking 
and exposure to secondhand smoke. The other chapters 
in this section provide updates on critical topics and on 
topics for which the evidence has advanced, since the 
previous reviews in the 2004 and 2006 Surgeon General’s 
reports, The Health Consequences of Smoking: A Report 
of the Surgeon General and The Health Consequences of 
Involuntary Exposure to Tobacco Smoke: A Report of the 
Surgeon General, including a brief review of the state of 
Figure 3. The health consequences causally linked to tobacco smoking. 
Sources: USDHHS 4, 2006, 2012, in 2014 Surgeon General’s report.13 Note: conditions in bold and followed by an 
asterisk are new diseas s that have been added as causally linked to smoking in t e 2014 report.
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The burden of smoking-related cancers
Between 2000 –2007, tobacco use has been associated with 5 –6 million deaths per 
year worldwide, around 15% of which are cancer deaths.6 
Lung cancer represents the main smoking-related diagnosed cancer and has been the 
most commonly diagnosed cancer worldwide for several decades.21 Seventy-one per-
cent of lung cancer deaths worldwide are attributable to smoking22 (75% in the US).23 
Because of the strong causal relation between smoking and lung cancer, its disease 
patterns and trends are more influenced by changes in smoking prevalence than those 
of other smoking-related cancers. Other risk factors of lung cancer (Table 1) include 
outdoor and indoor air pollution, radon, and occupational exposure. They play a more 
important role in lung cancer occurrence in populations with low smoking prevalence. 
Globally, about a quarter of lung cancer cases occurs in people who have never smoked 
(only 10-15% in Europe and the US).24 In Eastern Asia, lung cancer is common in 
non-smoking women, likely as a result of exposure to indoor air pollution, genetic 
susceptibility of some Asian populations, and cooking oil heating (oil heated to high 
temperatures in woks for stir-frying food emits volatile carcinogens) in some regions.25 
Worldwide, there were an estimated 1.8 million new lung cancer cases (13% of all 
cancer diagnoses) and 1.6 million deaths (19% of all cancer deaths) in 2012.21 The an-
nual number of deaths is close to the number of new cases due to the poor prognosis 
of patients with lung cancer, even in high income countries (5-year relative survival of 
19% in 2005–2009 in the US and 15% in the Netherlands).28 
Lung cancer incidence and mortality rates vary 80–fold from one country to another.21 
Incidence and mortality rates are higher in men than in women, reflecting historical 
differences in smoking behavior. The global maps presented in Figure 4a show the 
lung cancer mortality in each sex. On the one hand, in men (Figure 4A), the highest 
lung cancer incidence rates are in Europe, Eastern Asia, and Northern America. Among 
women, the highest lung cancer rates are in Northern America, Northern and Western 
Europe, Australia/New Zealand, and Eastern Asia (Figure 4)Figure 4B. These are the 
regions where smoking prevalence has been the highest or still is.29 On the other hand, 
rates are low in Africa, parts of Asia and Latin America. 
Table 1. Risk factors of lung cancer
Tobacco smoking, including secondhand smoke
Radon
Occupational exposure to polycyclic aromatic hydrocarbons, certain metals, asbestos, crystalline silica, and wood 
dust
Outdoor air pollution, specifically to particulate matter and diesel engine exhaust
Indoor air pollution, including emissions from household combustion of coal, and cooking oil heating
Genetic factors
COPD
Sources25-27
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If the distribution of the lung cancer mortality depicted on the worldwide maps 
shadows the differences in prevalence of lung cancer risk factors (mainly smoking) 
within countries, lung cancer incidence and mortality rates also vary at sub-national 
level. For instance, lung cancer rates are higher in the Netherlands in regions where 
tobacco-transformation industries are established30 and in the US in states31 where 
tobacco is grown.
Women started to massively smoke cigarettes later than men, after new cigarettes 
(filtered, ‘light’ and ‘low tar’) had been made available on the market. Those new 
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Figure 4a. Estimated age-standardized (world) lung cancer mortality rate in men in 
2012. 
Source: http://globocan.iarc.fr/
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Figure 4b. Estimated age-standardized (world) lung cancer mortality rate in women in 
2012. 
Source: http://globocan.iarc.fr/
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cigarettes, marketed as ‘safer’, generated as many lung cancer cases, but different 
types of lung cancer (more on this in chapter 2.2). In the US, cigarette smoking 
peaked during World War II among men born the 1920s, and approximately ten years 
later among women born in the 1930s.
According to the Surgeon General, smoking causes 11 types of cancer besides lung 
cancer.13 The risk of lung cancer diagnosis among current or former smokers is gener-
ally higher than for other tobacco-related cancers.32 The risks of cancer diagnosis in 
former and current cigarette smokers as compared to never smokers in smoking-
related disease is similar to the risk of cancer.32 For instance, the risk of dying from 
liver cancer for current and former smokers compared with never smokers (around 
2 and 1.3, respectively) is similar to the risk of dying from stroke. The risk of cancer 
diagnosis and cancer death are lower in former than current smokers. For example, 
current male smokers have 25 times more chances die from lung cancer than never 
smokers, and former male smokers have 7 times more chances die from lung cancer 
than never smokers (Table 2).
Table 2. Mortality risk estimates in former and current cigarette smokers as compared 
to never smokers, for smoking-related cancers and chronic diseases
Men Women
Former Current Former Current
Cancer
Lung 6.8 25.3 6.8 22.9
Laryngeal 2.4 13.9 11.6 103.8
Oral cavity and Pharyngeal 1.7 5.7 2.2 5.6
Esophageal 2.6 3.9 2.2 5.1
Bladder 2.4 3.9 2.3 3.9
Liver 1.5 2.3 1.1 1.8
Stomach 1.5 1.9 1.1 1.7
Acute myeloid leukemia 1.4 1.9 1.1 1.1
Kidney, Renal pelvis, Ureter 1.5 1.8 1.2 1.2
Pancreatic 1.0 1.6 1.2 1.9
Colorectal 1.2 1.4 1.2 1.6
Cervical - - 1.1 1.6
Other non-communicable diseases
COPD 7.5 27.8 9.2 25.0
Ischemic heart disease 1.5 2.6 1.6 3.0
Stroke 1.2 1.9 1.2 2.1
Sources: 13, 19,33
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The population attributable fraction (PAF) of tobacco smoking in cancer was computed 
by Parkin for the UK (Table 3).17 For example, 71% of esophageal cancer cases in 
women were explained by smoking.
The PAF in a population varies according to the prevalence of the exposure to the risk 
factor in that population (see Figure 9). Hence the listed estimates are only valid in 
populations with similar historical smoking patterns. Eventually, 19% of all new cancer 
cases were attributable to smoking in the UK in 2010,17 13% in Australia the same 
year,34 12% in Korea in 2009.35 Smoking caused 23% of all cancer deaths in Korea in 
2009,35 31% in France in 2010,36 29% in the US in 2011,23 and 31% in Indonesia in 
2013.37 
Although progress in early detection and implementation of screening in high risk 
groups are under way,38,39 as well as better staging and new therapies,40,41 lung cancer 
still has a high fatality rate.28 Further, improvement in survival over the last four 
decades has been only marginal (the 5-year relative survival increased from 12% 
in 1989–1991 to 15% in 2007–2009 in Dutch men42 and from 12% in 1975–1977 to 
18% in 2005–2011 in the US).43 Survival rates for some of the other smoking-related 
cancer are also very low: <10% for pancreatic cancer,44 <20% for liver28 and esopha-
geal cancers.44 Survival rates are intermediate in stomach (20–30%),28 in colon and 
Table 3. Proportion of cancer cases attributable to smoking in 2010 in the UK and cancer 
deaths attributable to smoking in 2011 in the US
Incidence (UK)a17 Mortality (US)23
Men (%) Women (%) Men (%) Women (%)
Lung 85 80 83 76
Laryngeal 79 79 72 93
Oral cavity and Pharyngeal 70 55 49 43
Esophageal 63 71 52 44
Bladder 38 34 47 41
Liver 27 15 28 14
Stomach 26 15 26 11
Acute myeloid leukemia 19 6 23 3
Kidney, Renal pelvis, Ureter 29 15 22 7
Pancreatic 26 31 10 14
Colorectal 7 10 11 8
Cervical - 7 - 22
Ovarian - 3
All cancers 23 16 34 24
a includes secondhand smoke
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rectum (>40%),28 oral cavity and laryngeal cancers (each around 60%),44 and high in 
for bladder cancer (around 75%).44
Primary prevention targeted at curbing smoking remains the best method to combat 
major cancers including lung, esophageal, oral cavity and pharyngeal, laryngeal, and 
bladder cancer, and also other smoking-related cancer. Smoking is a leading cause of 
cancer worldwide and the largest preventable cause of cancer in the European Union.45 
In practice, Stoeldraijer et al. recommend to make tobacco dependence treatment a 
standard of clinical care.46 Moreover, people often combine the tobacco smoking with 
other poor – modifiable – lifestyle choices such as alcohol abuse,47 unhealthy diet, and 
lack of physical activity, all of which make them more prone to cancer. 
The burden of chronic obstructive pulmonary disease
The definition of COPD has been changing over time since the first classification of 
obstructive airway diseases in 1959. Today, COPD is composed as a diverse syndrome 
with no single disease entity. It encompasses emphysema and the obstructive form of 
chronic bronchitis.48
The list of risk factors for COPD is very long, but the key cause of COPD is tobacco 
smoking (including passive exposure in-utero and during childhood) (Table 4).49 
Smokers are 25 times more likely to die from COPD than never smokers (Table 2).19 
Table 4. Risk factors of COPD that have a role during different stages of life
Stage of life Risk factor
Host factors • Family history of chronic obstructive pulmonary disease
• Family history of asthma/atopy
• Genetic constitution
• Bronchial hyper-responsiveness
• Atopy
• Low lung function
Perinatal factors • Maternal smoking
• Maternal exposure to air pollution
• Antibiotic use
• Mode of delivery
• Preterm birth
Childhood exposures • Respiratory tract infections
• Maternal smoking
• Indoor and outdoor air pollution
• Obesity/nutritional development
• Childhood asthma
• Airway failure to thrive
Adult exposures • Occupational exposures
• Indoor biomass exposure
• Cigarette smoking
• Outdoor air pollution
• Indoor air pollution
Source: Postma et al.49
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About 40–50% of lifelong smokers will develop COPD, compared with only 10% of 
never smokers.50 
The condition becomes clinically apparent around the age of 40–50 years, and in 
many instances, at least in High-income countries, COPD patients will die from an-
other cause.51 COPD is commonly under-diagnosed not only in its early stages, but 
also when lung function is severely impaired, and hence is generally under-treated.52 
As COPD takes years to develop, prevalence is preferred to incidence to measure 
the burden of the condition. Prevalence of COPD is estimated to be around 10% in 
adults aged 40+,53 with large differences between populations ranging from 13% in 
Guangzhou, China and Hannover, Germany to 14% in Manila, Philippines, 24% in Cape 
Town, South Africa,54 and 24% in Maastricht, Netherlands,55 and increases with age.52 
Despite being underestimated (73% undiagnosed in Spain, 88% in Latin America),56 
COPD imposes a significant burden in terms of impaired quality of life, ranking the 8th 
leading cause of Years of Lived with Disabilities worldwide in 2013.57
Historically, COPD has been far more frequent in men than in women, due to industrial 
occupational exposures and higher smoking prevalence in men. However, COPD preva-
lence seems to become more equally observed in men and women in high-income 
countries, where smoking is now similar between sexes. Today, the number of women 
dying from COPD in the US surpasses the number of men,13 and the gap is closing 
in the Netherlands (37% of COPD deaths in women in 2000 vs. 47% in 2014).58 
Whether women are more susceptible to development of COPD than men, given equal 
exposures, continues to be investigated, but some evidence lends support to this 
hypothesis. Women may have more symptoms than men for the same number of 
pack-years (a measure of duration and intensity of smoking) smoked.50 This question 
is important as women in low- and middle-income countries with historically a low 
prevalence of smoking are increasingly targeted by tobacco marketing to increase 
their cigarettes consumption.59 Another possible reason for the gender differences 
observed is that men and women smoked different cigarettes.
COPD male death rates were estimated60 to be the highest in Bulgaria, Georgia, 
Argentina and China (Figure 5A), in 2013. This is likely due to high past smoking 
prevalence.61 Female death rates were estimated to be highest in North Korea, Den-
mark, Greece, China and India, as well as in the USA and Argentina (Figure 5B). 
Smoking prevalence in Denmark and Greece is indeed high among women (30%62 and 
26%, respectively), but low in India and China (3% and 2%, respectively).61 In those 
Asian countries, other risk factors may play a more important role, such as indoor air 
pollution.63 Conversely, death rates were lowest in Africa and the Middle-East, in both 
males and females.
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According to the WHO, in 2015, COPD was the 4th leading cause of death worldwide 
with 3.2 million deaths (5.6% of all deaths), and is predicted to reach the 3rd place by 
2030, representing 6.5% of deaths.64 COPD deaths are expected to further increase 
due to increased exposition to risk factors (such as tobacco smoking in women in low- 
and middle-income countries, and outdoor air pollution) and to population aging and 
growth. As people live longer, they are more likely to experience the consequences of 
long-term exposure to COPD risk factors.50 Today, more than 100,000 people die from 
COPD each year in the US,13 9,000 in the Netherlands, and 35,000 in the UK.60
Although COPD can now be managed,65 it can hardly be considered as curable. The 
natural history and duration of COPD makes that burden of disease very high because 
for many years, it may go undiagnosed and untreated.
Both lung cancer and COPD are managed by pulmonologists and patients often have 
both conditions. For example, Dutch studies reported that COPD was the second most 
frequent comorbidity in lung cancer patients (found in 22% of patients), after cardio-
vascular disease (23% of patients) in 1993–1995,66 and was present in 30% of lung 
cancer patients in 1995–2004.67 As a result, it has been proposed to offer lung cancer 
screening to both smokers68 and never smokers69 who suffer from COPD. 
In 2000, in the US, lung cancer represented 1% of all smoking-related conditions, while 
chronic bronchitis and emphysema represented 35% and 24% of them, respectively.13 
COPD is a major burden to many individuals, societies and healthcare budgets52,70 
throughout the world. No other disease responsible for comparable morbidity, mortal-
ity and cost is neglected by healthcare providers as much as COPD. 
Recent trends in smoking-related disease burden and predictions
The global burden of disease attributable to tobacco smoking including secondhand 
smoke appears to be quite stable (from 6.1% to 6.3% of Disability-Adjusted Life Years 
[DALY] [see paragraph page 28] between 1990 and 2010).71 However, the burden 
has now shifted to different world regions cancelling out when DALYs are assessed at 
global level. The decreases in high-income regions were offset by increases in regions 
such as Asia. As cigarettes are made available to a larger number of people by the 
tobacco industry, particularly in low- and middle-income countries (Figure 6), the 
burden of smoking-related diseases is bound to increase.62 
Even in high-income countries, where the burden of smoking-related diseases is large 
but decreasing in men, the burden will continue to increase for some time in women, 
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as they massively picked-up smoking later than men. Also, the risk of lung cancer and 
COPD has increased over time due to changes in cigarettes.13 For instance, a recent 
study in northern Europe predicts that smoking-attributable mortality will remain 
important for the future, especially for women.46 In the Netherlands, the smoking-
attributable mortality in men is estimated to decline from 25% in 2009 to 14% in 2050 
(Figure 7). In contrast, in women, the smoking-attributable mortality is estimated to 
increase from 12% in 2009 to 23% in 2033 and then decline to 19% in 2050. Smoking 
also has an impact on the national life expectancy,74-76 and on the mortality gender 
gap.77 
As the diagnosis and death of smoking-related cancers and COPD occur after a couple 
of decades of exposure to tobacco smoking, even if smoking prevalence continues to 
decline worldwide, those diseases are likely to remain a major burden for the decades 
to come. The WHO predicts that the worldwide proportion of COPD deaths among all 
causes of deaths will increase from 6.6% in 2015 to 8.6% in 2030, and from 2.8% to 
3.4% for lung cancer, respectively (as reported in The European lung white book).50 
It takes time to see the benefits of policies —such as tobacco-control policies— to 
prevent non-communicable diseases such as cancer78 and COPD.79 
Figure 6. Estimated proportion of the world’s adult smokers (men and women com-
bined) living in each WHO region, with current tobacco control policies, over 2010-2100. 
AFRO (Africa), AMRO (the Americas), EMRO (the Eastern Mediterranean), EURO (Eu-
rope), SEARO (South-East Asia) and WPRO (the Western Pacific). 
Source: extrapolated from Mendez et al.,72 presented in the Tobacco Atlas73
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1.2  DaTa SOuRCES
To investigate the burden of COPD and cancer, I have benefited from preferred access 
to some databases thanks to the organizations I worked for: first at IARC, in France, 
then at the American Cancer Society (ACS), in the USA. While working at IARC, I had 
prime access to Cancer Incidence in Five Continents and GLOBOCAN data. I further 
took advantage of the EUROCOURSE project, which aims at improving the use of cancer 
registries in European countries, by using data (EUREG) from the European Network 
of Cancer Registries. The ACS closely works with the North American Association of 
Central Cancer Registries (NAACCR), which allowed me to access restricted data. 
A. Smoking prevalence 
  
B. Age-standardized smoking-attributable mortality fraction 
Figure 7. A. Smoking prevalence (%); B. Age-standardized smoking-attributable mor-
tality fraction (%) in the Netherlands for 1950–2009 (observations) and 2010–2050 
(projections), by sex. 
Source: Stoeldraijer et al.46
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Those data sources have limitations, as population coverage may be limited, the data 
may be of insufficient quality, not available for over long periods, or not recent. Data 
quality covers completeness of data, which depends not only on the completeness of 
the registries, but also on the degree of ascertainment (requiring access to specialized 
care and the availability and quality of death certificates).
Incidence
Incidence informs on the number of new cases over a defined period in a defined 
population. It can be expressed as an absolute number of new cases per year or as 
a rate per 100,000 persons per year. Incidence data were extracted from population-
based cancer registries, which collect, register and analyze information on all new 
cancer cases in a defined population. The following international datasets were 
exploited: Cancer Incidence in Five Continents (CI5) series80-83 and EUREG.84 Both 
of these datasets have passed through a high level of quality standards looking at 
comparability, completeness and validity of the data.80 Comparability is the extent 
to which a registry’s coding and classification procedures and definitions adhere to 
established international standards and guidelines. Completeness is the degree to 
which all diagnosed cancer within a registry’s catchment population are included in the 
registry database. Validity (or accuracy) is the proportion of cases recorded as having 
a given characteristic that truly do have that attribute. 
There are fewer long-standing high-quality cancer registries in low- and middle-income 
countries. In particular, population coverage in Africa is still very low (Figure 8).
In addition, for United States, data were obtained from the NAACCR85 and the Surveil-
lance, Epidemiology and End Results (SEER) program from the National Cancer Insti-
tute.86 NAACCR data provide quasi national coverage, while SEER offers information 
from population-based cancer registries in 17 geographic areas that encompass nearly 
26% of the US population for longer periods of time (nine registries started in 1973).
Global incidence estimates at national level in 2012 were derived from GLOBOCAN.21
Mortality
Mortality is the number of deaths occurring in a given period in a specified population. 
It can be expressed as an absolute number of deaths per year or as a rate per 100,000 
persons per year. International data for cancer and COPD deaths were obtained from the 
WHO mortality database,87 which compiles the cause of death data from national offices. 
For the US, I used data from the Centers for Diseases Control and Prevention (CDC).88 
All mortality datasets are at national level. Yet, mortality data are available for only 
for part of the national population (e.g. cause of death is registered in 4% of deaths in 
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China, 93% in Brazil, and 100% in the Netherlands). For my studies, only high-quality 
data were used for greater international comparisons (high population coverage, low 
frequency of ill-defi ned causes of death, and few missing age at death).
Survival
The standard survival index is relative survival. It measures the excess mortality 
experienced by cancer patients compared with the general population. It is calculated 
by dividing the observed survival from all causes of death for the patient cohort by 
the expected survival in a comparable group not diagnosed with cancer as estimated 
by life tables. Relative survival is a theoretical population-based measure representing 
cancer survival in the absence of other causes of death. However, to estimate the 
US burden of cancer (chapter 3.1), I was interested in cancer survival in Hispanics 
and in minorities in the US (i.e. Asians), for whom there are no life tables available. 
Therefore, cause-specifi c survival was used, as recommended by Howlader et al.89 
Cause-specifi c survival is a net survival measure representing cancer survival in the 
absence of other causes of death. It estimates the probability of surviving a specifi c 
 Figure 8. Location of the 290 cancer registries (black points) in 68 countries selected 
for data publication in Cancer Incidence in Five Continents Volume X (2003 to 2007). 
Source: http://ci5.iarc.fr/CI5-X/Pages/registry-map.aspx 
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cause of death (e.g. lung cancer). Estimates are calculated using a standard life table 
approach where individuals who die of causes other than the one specified are consid-
ered to be censored. Cause-specific survival data were provided by SEER.86 They were 
used to compute the cure fraction in the US. This fraction is a statistical measure of the 
proportion of the patients who will have the same probability of dying than the general 
population. The cure fraction was used to determine the proportion of patients who 
will survive after a cancer diagnosis and the proportion of patients who will eventually 
die from their cancer. 
Population
Population data were obtained from the corresponding sources where available (CI5,80 
SEER),86 or completed with UN estimates.90
Population data originate from national census and are interpolated for the years 
between the census. Depending on the census frequency and its quality, population 
estimates may or may accurately reflect the actual population.
Health surveys – tobacco prevalence
Smoking is measured by prevalence (the proportion of persons in a defined population 
who smoke in a given year). Smoking prevalence in the US came from two surveys. 
The first one, BRFSS (Behavioral and Risk Factor Survey System),91 is a health-related 
telephone survey that collects data about US residents regarding their health-related 
risk behaviors, chronic health conditions, and use of preventive services, in 50 states, 
Washington DC, and three U.S. territories. The BRFSS completes more than 400,000 
adult interviews each year. The second one, NHIS (National Health Interview Sur-
vey),92 has been collecting a broad range of health topics through personal household 
interviews, for over 50 years. The data are collected by the US Census Bureau in 
around 35,000 households containing about 87,500 persons, every year.
While those surveys are designed to be overall representative at state (BRFSS) or 
national (NHIS) level, the number of analyses by sub-group (sex, race/ethnicity, age) 
may be limited by sample size in some categories. Data from the 2 surveys on 14 
domains were compared, including smoking. It was concluded that BRFSS and NHIS 
provided comparable national estimates.93
1.3  METHODS
To assess the burden of cancer and COPD and differences over time, between coun-
tries, sexes and sub-populations (within the US), classic descriptive epidemiological 
methods (age-standardized rates, trend analysis), advanced methods involving mod-
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eling (age-period-cohort analysis), and complex indicators (Disability-Adjusted Life 
Years and population attributable fraction) were used.
Time trend analyses
To compare disease incidence or mortality between populations and over time, the 
event rate is standardized over a theoretical population, to obtain age-standardized 
rates (ASR). The world standard94 was employed for international studies and the US 
2000 population95 for US-only studies. This process of age-standardization of the rates 
further allows to overcome the effect of age, which is key factor in both cancer and 
COPD incidence and mortality. To assess the changes in the rates, Joinpoint regres-
sions96 were used. It involved fitting a series of joined straight lines to ASR trends and 
measuring the slope of the fitted lines.97 The monitoring of secular trends plays a direct 
role in determining possible causes of diseases, assessing the need for disease control 
measures, and in continually evaluating implemented disease-control programs.
age-Period-Cohort analysis
Analyses encompassing the three underlying time components of age, period of event 
(diagnosis or death) and birth cohort offers additional insights to temporal studies of a 
disease. Time happens to be key in diseases such as cancer and COPD. The odds of di-
agnosis and mortality increase with age, due to the accumulation of genetic mutations 
necessary for the normal cell to become abnormal, as a result of the exposure to risk 
factors or stochastic events. The introduction of new detection technics (e.g. prostate-
specific antigen blood concentration for prostate cancer, spirometry for COPD) in a 
population can increase the number of diagnoses, while the introduction of technics to 
remove pre-cancerous lesions (e.g. colonoscopy for colon cancer, PAP smear followed 
by treatment for cervical cancer) can decrease the number of diagnoses in a short 
period, in the entire population. Finally, successive cohorts can be increasingly ex-
posed to carcinogens or agents which cause COPD. For example, smoking prevalence 
can increase or decrease in successive generations, starting around age 15-20. As 
such, age-period-cohort analyses provide clues as to the factors that drive a disease, 
informing the debate on prevention strategies.98
Disability-adjusted Life Years
A composite index, called Disability-Adjusted Life Years (DALY) was developed in the 
1990s to assess the burden of diseases and injuries.99 One DALY can be thought of as 
the loss of one year of “healthy” life. The sum of these DALYs across the population, 
or the burden of disease, can be thought of as a measurement of the gap between 
current health status and an ideal health situation where the entire population lives to 
an advanced age, free of disease and disability.
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DALY for a disease or health condition are calculated as the sum of the Years of Life 
Lost (YLL) due to premature mortality in the population, and the Years Lost due to Dis-
ability (YLD) for people living with a decreased quality of life due to a health condition 
or its consequences.100
Population attributable fraction
Relative risk (RR) is the ratio of the probability of an event occurring (for example, 
developing a disease) in an exposed group, to the probability of the event occurring 
in a control, non-exposed group. The Population Attributable Fraction (PAF) estimates 
the contribution of a risk factor to the disease burden in a defined population. The PAF 
accounts for both an estimate of relative risk as well as prevalence of the risk factor in 
the population (Figure 9). The PAF describes the proportional reduction in disease that 
would occur if exposure to a risk factor were to be eliminated.
For estimating the smoking-attributable burden of cancer, the formula for multi-
category exposure101 was used
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3.4 Population attributable fraction 
 
Relative risk (RR) is the ratio of the probability of an event occurring (for example, 
developing a disease) in an exposed group, to the probability of the event occurring in a 
control, non-exposed group. The Population Attributable Fraction (PAF) estimates the 
contribution of a risk factor to the disease burden in a defined population. The PAF accounts 
for b th an estimate of relative risk as well as prevalence of th  risk fact r in the populatio  
(Fout! Verwijzi gsbron niet gevonden.). The PAF describes the proportional re uction in 
disease that would occ  if exposure to a isk fact r were to be liminated. 
For estimating the smoking-attributable burden of cancer, the formula for multi-category 
exposure101 was used 
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p0 is the proportion of never smokers, p1 of former smokers and p2 of current smokers. RR1 
is the relative risk for former smokers compared with never smokers, and RR2 for current 
smokers compared with never smokers. 
 
4. This thesis 
 
4.1 Rational 
 
The tobacco epidemic impacts numerous diseases (Fout! Verwijzingsbron niet gevonden.). 
My research aims to assess the burden of two major non-communicable diseases related to 
smoking, namely cancer and COPD. 
 
Despite the decline in smoking prevalence in some industrialized countries thanks to 
tobacco control and awareness of the deleterious effects of smoking on health, a substantial 
number of the population still smokes (e.g. 40 million in the US,102 172 million in Europe).103 
Declines in smoking prevalence are already reflected in declines in smoking-related diseases 
in some countries, including in smoking-related cancers and COPD. Nevertheless, the 
Surgeon General’s Report
Methodology Used by CDC to Compute Smoking-Attributable 
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calendar time points. The estimates represent the SAM for 
a population with a defined smoking prevalence profile 
and a set of disease-specific RR estimates for a given year, 
based on the assumption that the RR estimates accurately 
represent those in the population of interest. 
There are several methods that have been used for 
calculating SAM (see Appendix 12.1). The first approach 
historically, the PAF calculation, is used most commonly 
a d can be calculated as: 
                 P(RR – 1)PAF =  –––––––––––––
P (RR – 1) + 1 
where P is the prevalence of exposure in the population 
and RR is the relative risk for disease associated with expo-
sure assumed for the population. The formula shows that 
PAF varies from 0 (if eithe  P = 0 or RR = 1) to approxi-
mately 1 at very high values for P or RR (Figure 12.1). 
This approach currently underlies the SAMMEC 
methodology (CDC 2011). The PAF and variants have 
also been referred to as assigned share, excess risk, etio-
logic fraction, attributable proportion, attributable risk, 
and incidence density fraction (Levin 1953; Walter 1976; 
The overall approach to estimating SAM includes 
the foll wing omponents: 
• Identifying those diseases caused by (cigarette)
smoking;
• Developing relative risk (RR) estimates for those dis-
eases f r current and former smokers in comparison
to lifetime nonsmokers;
• Developing estimates of smoking prevalence for the
population and years of interest;
• Estimating disease- and gender-specific PAFs by age
group; and
• Applying the PAFs to disease-specific mortality data
for the population to estimate SAM.
Understanding the parameters of PAF allows
researchers to describe any uncertainties associated 
with the resulting PAF estimates and acknowledges the 
cross-sectional nature of the SAM estimates for particular 
Figure 12.1 The relationship of relative risk (RR) to the population-attributable fraction at different 
prevalence levels
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Figure 9. The relationship of relative risk (RR) to the population attributable fraction at 
different prevalence levels.13
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p0 is the proportion of never smokers, p1 of former smokers and p2 of current smokers. 
RR1 is the relative risk for former smokers compared with never smokers, and RR2 for 
current smokers compared with never smokers.
1.4  THIS THESIS
Rational
The tobacco epidemic impacts numerous diseases (Figure 3). My research aims to as-
sess the burden of two major non-communicable diseases related to smoking, namely 
cancer and COPD.
Despite the decline in smoking prevalence in some industrialized countries thanks 
to tobacco control and awareness of the deleterious effects of smoking on health, a 
substantial number of the population still smokes (e.g. 40 million in the US,102 172 
million in Europe).103 Declines in smoking prevalence are already reflected in declines 
in smoking-related diseases in some countries, including in smoking-related cancers 
and COPD. Nevertheless, the burden of these two diseases is considerable. Smoking 
caused 6.1 million deaths in 2013 globally, and was the second leading risk factor for 
DALYs.104 Furthermore, smoking prevalence is increasing in developing countries due 
to the investment of the tobacco industry into those untapped markets, where tobacco 
control is still weak. Smoking-related morbidity and mortality need to be prevented in 
those countries as well.
While it is known that smoking causes cancer and COPD, to what extent does it explain 
diseases occurrence today? And which populations are most impacted by smoking-
related cancers and COPD? Where is the burden of these diseases increasing and 
decreasing?
In this thesis, I will specifically address these questions:
What is happening in the gender gap in smoking-related cancers?
• In which populations is the gender-specific incidence of smoking-related cancer 
still increasing in Europe? 
• How does cigarette type influence lung cancer histology in men and in women? 
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What is the burden of smoking-related cancers in the US?
• Do non-Hispanic Blacks have a higher cancer burden and smoking-related cancer 
burden than other racial/ethnic groups in the US?
• Do people living in tobacco-growing states of the US have a higher burden of 
cancer mortality attributable to cigarette smoking?
What is the impact of smoking on another important non-communicable disease: COPD?
My contribution in assessing the burden of those two diseases is the highlight of 
the areas of progress —where the burden is decreasing— and areas of concern. My 
work provides the tools needed to continue the advocacy for tobacco control, and 
also for planning for health care resources —both of which are integral components 
of disease control programs. My strategy is to decipher the present smoking-related 
disease burden by getting clues from the past (smoking history and recent diseases 
trends), and to instruct evidence-based decisions today to improve the future burden 
of diseases. The ultimate objectives of this thesis are to stress the continuing need for 
tobacco control and to identify priority populations for tobacco control. 
This research is performed at international-level, and at country-level in the US. 
The international-level perspective reports smoking-related cancers and COPD bur-
dens and trends. Countries in different regions of the world are at different stages 
of the tobacco epidemic, as updated by Thun et al.105 In the first of the four stages, 
smoking prevalence is very low but increasing, while smoking-related deaths (includ-
ing cancers) in the middle-ages are very rare (e.g. in women in sub-Saharan Africa).106 
During the second stage, smoking prevalence is still increasing and smoking-related 
deaths are increasing too. During the next stage, smoking prevalence are leveling off 
then decreasing, while smoking-related deaths are still on the increase (e.g. in Dutch 
women). Finally, in the fourth stage, both smoking prevalence and smoking-related 
deaths are declining (e.g. in both sexes in the US and the UK, and in Dutch men).105
The national-level perspective allows the examination of the influence of social norms 
and tobacco control on the epidemic of smoking and the subsequent rise (and fall) of 
smoking-related diseases at a finer level. The US are a key country in the history of 
smoking epidemic for at least three reasons. First, tobacco is native to the Americas. 
It was used as a medicine and as a hallucinogen by native American, and brought back 
to Europe by Spanish explorers in the sixteenth century. Second, it is in the US that 
the shift from roll-your-own cigarettes and pipes to manufactured cigarettes operated, 
thanks to the invention of the automated cigarette machine in the 1880s. Thirdly, the 
US played a pivotal role in the ascertainment of the crucial role of tobacco in the up-
surge of several diseases, building on what had been initiated by European scientists. 
The natural progression of this discovery was the implementation of tobacco control 
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measures and the tentative to eliminate — or at least weaken— the tobacco industry, 
which key steps also involved the US. Moreover, the US has a large and diverse popu-
lation which permits to investigate diseases at various levels such as state and race/
ethnicity. Finally, the late stage of the smoking epidemic in the US is illustrative of the 
situation of other high-income countries, and can forecast the situation in countries 
where the smoking epidemic is at an earlier stage.
Finally, I acknowledge that the approach to answer the overarching study question 
“what is the impact of smoking on two non-communicable diseases?” has been largely 
influenced by the two organizations I worked for while pursuing my PhD. I started my 
thesis while working at IARC, for the Cancer Surveillance Section under the supervi-
sion of Dr. Freddie Bray. The key focus of the Section is the “systematic and ongoing 
pursuit of global cancer data and statistics for cancer control action, in keeping with 
one of the primary aims of IARC —to describe and elucidate cancer occurrence world-
wide.” The Section has a keen interest on cancer registry support and development, 
in global cancer indicators, and in advancing descriptive epidemiology of cancer. As a 
WHO agency, the mission of IARC is at global level. Hence, the first two articles of this 
corpus, written at IARC, have a strong international outlook. In particular, the study 
on trends in new cancer cases in European aimed at demonstrating the value of a new 
European incidence database (EUREG). Meanwhile, the goal of the Surveillance and 
Health Services Research program I worked for at the American Cancer Society (ACS) 
under the supervision of Dr. Ahmedin Jemal is to analyze population-based informa-
tion on cancer occurrence, its causes, prevention, and treatment to “strengthen the 
scientific basis for cancer prevention and control nationally and globally”. In particular, 
this group has a strong interest in racial/ethnic disparities in the US, which motivated 
the studies of the burden of cancer and of the smoking-related cancer by race and 
ethnicity. Results from the group, and other groups in the Intramural Research Depart-
ment, are directly used by the ACS lobby at national, and at state-level, to advocate 
for laws preventing cancer (such as tobacco control laws and the Affordable Care 
Act), and in favor of cancer patients and survivors. Advancing the agenda of state-
level tobacco control policy was the rationale behind the study comparing state-level 
smoking-attributable cancer mortality fractions. Finally, ACS also reaches to other 
academic and non-governmental organizations working on other non-communicable 
diseases to fight common risk factors (such as smoking). This is how the last piece of 
work on COPD was made possible in a cancer-focused organization. Regardless of the 
differences in tactics, both IARC and ACS endeavor at reducing the burden of cancer.
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Smoking causes at least 12 cancers and I examine the incidence trends in Europe of 
the four cancers that are the most associated with smoking (laryngeal, lung, esopha-
geal and oral cavity and pharyngeal cancers) (Chapter 2.1). I detect the convergence 
of male and female incidence rates. Cigarette is a product that has evolved over time, 
to meet the needs of consumers anxious about their health. Cigarettes gained a filter, 
and became low-tar –making them supposedly less deleterious. Those changes have 
shifted the type (histology) of the most frequent cancer caused by smoking: lung 
cancer. This shift is reported in Europe, Northern America and Australia in Chapter 
2.2 and gender differences are stressed. 
As a preliminary step to the evaluation of the smoking-related burden of cancer in 
the US by race/ethnicity, I assess the burden of all cancers in the country, using 
DALY. With the DALY index, I compare the healthy life years loss due to each cancer 
and highlight cancer control priorities (Chapter 3.1). Then, I assess the tobacco-
attributable fraction of the burden of cancer by race/ethnicity, as it turns out that each 
group has a different smoking prevalence based on social norms — fueled by targeted 
tobacco industry marketing — and level of acculturation (Hispanics, Asians) (Chapter 
3.2). Subsequently, I study geographic (state) disparities in the US smoking-related 
cancer mortality, as most of tobacco control policies in the US are decided at state 
level (Chapter 3.3). 
Finally, I contrast international trends of COPD and lung cancer mortality rates in an 
effort to tease out the influence of smoking on COPD mortality (Chapter 4.1).
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 2.1
Convergence of male and female 
incidence rates in major tobacco-
related cancers in Europe 
in 1988–2010
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Introduction: Smoking prevalence has been declining in men all over Europe, while 
the trend varies by European region among women. To study the impact of past 
smoking prevalence, we present a comprehensive overview of the most recent trends 
in incidence, during 1988–2010, in 26 countries, of four of the major cancers in the 
respiratory and upper gastro-intestinal tract associated with tobacco smoking.
Methods: Data from 47 population-based cancer registries for lung, laryngeal, oral 
cavity and pharyngeal, and oesophageal cancer cases were obtained from the newly 
developed data repository within the European Cancer Observatory (http://eco.iarc.
fr/). Truncated age-standardised incidence rates (35–74 years) by calendar year, aver-
age annual percentage change in incidence over 1998–2007 were calculated. Smoking 
prevalence in selected countries was extracted from the Organisation for Economic 
Co-operation and Development and the World Health Organization databases. 
Results: There remained great but changing variation in the incidence rates of tobacco-
related cancers by European region. Generally, the high rates among men have been 
declining, while the lower rates among women are increasing, resulting in convergence 
of the rates. Female lung cancer rates were above male rates in Denmark, Iceland and 
Sweden (35–74 years). In lung and laryngeal cancers, where smoking is the main 
risk factor, rates were highest in central and eastern Europe, southern Europe and the 
Baltic countries. Despite a lowering of female smoking prevalence, female incidence 
rates of lung, laryngeal and oral cavity cancers increased in most parts of Europe, 
but were stable in the Baltic countries. Mixed trends emerged in oesophageal cancer, 
probably explained by differing risk factors for the two main histological subtypes.
Conclusions: This data repository offers the opportunity to show the variety of inci-
dence trends by sex among European countries. The diverse patterns of trends reflect 
varied exposure to risk factors. Given the heavy cancer burden attributed to tobacco 
and the fact that tobacco use is entirely preventable, tobacco control remains a top 
priority in Europe. Prevention efforts should be intensified in central and eastern Eu-
rope, southern Europe and the Baltic countries.
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InTRODuCTIOn
Tobacco was introduced into Europe by Spanish explorers returning from the Americas 
in the late fifteenth century. By the late nineteenth century, tobacco was being widely 
used by men in Europe (1), first in the forms of pipe-, cigar-smoking and snuff-taking. 
Then, after mass production became possible at the end of the nineteenth century, 
cigarettes, strongly promoted by advertising and marketing efforts, became the norm 
for tobacco consumption. From the 1930s, together with the forces of emancipa-
tion, women began adopting the habit on a large scale, first in North America and in 
northern and western Europe, until the 1970s. By the 1960s, the smoking prevalence 
in men was at least 70% in Denmark, the UK and Belgium, and 90% in the Nether-
lands, and around 30% in women (2). Thereafter, the proportion of smokers rapidly 
decreased in men in these parts of Europe, falling to around 40–50% by 1988. In 
contrast, in women, the prevalence rose gradually over time, but remained lower than 
in men. In southern Europe, the tobacco epidemic lagged behind that in northern and 
western Europe, especially in women. In Russia, a small but significant rise in the 
prevalence of tobacco smoking among men was reported, from 57% in 1992 to 63% in 
2003, whereas rates among women more than doubled from 7% to 15% in the same 
period (3). From the mid-1990s until 2002, the prevalence of smoking among men 
in Estonia, Latvia and Lithuania was around 50% (compared to 29% in Finland), and 
ranged between 10% and 20% among women. Smoking increased among Lithuanian 
women from 6% in 1994 to 13% in 2002, but decreased among Estonian men and 
women (4). Mass cigarette use followed the economic development in Europe: firstly 
in northern and western Europe, secondly in southern Europe, thirdly in central and 
eastern Europe.
Cigarette smoking is a causal agent for cancers of the oral cavity, oropharynx, na-
sopharynx, hypopharynx, oesophagus, stomach, colorectum, liver, pancreas, nasal 
cavity, paranasal sinuses, larynx, lung, uterine cervix, ovary, urinary bladder, kidney, 
ureter and bone marrow (myeloid leukaemia). Second-hand tobacco smoke and 
smokeless tobacco also induce cancer (5). The European Prospective Investigation 
into Cancer and Nutrition Study (EPIC) calculated that among the 19 above-mentioned 
tobacco-related cancer cases, 35% of them were attributable to cigarette smoking 
(42% in men and 23% in women) (6). In 2012 in Europe (40 countries), there were an 
estimated almost 600,000 new cases of: lung (410,000), oral cavity and pharyngeal 
(100,000), oesophageal (46,000) and laryngeal cancer (40,000) (7), the cancers for 
which the fraction attributable to smoking is highest (with lower urinary tract). For 
each of these sites, men represented 71% to 90% of the patients. 
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Using high-quality population-based cancer registration data, this study aims to 
identify patterns in the incidence of major tobacco-related cancers (lung, laryngeal, 
oral cavity and oesophageal cancer), between 1988 and 2010, especially contrasting 
trends in men and women. We analysed data from 47 cancer registries covering 328 
million inhabitants, representing 26 European countries, using age-standardised rates 
and average annual percentage change and compared smoking prevalence to lung 
cancer incidence. 
METHODS
Incidence data by year, 5-year age group, cancer and sex and corresponding popula-
tion figures were obtained from the EUREG database, part of the European Cancer Ob-
servatory (ECO) website (http://eco.iarc.fr) (8) hosted by the International Agency for 
Research on Cancer (IARC). The ECO website was developed within the framework of 
the EUROCOURSE project to enable the rapid exploration of geographical patterns and 
temporal trends of incidence, mortality and survival observed in European population-
based cancer registries. The cancer registries were invited to submit their data, in 
2010, through a web portal. As of mid-2013, 130 of the 200 European registries had 
contributed.
To ensure a high level of data quality and data comparability for this study, cancer 
registries from the EUREG database were only included in this study if they had been 
published in Volume IX of Cancer Incidence in Five Continents (CI5) (9) and had 
available annual incidence data for at least ten consecutive years from 1998 onwards. 
The rigorous process of data quality assurance in CI5 is described elsewhere (9). 
To assess recent trends, the period of analysis was restricted to 1988 and thereafter.
The Malta National Cancer Registry submitted data to the EUREG database for 1994-
2009. To expand the length of the study period additional data for 1992–1993 were 
extracted from CI5plus (10), which contains annual incidence for selected cancer 
registries published in CI5 for the longest possible period. Additional Norwegian 
(2008–2009), Danish and Finnish (2008–2010) data were extracted from NORDCAN 
(11), a database maintained by the Association of the Nordic Cancer Registries. Lastly, 
Russian data were available through the Ministry of Health and Social Development 
(12), as data from the St Petersburg registry published in CI5 were only available 
for 1992–1997. Russia is a populous European country whose cancer trends serve as 
references for the other central and eastern European countries. Russian national data 
presented a high percentage of microscopically verified records (>85%), acceptable 
for CI5 selection standards.
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Finally, population-based registries from 26 European countries (Table 1) were included 
in this study and grouped into four regions, according to the United Nations classifica-
tion (13). Of the 26 countries, 19 had national data. For the remaining seven countries, 
data from regional registries were aggregated to obtain an estimate of the (unknown) 
national incidence (see footnote of Table 1 for the list of the regional registries). When 
combining regional registries, we aimed to maximize the population coverage of the 
country by selecting as many registries as possible that had a common registration 
Table 1. Populations studied by country (N=26), study period, population covered by the 
registration area and proportion of the national population covered by the 47 national 
or regional studied registries
Region Countries Years
2007 population in 
the studied registries 
(thousands)
Proportion of the 
national population 
covered (%)
Central & eastern Europe    
 Belarus 1988–2007 9,702 100
 Bulgaria 1993–2008 7,660 100
 Czech Republic 1988–2008 10,323 100
 Poland§ 1988–2008 2,042 5.2
 Russian Federation 1993–2008 142,115 100
 Slovakia 1988–2007 5,398 100
Northern Europe    
 Denmark 1988–2010 5,461 100
 Estonia 1988–2007 1,341 100
 Finland 1988–2010 5,289 100
 Iceland 1988–2010 311 100
 Ireland 1994–2007 4,339 100
 Latvia 1988–2007 2,276 100
 Lithuania 1988–2007 3,376 100
 Norway 1988–2009 4,708 100
 Sweden 1988–2009 9,148 100
 United Kingdom§ 1988–2007 56,236 88.3
Southern Europe    
Croatia 1988–2007 4,436 100
 Italy§ 1988–2007 4,359 6.9
 Malta 1992–2009 409 100
 Slovenia 1988–2007 2,019 100
 Spain§ 1988–2005 3,502a 7.7
Western Europe    
Austria 1990–2009 8,301 100
 France§ 1988–2009 4,388 6.8
 Germany§ 1998–2007 13,888 16.1
 Switzerland§ 1988–2008 968 12.3
 The Netherlands 1989–2008 16,382 100
Total 328,376
§Regional registries: France (Doubs, Herault, Isere, Haut-Rhin, Somme, Tarn); Germany (Brandenburg, Hamburg, 
Saxony, Mecklenburg, North Rhine-Westphalia, Saarland); Poland (Kielce, Cracow); Italy (Modena, Parma, Ragusa, 
Romagna, Torino, Varese); Spain (Granada, Murcia, Navarra, Tarragona); Switzerland (Geneva, St Gall-Appenzell), 
United Kingdom (England and Scotland)
aPopulation data from 2005.
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period and which met the inclusion criteria. Unfortunately, in Italy, due to the selection 
process, only registries from the northern part of the country were eligible.
Of the 19 cancer sites associated with tobacco, lung and larynx were estimated to 
have the highest population attributable fraction (AFp) due to cigarette smoking, 82% 
and 84% respectively, in the EPIC study (6). Therefore, trends in both lung and laryn-
geal cancers may be largely explained by historical trends in tobacco use. For other 
cancers however, the AFp is smaller, and other factors such as alcohol (14), infections 
(15) and diet (16) may also be important in determining trends in incidence. Although 
smoking would undoubtedly contribute to additional new cases, it would not be wise 
to ascribe changes in incidence of these cancers primarily to changes in tobacco use. 
This study is hence confined to cancer sites where at least 30% of the new cases 
are due to cigarette smoking (AFp > 30%) based on the findings of the EPIC study 
(6). The eligible cancer sites (and corresponding ICD-10 codes) are: Oral cavity and 
Pharynx (C00-14), Oesophagus (C15), Larynx (C32) and Lung, bronchus, trachea 
(C33-34). An exception was made for cancer of the lower urinary tract (C65-C68); 
while up to half of the cases are attributed to smoking, we excluded this site because 
different and changing classification/coding practices (17) during the study period 
render international comparisons difficult. Stomach and colorectal cancer incidence 
are examined by Arnold et al (18).
We restricted this study to age group 35 to 74 to analyse larger, more stable rates. 
Annual truncated age-standardised incidence rates (ASR) were calculated for each 
country by sex, using the European standard population (19). To graphically sum-
marize the trends, locally weighted regression (Lowess) curves were fitted to provide 
smoothed lines through the scatterplot of ASRs by calendar period. A bandwidth of 0.3 
was used, i.e. 30% of the data were used in smoothing each point, except for female 
oesophageal and laryngeal trends, where 50% of the data were used because of the 
random fluctuations inherent in the small numbers involved. Rates are plotted on a log 
scale. Of note, for each cancer, the incidence scale is adapted to the range in incidence 
across the continent and varies by sex.
Changes in incidence rates were quantified for age groups 35 to 64, 65 to 74 and 35 to 
74, for the 1998–2007 period (except Spain, for which 1996–2005 was used) through 
average annual percentage change (AAPC) and corresponding 95% confidence inter-
vals [C.I.] based on the model from Clegg et al. (20). AAPCs were estimated using the 
Joinpoint Regression Program (version 3.5.3) from the Surveillance Research Program 
of the US National Cancer Institute (21), and we used the number of cases as the 
dependent variable, calendar year as the independent variable, and the Poisson vari-
ance of the person-years at risk.
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The proportions of adenocarcinomas (AdC) and squamous cell carcinomas (SCC) 
among oesophageal cancers for 1998–2002 were extracted from CI5 volume IX (9).
To illustrate the association between smoking and lung cancer incidence, and to further 
clarify the stage of the smoking epidemic (22), we plotted the national prevalence of 
daily smokers aged 15 and above and the national or regional lung cancer incidence 
rates for ages 35 and above, for the maximum time period available in EUREG and 
CI5plus databases (since 1955 for Denmark). The percentage of adult daily smokers 
was extracted from the Organisation for Economic Co-operation and Development 
(23) and the World Health Organization (WHO) (24) databases. In each of the four 
regions, for illustrative purposes, we selected one country with a long series of smok-
ing prevalence and lung cancer incidence data.
RESuLTS 
Lung cancer
Lung cancer incidence for men aged 35–74 differed markedly between countries, be-
ing highest in Belarus (161 cases per 100,000 in 2007) and lowest in Sweden (40 
cases per 100,000 in 2009), in the most recent period (Figure 1). In most European 
countries, rates for men have decreased since the early 1990s, with the exception of 
Norway, Finland, Spain and France, where rates have remained broadly stable (Figure 
1). Over the 1998–2007 period, a significant decline in lung cancer incidence rates in 
men was observed in 14 of the 26 countries in middle ages (35–64 years old) and 15 
countries in older ages (65–74 years old) (Figures 2a and 2b and Appendix Table 1). 
The declines were stronger in older men. In the figure presenting the recent incidence 
rate versus the 1998-2007 AAPC in middle-aged men (Figure 2a), the countries were 
clustered by region: in northern European countries (but Baltic countries), lung cancer 
incidence rates were low and stable. Rates were intermediate and declining in western 
European countries, and high and declining in central and eastern European and Baltic 
countries. Rates in southern European countries did not have a uniform behaviour. 
Among women, in the most recent period, the highest incidence rates were observed 
in Iceland and Denmark, with rates of 95 and 93 per 100,000 in 2010, respectively, as 
well as in the Netherlands (71 cases per 100,000 in 2007). Denmark appears as hav-
ing a higher rate than Iceland in the graph (Figure 3) due to smoothing. In the same 
period, the lowest female rates were in Belarus and Lithuania (13 cases per 100,000 in 
2007). In contrast to the decreasing trends observed in men, among women rates of 
lung cancer by age group have increased over time (Figures 4a and 4b and Appendix 
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Figure 1. Trends in lung cancer age-standardised (European) incidence in men aged 35–
74 by country and region, from 1988 to the most recent year available (2005 to 2010).
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Table 1), with the notable exceptions of the declines in older Russian and Lithuanian 
women in 1998–2007. Very recently (after 2005), early signs of stabilisation could 
be detected in women aged 35–74 in central and eastern Europe, northern Europe, 
Switzerland and Malta (Figure 3). Figure 4a (incidence rate vs. AAPC in middle-aged 
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women) showed regional clusters of countries: moderate increases in lung cancer 
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Figure 5. Age-standardised (European) lung cancer incidence rates per 100,000 in men 
and women aged 35–74, in European countries, by region (2006–2008).
incidence in northern countries (but stable in Baltic countries and Iceland), upper high 
and increasing incidence rates in western countries, low to intermediate rates with 
strong increases in southern Europe (but in Italy) and finally low to intermediate rates 
in central and eastern Europe.
Due to the convergence of the trends by sex, the male-to-female ratio has decreased 
during the last 20 years. Noticeably, in the most recent years (2006–2008), the high-
est male (aged 35–64) rates were found where the lowest female rates were: in cen-
tral and eastern Europe, the Baltic countries and some southern European countries. 
Conversely, the lowest male rates and the highest female rates are found in northern 
Europe (excepting the Baltic countries) (Figure 5). The sex ratio was closest to 1 in 
northern countries, with incidence even higher in women than in men in Denmark, 
Sweden and Iceland, among people aged 35–64 (Figure 5).
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Oral cavity and pharyngeal cancer 
Within Europe, incidence of cancers of the oral cavity and pharynx among men in the 
most recent period varied almost 6-fold, from 12 (in Iceland in 2010) to 64 (in Slovakia 
2007) per 100,000 (Figure 6). During the 1998–2007 decade, rates among men were 
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Figure 6. Trends in age-standardised (European) oral cavity and pharyngeal cancer in-
cidence in men aged 35–74 by country and region, from 1988 to the most recent year 
available (2005 to 2010).
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stable in most countries in northern, western and central and eastern Europe (Figure 
7 and Appendix Table 2). In southern European countries (Croatia, Italy, Slovenia, 
Spain), as well as in other countries (Russia, France, Estonia, Switzerland and Poland), 
declines were consistently observed. In the same period, rates in women were very 
low in the former Soviet countries, e.g. in Belarus and Lithuania (4 and 5 per 100,000 
respectively, in 2007), and were highest in western Europe, e.g. in Switzerland (17 
per 100,000 in 2008) (Figure 8). In women, rates stabilized or increased over the 
1988–2007 period, with the highest increase in the Czech Republic (average increase 
of 6.4% per year, [95% C.I. 4.0; 8.9]) (Figure 9 and by age group in Appendix Table 
2). While incidence rates were higher in men compared to women throughout the 
study period, as a consequence of the converging male and female incidence trends, 
the male-to-female ratio has decreased during the last 20 years. In 2006–2008, this 
ratio ranged from 12.6 in Belarus to 1.3 in Iceland.
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Figure 7. Average annual percentage change (AAPC) between 1998–2007 (except 
1996–2005 for Spain) and age-standardised (European) incidence rates (ASR) of the 
most recent year of oral cavity and pharyngeal cancer in men aged 35–74. 
Dots indicate statistically significant AAPC (p≤0.05); triangles indicate non-significant AAPC. Colours indicate Euro-
pean regions: Central and eastern (blue), northern (green), southern (red) and western (brown).
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Figure 8. Trends in age-standardised (European) oral cavity and pharyngeal cancer inci-
dence in women aged 35–74 by country and region, from 1988 to the most recent year 
available (2005 to 2010).
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Laryngeal cancer
In the most recent period, incidence of cancer of the larynx among men 35–74 was 
lowest in northern European countries (excluding the Baltic countries) and highest in 
central and eastern Europe, Baltic countries, Spain and Croatia: rates ranged from 4 
per 100,000 in Sweden in 2009 to 30 per 100,000 in Bulgaria in 2008 (Figure 10). 
Rates tended to decline in most countries (Figures 10 and 11, and by age group in Ap-
pendix Table 3), with the greatest declines observed among men in Iceland and Poland 
(Average Annual Percentage Change (AAPC) of -13.7 [95% C.I. -23.3; -2.9] and -6.7 
[-8.8; -9.4], respectively). In women, the incidence rates of laryngeal cancer were 
rather low, ranging from 0.5 to 2 per 100,000 in Belarus in 2007 and the Netherlands 
in 2008, respectively (Figure 12). Although the patterns were somewhat erratic due to 
the low number of cases, there was a suggestion of an increase over the 1998–2007 
decade in middle-aged women and a decrease at older ages (Appendix Table 3). The 
figures presenting the recent incidence versus AAPC (Figures 11 and Appendix Figure 
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Figure 9. Average annual percentage change (AAPC) between 1998–2007 (except 
1996–2005 for Spain) and age-standardised (European) incidence rates (ASR) of the 
most recent year of oral cavity and pharyngeal cancer in women aged 35–74. 
Dots indicate statistically significant AAPC (p≤0.05); triangles indicate non-significant AAPC. Colours indicate Euro-
pean regions: Central and eastern (blue), northern (green), southern (red) and western (brown).
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1) revealed regional clusters of countries (with Baltic countries included in the central 
and eastern European countries’ cluster, in men).
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Figure 10. Trends in age-standardised (European) laryngeal cancer incidence in men 
aged 35–74 by country and region, from 1988 to the most recent year available (2005 
to 2010).
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Oesophageal cancer
The variation in recent incidence of oesophageal cancer among men was 5-fold, with 
incidence highest in the Netherlands (24 per 100,000 in 2008) and lowest in Malta (5 
per 100,000 in 2009) (Figure 13). Over the 1998–2007 period, in men aged 35–74, in 
general, countries in the northern half of Europe have seen increases in oesophageal 
cancer incidence (with the highest increase in the Netherlands: AAPC of 3.5 [95% C.I. 
2.8; 4.3]), while countries in the southern half saw declines in incidence (AAPC greater 
than -3.0 in France, Spain and Italy) (Figure Appendix Figure 2). The increases were 
most pronounced in middle-aged men (AAPCs of 4.4 in the Netherlands [95% C.I. 
3.1; 5.7], 4.2 in Norway [95% C.I. 0.7; 7.8], and 4.1 in Finland [95% C.I. 0.6; 7.8] in 
men aged 35–64 years) (Appendix Table 4). The male-to-female ratio was higher for 
oesophageal cancer relative to other smoking-related cancers in this study, ranging 
from 2.7 in Ireland to 20.8 in Belarus in 2006–2008. Because of the random fluctua-
tions inherent in the small numbers involved, it is difficult to discern trends in women. 
However, incidence rates appeared to have increased over the whole study period in 
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Figure 11. Average annual percentage change (AAPC) between 1998–2007 (except 1996–
2005 for Spain) and age-standardised (European) incidence rates (ASR) of the most 
recent year of laryngeal cancer in men aged 35–74. 
Dots indicate statistically significant AAPC (p≤0.05); triangles indicate non-significant AAPC. Colours indicate Euro-
pean regions: Central and eastern (blue), northern (green), southern (red) and western (brown).
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Figure 12. Trends in age-standardised (European) laryngeal cancer incidence in women 
aged 35–74 by country and region, from 1988 to the most recent year available (2005 
to 2010).
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most countries in western, central and eastern Europe in women aged 35–74 (Figure 
14), with the exception of a decline in Russia. Over the 1998–2007 period, in women, 
increases were significant only in Iceland, Germany, Denmark and the Netherlands 
(Appendix Figure 3).
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Figure 13. Trends in age-standardised (European) oesophageal cancer incidence in men 
aged 35–74 by country and region, from 1988 to the most recent year available (2005 
to 2010).
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Figure 14. Trends in age-standardised (European) oesophageal cancer incidence in 
women aged 35–74 by country and region, from 1988 to the most recent year available 
(2005 to 2010).
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Table 2 presents the proportion of the two main histological subtypes of oesophageal 
cancer, SCC and AdC, by country and by sex, in 1998–2002. In men, the majority 
of the cases were SCC. Less than 10% of the cases were AdC in central and eastern 
Table 2 Proportion of oesophageal cancer by main histological sub-type, by sex, in 
1998–2002, ages 35–74. Source: Cancer Incidence in Five Continents Volume IX (9). 
  Men  Women
 Region Country Squamous 
Cell 
Carcinoma 
(%)
Adenocarcinoma 
(%)
Squamous 
Cell 
Carcinoma 
(%)
Adenocarcinoma 
(%)
Central & eastern Europe      
 Belarus 66 9 43 18
 Bulgaria - - - -
 Czech Republic 56 23 55 18
 Poland§ - - - -
 Russian 
Federation
55 8 51 9
 Slovakia 70 9 55 26
Northern Europe
 Denmark 43 44 65 25
 Estonia 82 5 82 0
 Finland 52 37 75 19
 Iceland 34 63 22 44
 Ireland 34 54 64 24
 Latvia 63 9 31 17
 Lithuania 63 8 63 12
 Norway 50 42 66 26
 Sweden 46 47 73 23
 United Kingdom§ 25 59 55 27
Southern Europe
 Croatia 56 6 50 12
 Italy§ 66 18 68 13
 Malta 36 43 60 20
 Slovenia 77 9 63 22
 Spain§ 74 17 63 18
Western Europe
 Austria 54 25 50 18
 France§ 77 17 81 11
 Germany§ 61 17 64 14
 Switzerland§ 62 31 74 17
 The Netherlands 36 56 58 33
§Regional registries: France (Doubs, Herault, Isere, Haut-Rhin, Somme, Tarn); Germany (Brandenburg, Hamburg, 
Saxony, Mecklenburg, North Rhine-Westphalia, Saarland); Poland (Kielce, Cracow); Italy (Modena, Parma, Ragusa, 
Romagna, Torino, Varese); Spain (Granada, Murcia, Navarra, Tarragona); Switzerland (Geneva, St Gall-Appenzell), 
United Kingdom (England and Scotland)
Proportions in Bulgaria and Poland are not displayed due to the low proportion of microscopically verified cases (35% 
in men and 27% in women in Bulgaria, 57% and 43% in Poland Cracow and 77% and 74% in Kielce respectively). 
The other histological subtypes not displayed are: Other specified carcinoma, Unspecified carcinoma, Sarcoma, Other 
specified morphology and Unspecified morphology.
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Europe (except in Czech Republic), the Baltic countries, Croatia and Slovenia. In the 
other countries of northern Europe, and in the Netherlands and Malta, AdC cases 
were more frequent than SCC. In women, SCC always represented the majority of 
the cases, except in Iceland and Latvia. The highest proportions of SCC were found in 
Sweden, Switzerland, Finland, France and Estonia, ranging from 73% to 82%.
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Figure 15 a. Age-standardised (European) lung cancer incidence rates per 100,000 in 
men aged 35 and above and prevalence of daily smokers in men aged 15 and above in 
Czech Republic, Denmark, Italy and France
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Temporal trend of cigarette smoking and lung cancer incidence
National smoking prevalence (daily smokers aged 15 and above) and age-standardised 
lung cancer incidence in adults (aged 35 and above) are plotted by sex in Figures 15a 
and 15b, for four selected countries, one in each European region: Czech Republic 
(central and eastern Europe), Denmark (northern Europe), Italy (southern Europe) 
and France (western Europe). Although historically in those four countries the highest 
reported prevalence in Europe was as high as 70% (e.g. in Danish men circa 1967), the 
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Figure 15 b. Age-standardised (European) lung cancer incidence rates per 100,000 in 
women aged 35 and above and prevalence of daily smokers in women aged 15 and 
above in Czech Republic, Denmark, Italy and France
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highest current smoking prevalence was 29%, in French men. In men, the decline in 
smoking prevalence was reflected in a later decline or stabilization (Denmark, France) 
in the lung cancer incidence, with a two- to three-decade lag time. In women, smoking 
prevalence has been increasing in France since the 1960s, but remained stable in 
the Czech Republic since the mid-1980s and in Italy since the 1980s. Conversely, 
prevalence has markedly declined over time in Denmark, especially since the late 
1990s, with current prevalence of smokers at 20% among Danish women. In contrast 
to the temporal trend in men, lung cancer incidence continued to increase in women 
in the Czech Republic, Italy and France. The high incidence in Denmark (110 cases per 
100,000 in 2010) has stabilised very recently, four decades after the peak of smoking 
prevalence. 
DISCuSSIOn
There remained large but changing variation in the incidence rates of tobacco-related 
cancers. Generally, male rates have been declining in lung, oral cavity and pharyngeal 
and laryngeal cancers, while female rates have been increasing in lung, oral cavity and 
pharyngeal cancers. In lung and laryngeal cancers, rates were highest in central and 
eastern Europe, southern Europe and the Baltic countries (in men). With respect to 
oesophageal cancer, mixed trends emerged.
Lung cancer
These analyses reveal that the gap between male and female lung cancer incidence 
is narrowing, particularly in northern and western Europe, with lung cancer rates in 
women aged 35–64 in 2006–2008 even higher than rates in men in Denmark, Iceland 
and Sweden. This phenomenon has also been observed in the Netherlands since the 
mid-1990s in women <50 years old (25). In southern Europe, declines in male inci-
dence were also reported by Znaor et al. in central Serbia over the 1999-2008 period 
(26). While the peak of lung cancer cases seems to have been reached in men, as 
already reported by Malvezzi et al.(27), our analyses indicate that it has not yet been 
reached in women. It was estimated that, in Europe, in 2012, lung cancer—the major-
ity of cases of which are attributable to smoking—was the most commonly diagnosed 
cancer in 15 countries and the second most common cancer in 13 further countries in 
men, and ranked second in three countries among women (Albania, Iceland and the 
UK). This neoplasm was estimated to be the most frequent cause of death by cancer in 
men in all European countries, with the exception of Sweden. In women, lung cancer 
surpassed breast cancer mortality in 12 of the 40 countries of the European region (7). 
Consequently, the pattern of the cancer burden in women in Europe is approaching 
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the cancer burden in men. Tobacco certainly plays a major role (AFp of 82%), but 
occupational exposure (such as asbestos (28)) and environmental exposures also ac-
count for a small proportion of the lung cancer cases, possibly explaining some of the 
observed between-country differences in rates.
Oral cavity and pharyngeal cancers
Although oral cavity and pharyngeal cancers are strongly related to smoking -- with 
a cumulative risk among lifelong male smokers around 16 times higher than in never 
smokers -- (29) the trends in oral cavity and pharyngeal cancers differ noticeably from 
those of lung cancer. In particular, male rates have been increasing or remained stable 
in some countries while lung cancer incidence rates have declined (e.g., Czech Repub-
lic, Denmark, the UK and the Netherlands). This suggests that other detrimental risk 
factors, such as alcohol (14) and human papillomavirus (HPV) (15) may substantially 
modify the trends. Conversely, diets rich in fruit and vegetables may prevent upper 
aerodigestive tract cancers (30). For oral cavity cancer, the population attributable 
risk is 22% for tobacco alone and 40% for tobacco in combination with alcohol (14). 
According to the WHO, alcohol consumption has been increasing in Czech Republic 
and Denmark from around 9 litres of pure alcohol per year per person aged 15+ to 15 
litres and from 7 litres to 11, respectively, over the 1960-2010 period (24). This may 
partly explain the increase in the number of new oral and pharyngeal cancer patients. 
Conversely, the highest levels of consumption in Europe used to be around 25 litres 
in France, 18 litres in Italy, 14 litres in Spain at the beginning of the 1960’s, but 12, 
6 and 10 litres respectively in 2010 (24). As heavy alcohol consumption (i.e., ≥4 
drinks/day) is associated with an increased risk of about 5-fold for oral and pharyngeal 
cancer (31), the decrease in average consumption may partly explain the decline in 
the number of new cases in those countries among men -- who, on average, drink 
more than women. However, even low doses of alcohol consumption (i.e., ≤1 drink/
day) increase the risk of cancer by about 20% (31). In Europe, around year 2000, the 
proportion of people abstaining from drinking alcohol for the past 12 months was, on 
average in each country, 18% among men and 32% among women (24), putting the 
rest of the population at increased risk of cancer due to alcohol consumption. 
The AFp for HPV varies by sub-site and also by European region. In the oropharynx, 
including tonsil and base of tongue, it has been estimated to range from 17% in south-
ern Europe to 38–39% in northern, western and eastern Europe (15). Oropharyngeal 
cancer incidence significantly increased among men, and at younger ages, over the 
1983-2002 period, in the Netherlands, Slovakia, Denmark and the UK, thereby in-
creasing the total number of new oral cavity and pharyngeal cancer cases. On the 
contrary, oropharyngeal cancer incidence declined in France and Italy (32).
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Laryngeal cancer
Tobacco and alcohol are the main drivers behind the trends of laryngeal cancer inci-
dence. They have a synergistic effect on this cancer (33). In the ARCAGE multicentre 
case–control study in Europe of upper aerodigestive tract cancers, the risk estimate 
of hypopharyngeal/laryngeal cancer for tobacco alone was 6.7 and 1.0 for alcohol 
alone. However, joint exposure to tobacco and alcohol triggered an odd of 14.5 (14). 
The effect of alcohol on laryngeal cancer also differs by sub-site, i.e. cancer of the 
supraglottis is more strongly related to alcohol consumption compared to the glottis/
subglottis (34). Finally, occupational exposures (35) may also have an impact on the 
incidence, and explain country-level differences.
Oesophageal cancer
In men, while lung cancer incidence is declining, oesophageal cancer incidence is 
increasing in a number of countries, particularly in the Netherlands, Finland, Belarus, 
Germany and the UK (ages 35–74). The difference in the observed trends for lung 
cancer (a proxy for past smoking behaviours) and oesophageal cancer is probably ex-
plained in part by differing risk factors for the two main subtypes of oesophageal can-
cer: more distantly located adenocarcinomas (AdC) and more proximal squamous cell 
carcinomas (SCC). They have different aetiologies. Tobacco has a stronger association 
with SCC, whereas gastro-oesophageal reflux disease, presence of abdominal fat and 
Barrett oesophagus markedly increase the risk of AdC of the oesophagus (36). In our 
study, the proportion of AdC in men (35–74 years old) was highest in the Netherlands, 
Ireland, the UK and Nordic countries (Table 2). Hence, in those countries, the observed 
increasing oesophageal cancer trends are likely to be mainly driven by risk factors 
other than smoking. A global assessment by Edgren of the oesophageal AdC epidemic 
showed that it started between the 1960s (the UK) and the 1990s (Scandinavia), with 
considerable magnitude in variation between cancer registries (37). Other local factors 
such as consumption of hot tea may also explain the marked differences for the high 
UK rates in both sexes (38). As for SCC, alcohol further modifies the risk related to 
tobacco smoking (14). Heavy alcohol consumption (i.e., ≥4 drinks/day) increases the 
risk of oesophageal SCC about 5-fold and low doses of alcohol consumption by about 
30% (31). As in oral cavity and pharyngeal cancers, the important decline in the 
average alcohol consumption in some countries (e.g., France, Spain and Italy) may 
already have had a positive impact and could partly explain the marked decrease in 
incidence of oesophageal cancers in men in these countries.
Temporal trends in cigarette smoking and lung cancer
Recently, Thun et al. have modified the four stages of the “tobacco epidemic” (22) to 
accommodate gender differences (39). Some of the variations in smoking prevalence 
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between countries can be explained by differences in economic development. Today, 
on the one hand, in most European countries, men have reached the final stage, which 
involves falling smoking rates (40) and widening socioeconomic differences in smok-
ing (41). On the other hand, women are at contrasting stages within the epidemic 
continuum. In most of northern Europe, the tobacco epidemic in women seems to 
have reached the fourth stage, whereas France still lags behind and is only at the 
second stage, characterized by an increase in both smoking prevalence (2) and lung 
cancer. We also observed longer lag times between the peak of smoking prevalence 
and lung cancer incidence than previously reported in the USA and Japan (40 vs. 
15–30 years) (42). This could be due to differences in smoking behaviour and pattern, 
cigarette type, other carcinogenic exposures and susceptibility to lung cancer between 
countries. 
The figures presenting the recent incidence rates versus the AAPC during 1998—2007 
revealed regional clustering, most notably for lung and laryngeal cancers. We observed 
closer relationship within regions with the current burden (recent incidence rate) than 
with the trend (AAPC). We can infer that the today’s burden in those cancer sites is 
the result of past regional influence, while what will happen in the future (estimated 
by the recent AAPC) is determined at the country level.
Some limitations of this study are worth mentioning. Firstly, seven countries had no 
national registration coverage. We therefore combined several regional registries to 
obtain a proxy of the national incidence. Still, for four countries (France, Italy, Spain 
and Poland) the population coverage was still less than 10%. In our analyses, we 
hence assumed that the cancer incidence in the rest of the population was equivalent 
to that in the areas covered by the regional registries. This may (or may not) be a 
reasonable assumption depending on whether the populations covered by the regional 
registries are representative of the national population, particularly in terms of smok-
ing patterns. Secondly, although we chose cancer registries that had passed the most 
rigorous selection process of CI5 publication, data quality may have changed over time. 
In particular, there may have been improvements in completeness in some registries 
(43). Thirdly, in an effort to standardise our analysis across countries, we assessed 
the changes in rates over the 1998–2007 period. As such, this method fails to capture 
very recent changes (after 2005), e.g., in lung cancer in women. Finally, we grouped 
countries by geographical region according to the UN classification, yet heterogeneity 
exists within region. For example, the rates and trends in Baltic countries (Latvia, 
Estonia and Lithuania) resemble more closely those of the former communist states of 
central and eastern Europe (including Poland, Slovakia, Russian Federation, Bulgaria, 
Belarus and Czech Republic) than those of the other countries of northwestern Europe, 
possibly because of shared history and lifestyles. Likewise, incidence trends in the 
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Netherlands, classified as being in western Europe, more closely resemble those of the 
UK, Ireland and Denmark.
COnCLuSIOnS 
Our study illustrates the impact of the economic conditions as well as successes 
and failures of tobacco control policies in Europe. These policies have contributed 
to decreasing smoking prevalence in men, but have failed thus far to prevent smok-
ing initiation in women or to support them in quitting smoking. Implementation was 
far too late in central and eastern Europe and the Baltic countries. Tobacco control 
remains a top priority for cancer control in Europe (44); advances in cancer therapy 
have not had much success in improving survival for the cancers in this study (45, 
46). Key targets for prevention efforts should include men in central and eastern 
Europe (27), southern Europe and Baltic countries and young women across Europe 
(7). In recognition of the heterogeneity and diversity between populations, targeted 
and adaptable approaches to cancer prevention are essential (47). As the EUREG 
database is continuously updated with new incidence, mortality and survival data and 
new population-based cancer registries, it offers enormous opportunities to increase 
the knowledge on cancer and its control in the years to come.
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aPPEnDIx 
Appendix Table 1. Average annual percentage change (AAPC) in the incidence of lung 
cancer in Europe for the 1998–2007 period, with 95% confidence intervals, in lung can-
cer incidence by age group and sex
Men Women
Region Country 35–64 yrs 65–74 yrs 35–64 yrs 65–74 yrs
Central and eastern Europe
Belarus -2.5* (-3.1; -1.9) -0.4 (-1.3; 0.4) 2.5* (0.1; 4.8) -0.4 (-2.7; 2.0)
Bulgaria -0.0 (-1.0; 0.9) 1.8* (0.6; 3.1) 3.1* (1.2; 5.1) -0.5 (-2.0; 1.0)
Czech Republic -1.4* (-2.1; -0.7) -1.6 (-3.7; 0.6) 4.2* (3.1; 5.3) 2.3* (0.8; 3.8)
Poland§ -2.3* (-3.7; -0.8) -3.7* (-5.3; -2.1) 9.1* (5.6; 12.6) 3.6* (1.0; 6.4)
Russian Federation -2.2* (-2.8; -1.6) -2.0* (-2.5; -1.5) 0.2 (-0.7; 1.1) -2.7* (-3.3; -2.0)
Slovakia -1.3* (-1.9; -0.7) -1.7* (-2.3; -1.1) 5.6* (3.3; 7.9) 3.0 (-0.2; 6.4)
Northern Europe
Denmark 0.5 (-0.6; 1.5) -1.5* (-2.7; -0.4) 2.2* (1.1; 3.3) 1.5* (0.1; 3.0)
Estonia -3.9* (-5.5; -2.3) -3.0* (-4.5; -1.5) 3.8 (-0.3; 8.0) -1.5 (-4.4; 1.6)
Finland -0.2 (-1.3; 1.0) -3.8* (-4.8; -2.9) 4.3* (2.3; 6.2) 0.3 (-1.9; 2.6)
Iceland -0.9 (-6.1; 4.5) 2.5 (-2.7; 8.1) -1.5 (-5.3; 2.6) -2.2 (-8.7; 4.7)
Ireland -0.4 (-2.0; 1.3) -2.2* (-3.2; -1.2) 2.3* (0.4; 4.2) 1.2 (-0.2; 2.6)
Latvia -1.9* (-2.6; -1.2) 0.8 (-1.1; 2.8) 2.0 (-0.6; 4.6) 1.7 (-0.5; 3.9)
Lithuania -2.9* (-4.1; -1.8) -1.2* (-1.9; -0.5) 0.8 (-1.4; 3.1) -3.1* (-5.4; -0.7)
Norway 0.7 (-0.3; 1.8) 0.1 (-1.5; 1.8) 2.8* (1.3; 4.3) 4.5* (2.3; 6.7)
Sweden -0.4 (-1.9; 1.1) -0.7 (-1.6; 0.1) 3.2* (2.2; 4.2) 4.3* (3.6; 5.1)
United Kingdom§ -1.6* (-2.1; -1.1) -2.9* (-3.2; -2.6) 1.1* (0.3; 1.9) -0.6 (-1.4; 0.2)
 Southern Europe
Croatia -1.3 (-2.9; 0.3) -3.1* (-4.3; -1.8) 4.3* (1.6; 7.0) -0.1 (-3.1; 3.1)
Italy§ -5.6* (-6.7; -4.4) -3.5* (-4.4; -2.6) 1.2 (-0.2; 2.7) 1.0 (-0.9; 2.8)
Malta -1.2 (-6.2; 4.0) -2.5 (-5.7; 0.7) 8.4* (1.2; 16.0) 0.5 (-5.3; 6.7)
Slovenia 0.5 (-1.5; 2.5) -2.3* (-3.7; -0.9) 4.3* (2.8; 5.9) 0.6 (-2.0; 3.4)
Spain§ -1.9* (-3.3; -0.4) 0.1 (-0.9; 1.1) 5.2* (0.8; 9.8) 4.9* (2.5; 7.4)
Western Europe
Austria -0.9* (-1.9; -0.0) -2.8* (-3.6; -2.0) 4.1* (3.1; 5.1) 0.9 (-0.5; 2.4)
France§ 1.2* (0.5; 2.0) -0.5 (-2.1; 1.0) 6.4* (4.1; 8.7) 5.8* (3.3; 8.4)
Germany§ -2.9* (-3.5; -2.3) -3.2* (-3.8; -2.7) 4.2* (3.4; 5.1) 1.2* (0.5; 1.9)
Switzerland§ -2.6 (-5.2; 0.1) -1.4 (-4.1; 1.3) 1.7 (-1.4; 4.8) 2.5 (-0.5; 5.5)
 The Netherlands -1.6* (-3.1; -0.1) -2.5* (-2.8; -2.2) 5.1* (4.5; 5.7) 4.4* (3.5; 5.2)
§Regional registries: France (Doubs, Herault, Isere, Haut-Rhin, Somme, Tarn); Germany (Brandenburg, Hamburg, 
Saxony, Mecklenburg, North Rhine-Westphalia, Saarland); Poland (Kielce, Cracow); Italy (Modena, Parma, Ragusa, 
Romagna, Torino, Varese); Spain (Granada, Murcia, Navarra, Tarragona); Switzerland (Geneva, St Gall-Appenzell), 
United Kingdom (England and Scotland)
*p-value<0.05
Period for Spain is 1996–2005 
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Appendix Table 2. Average annual percentage change (AAPC) for the 1998–2007 period, 
with 95% confidence intervals in oral cavity and pharyngeal cancer incidence by age 
and sex
Men Women
Region Country 35–64 yrs 65–74 yrs 35–64 yrs 65–74 yrs
Central and eastern Europe
Belarus 0.6 (-0.6; 1.8) 1.1 (-1.1; 3.2) 1.2 (-1.0; 3.5) -4.6* (-7.7; -1.5)
Bulgaria -1.0 (-2.4; 0.5) 1.8 (-0.4; 4.0) 4.5 (-0.4; 9.7) -1.8 (-6.7; 3.4)
Czech Republic 1.5* (0.1; 2.9) 1.4 (-0.9; 3.8) 7.9* (5.4; 10.3) 4.4* (0.1; 8.8)
Poland§ -2.4 (-6.3; 1.6) -6.2* (-10.4; 
-1.8)
3.3 (-2.7; 9.6) -0.7 (-8.0; 7.1)
Russian Federation -1.5* (-2.0; -1.1) -1.7* (-2.2; -1.2) 0.6 (-0.8; 2.1) -2.2* (-3.0; -1.3)
Slovakia -0.4 (-1.2; 0.4) 2.2* (0.7; 3.6) 5.7* (2.6; 8.9) 0.1 (-4.0; 4.4)
 Northern Europe
Denmark 1.8* (0.4; 3.2) 0.9 (-2.2; 4.1) 3.7* (1.7; 5.8) -1.0 (-4.7; 2.9)
Estonia -3.6* (-6.4; -0.8) -1.3 (-3.9; 1.4) 1.7 (-2.1; 5.7) -1.7 (-12.1; 10.0)
Finland 1.0 (-1.3; 3.3) -2.3 (-5.0; 0.5) 4.5* (2.4; 6.7) 3.4 (-0.4; 7.5)
Iceland 1.3 (-11.8; 16.4) 4.7 (-10.4; 22.4) -1.1 (-12.3; 
11.6)
2.0 (-8.6; 13.9)
Ireland 1.1 (-1.3; 3.6) -3.1 (-8.2; 2.3) 2.6 (-1.5; 6.8) 6.3* (3.8; 8.9)
Latvia -1.0 (-4.1; 2.2) -2.9 (-8.4; 3.1) 4.6 (-1.8; 11.3) -4.3 (-8.9; 0.6)
Lithuania -0.9 (-2.8; 1.0) -0.3 (-3.0; 2.5) 0.7 (-4.6; 6.4) -0.1 (-3.8; 3.6)
Norway -0.4 (-2.1; 1.4) 0.7 (-1.0; 2.5) 1.8 (-2.9; 6.7) 5.8* (0.3; 11.7)
Sweden 0.9 (-0.2; 2.1) -0.7 (-3.3; 1.9) 1.3 (-2.1; 4.9) 2.3 (-0.2; 5.0)
United Kingdom§ 3.5* (2.8; 4.1) 1.4* (0.1; 2.8) 2.4* (1.4; 3.4) 1.1* (0.2; 2.0)
 Southern Europe
Croatia -3.1* (-5.9; -0.3) -3.9 (-7.8; 0.2) -3.1 (-7.2; 1.1) 0.1 (-2.3; 2.6)
Italy§ -3.6* (-4.3; -2.9) -0.7 (-3.1; 1.8) 2.3 (-1.6; 6.2) 2.2 (-1.0; 5.5)
Malta 2.5 (-5.5; 11.1) -4.4 (-13.1; 5.1) 2.4 (-5.2; 10.6) 11.8 (-13.5; 44.7)
Slovenia -1.6 (-3.6; 0.5) -4.3* (-6.3; -2.2) 0.3 (-2.9; 3.6) 2.0 (-6.3; 10.9)
Spain§ -5.4* (-6.9; -3.9) -4.6* (-6.9; -2.3) 0.9 (-6.1; 8.3) 1.1 (-4.4; 6.9)
 Western Europe
Austria -0.6 (-1.8; 0.6) -0.3 (-2.3; 1.6) 1.6 (-0.8; 4.0) 0.7 (-3.9; 5.5)
France§ -2.7* (-4.2; -1.2) -1.8 (-4.6; 1.1) 1.8 (-2.2; 6.0) 4.2 (-1.2; 9.9)
Germany§ 1.7* (0.9; 2.4) 1.8* (0.1; 3.6) 3.7* (2.0; 5.5) 3.3* (0.8; 5.7)
Switzerland§ -3.7 (-7.5; 0.3) -2.3 (-7.2; 2.9) 1.9 (-4.6; 8.8) -1.4 (-11.5; 9.8)
 The Netherlands 0.0 (-1.3; 1.4) -1.1 (-3.0; 0.9) 2.0* (0.8; 3.2) 2.2 (-0.2; 4.7)
§Regional registries: France (Doubs, Herault, Isere, Haut-Rhin, Somme, Tarn); Germany (Brandenburg, Hamburg, 
Saxony, Mecklenburg, North Rhine-Westphalia, Saarland); Poland (Kielce, Cracow); Italy (Modena, Parma, Ragusa, 
Romagna, Torino, Varese); Spain (Granada, Murcia, Navarra, Tarragona); Switzerland (Geneva, St Gall-Appenzell), 
United Kingdom (England and Scotland)
*p-value<0.05
Period for Spain is 1996–2005
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Appendix Table 3. Average annual percentage change (AAPC) for the 1998–2007 period, 
with 95% confidence intervals in laryngeal cancer incidence by age and sex
 
Men Women
Region Country 35–64 yrs 65–74 yrs 35–64 yrs 65–74 yrs
Central and eastern Europe
Belarus -1.4 (-3.4; 0.6) 0.0 (-2.0; 2.1) 0.1 (-8.2; 9.2) 7.7 (-9.2; 27.7)
Bulgaria 1.8* (0.6; 2.9) 5.7* (2.4; 9.1) 3.9 (-1.4; 9.5) 0.9 (-7.3; 9.9)
Czech Republic -0.4 (-1.6; 0.9) 1.4 (-0.6; 3.4) -1.5 (-5.6; 2.8) 0.2 (-7.9; 8.9)
Poland§ -6.0* (-8.3; -3.7) -7.4* (-11.4; 
-3.3)
-6.3 (-15.4; 3.9) -3.0 (-14.4; 9.9)
Russian Federation -2.0* (-2.5; -1.5) -1.9* (-2.6; -1.2) 0.7 (-1.1; 2.5) -2.6* (-4.7; -0.4)
Slovakia -1.6 (-3.5; 0.3) 1.7 (-1.9; 5.4) 0.9 (-8.5; 11.3) 3.3 (-7.6; 15.5)
Northern Europe
Denmark 0.4 (-2.7; 3.6) -1.9 (-4.9; 1.2) 0.1 (-8.0; 8.9) 0.6 (-6.0; 7.6)
Estonia -5.4* (-9.1; -1.7) -0.1 (-5.7; 5.9) -2.0 (-13.8; 
11.6)
-4.4 (-16.6; 9.6)
Finland -0.7 (-4.2; 3.0) -0.8 (-5.3; 4.0) 8.1 (-0.2; 17.0) -11.8* (-18.7; 
-4.4)
Iceland -13.7* (-25.0; 
-0.6)
-6.6 (-18.5; 7.1) -11.1 (-21.3; 
0.4)
-0.1 (-15.2; 17.6)
Ireland -0.1 (-2.2; 2.1) 2.3 (-3.0; 7.9) -2.1 (-9.9; 6.4) 2.1 (-8.9; 14.4)
Latvia 0.7 (-1.9; 3.3) -1.2 (-6.5; 4.3) 7.2 (-4.7; 20.6) -2.1 (-17.5; 16.1)
Lithuania -0.7 (-2.6; 1.3) 0.0 (-4.4; 4.6) 3.6 (-5.4; 13.5) 5.7 (-10.6; 24.9)
Norway -0.6 (-5.1; 4.0) -1.8 (-5.9; 2.4) 0.1 (-7.0; 7.7) -8.1 (-18.8; 4.0)
Sweden 0.9 (-3.1; 5.1) -2.3* (-4.2; -0.3) 0.6 (-6.6; 8.4) -0.9 (-8.2; 7.0)
United Kingdom§ -0.2 (-3.4; 3.1) -1.5* (-2.9; -0.2) -1.0 (-3.1; 1.2) -3.1* (-4.4; -1.8)
Southern Europe
Croatia -1.6 (-3.3; 0.2) -4.2* (-7.8; -0.5) 0.1 (-7.2; 8.0) -6.2 (-13.4; 1.7)
Italy§ -4.0* (-5.6; -2.4) -3.9* (-6.5; -1.2) 4.2 (-0.7; 9.2) 0.7 (-8.0; 10.2)
Malta -3.7 (-10.4; 3.6) 1.6 (-11.0; 15.9) 4.6 (-12.4; 24.8) 6.6 (-7.5; 22.9)
Slovenia -2.1 (-5.7; 1.7) -2.4 (-6.6; 2.1) 1.8 (-7.7; 12.3) -13.8* (-22.2; 
-4.5)
Spain§ -4.4* (-5.5; -3.4) -3.4 (-7.0; 0.4) 6.3 (-3.8; 17.4) -0.8 (-16.0; 17.2)
Western Europe
Austria -2.0* (-3.6; -0.4) -4.2* (-6.9; -1.3) 2.5 (-2.4; 7.7) -4.4 (-12.6; 4.5)
France§ -1.9 (-3.9; 0.1) -2.0 (-5.1; 1.1) -0.9 (-6.3; 4.8) -5.3 (-18.2; 9.7)
Germany§ -1.3 (-3.0; 0.4) -0.0 (-2.2; 2.1) 2.7 (-2.8; 8.4) -0.9 (-7.3; 6.0)
Switzerland§ -7.6* (-12.8; -2.0) -1.5 (-7.9; 5.4) 0.8 (-13.0; 16.7) 14.8 (-2.4; 35.1)
 The Netherlands -1.0 (-2.4; 0.5) -3.3* (-5.0; -1.5) 0.3 (-2.5; 3.2) -2.8 (-9.3; 4.1)
§Regional registries: France (Doubs, Herault, Isere, Haut-Rhin, Somme, Tarn); Germany (Brandenburg, Hamburg, 
Saxony, Mecklenburg, North Rhine-Westphalia, Saarland); Poland (Kielce, Cracow); Italy (Modena, Parma, Ragusa, 
Romagna, Torino, Varese); Spain (Granada, Murcia, Navarra, Tarragona); Switzerland (Geneva, St Gall-Appenzell), 
United Kingdom (England and Scotland)
*p-value<0.05
Period for Spain is 1996–2005
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Appendix Table 4. Average annual percentage change (AAPC) for the 1998–2007 period, 
with 95% confidence intervals in oesophageal cancer incidence by age and sex
Men Women
Region Country 35–64 yrs 65–74 yrs 35–64 yrs 65–74 yrs
Central and eastern Europe
Belarus 2.0* (0.6; 3.5) 2.1 (-1.0; 5.3) -0.0 (-7.2; 7.7) -0.4 (-7.3; 7.1)
Bulgaria 0.3 (-6.6; 7.7) 0.1 (-3.4; 3.7) 1.9 (-5.3; 9.7) -1.3 (-7.4; 5.3)
Czech Republic 1.0 (-1.6; 3.7) 3.1* (0.8; 5.6) 6.5 (-0.5; 13.9) 1.4 (-3.6; 6.6)
Poland§ -1.3 (-7.0; 4.9) -1.4 (-5.9; 3.4) 9.7 (-2.8; 23.8) -4.5 (-14.3; 6.3)
Russian Federation -0.9 (-1.9; 0.1) -2.2* (-3.3; 
-1.0)
-2.5* (-4.8; -0.1) -4.9* (-5.9; -4.0)
Slovakia -1.5 (-4.2; 1.2) 0.2 (-4.1; 4.7) 2.1 (-9.9; 15.9) 2.0 (-6.5; 11.3)
Northern Europe
Denmark 0.7 (-1.8; 3.3) -0.9 (-4.4; 2.7) 3.8* (0.6; 7.2) 2.2 (-2.9; 7.6)
Estonia 0.7 (-4.9; 6.6) -4.0 (-10.9; 
3.4)
8.7 (-5.2; 24.8) -1.9 (-15.1; 13.3)
Finland 4.1* (0.6; 7.8) 0.2 (-4.4; 5.0) 3.8 (-3.6; 11.7) -0.6 (-5.2; 4.2)
Iceland -2.8 (-15.2; 11.5) 10.7* (2.5; 
19.5)
6.6 (-1.9; 15.9) 8.2 (-3.8; 21.7)
Ireland 2.6 (-1.0; 6.4) 0.4 (-2.6; 3.4) -0.1 (-3.4; 3.3) -0.6 (-5.3; 4.3)
Latvia 1.9 (-1.8; 5.8) 3.4 (-2.3; 9.5) 2.0 (-9.4; 14.8) 13.7* (1.9; 26.8)
Lithuania 2.7* (0.8; 4.6) -0.1 (-3.8; 3.6) 2.1 (-3.3; 7.8) 0.2 (-10.1; 11.7)
Norway 4.2* (0.7; 7.8) -0.4 (-4.6; 3.9) -2.4 (-7.7; 3.2) 0.1 (-6.4; 7.1)
Sweden 1.3 (-1.9; 4.7) -0.0 (-2.7; 2.7) 2.3 (-9.8; 15.9) -1.0 (-5.2; 3.3)
United Kingdom§ 1.9* (1.3; 2.5) 0.8* (0.4; 1.2) 0.8 (-0.4; 2.0) -1.5* (-2.8; -0.2)
Southern Europe
Croatia -1.4 (-2.8; 0.1) -1.8 (-4.6; 1.1) -5.1 (-12.7; 3.2) -0.8 (-13.9; 14.1)
Italy§ -2.5 (-6.2; 1.5) -4.6 (-9.6; 0.6) -3.4 (-9.5; 3.2) 0.3 (-6.7; 7.9)
Malta 4.1 (-4.7; 13.8) 3.3 (-9.9; 18.3) 6.9 (-10.0; 27.1) 11.2 (-1.3; 25.2)
Slovenia 0.1 (-3.0; 3.2) -5.3 (-10.9; 
0.6)
2.8 (-6.8; 13.5) -9.0* (-16.4; -1.0)
Spain§ -4.2* (-6.9; -1.3) 0.1 (-3.4; 3.8) 4.4 (-6.6; 16.6) 0.2 (-11.5; 13.5)
Western Europe
Austria 2.3* (0.5; 4.2) -1.8 (-3.6; 0.1) 1.8 (-3.2; 6.9) 0.6 (-3.1; 4.5)
France§ -2.1* (-4.0; -0.1) -3.8* (-5.9; 
-1.7)
4.7 (-0.4; 10.0) 1.3 (-6.1; 9.2)
Germany§ 0.1 (-0.9; 0.7) 1.6* (0.3; 2.9) 0.9 (-2.9; 4.7) 0.8 (-1.8; 3.6)
Switzerland§ -1.0 (-5.6; 3.9) -0.4 (-5.1; 4.4) 3.2 (-0.9; 7.4) 1.7 (-18.6; 27.1)
 The Netherlands 4.4* (3.1; 5.7) 2.1* (0.6; 3.7) 2.9* (1.2; 4.7) 2.6* (0.5; 4.9)
§Regional registries: France (Doubs, Herault, Isere, Haut-Rhin, Somme, Tarn); Germany (Brandenburg, Hamburg, 
Saxony, Mecklenburg, North Rhine-Westphalia, Saarland); Poland (Kielce, Cracow); Italy (Modena, Parma, Ragusa, 
Romagna, Torino, Varese); Spain (Granada, Murcia, Navarra, Tarragona); Switzerland (Geneva, St Gall-Appenzell), 
United Kingdom (England and Scotland)
*p-value<0.05
Period for Spain is 1996–2005
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Appendix Figure 1. Average annual percentage change (AAPC) between 1998–2007 
(except 1996–2005 for Spain) and age-standardised (European) incidence rates (ASR) 
of the most recent year of laryngeal cancer in women aged 35–74. 
Dots indicate statistically significant AAPC (p≤0.05); triangles indicate non-significant AAPC. Colours indicate Euro-
pean regions: Central and eastern (blue), northern (green), southern (red) and western (brown).
§ regional registries
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Appendix Figure 2. Average annual percentage change (AAPC) between 1998–2007 
(except 1996–2005 for Spain) and age-standardised (European) incidence rates (ASR) 
of the most recent year of oesophageal cancer in men aged 35–74. 
Dots indicate statistically significant AAPC (p≤0.05); triangles indicate non-significant AAPC. Colours indicate Euro-
pean regions: Central and eastern (blue), northern (green), southern (red) and western (brown).
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Appendix Figure 3. Average annual percentage change (AAPC) between 1998–2007 
(except 1996–2005 for Spain) and age-standardised (European) incidence rates (ASR) 
of the most recent year of oesophageal cancer in women aged 35–74. 
Dots indicate statistically significant AAPC (p≤0.05); triangles indicate non-significant AAPC. Colours indicate Euro-
pean regions: Central and eastern (blue), northern (green), southern (red) and western (brown).
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 2.2
International trends in lung cancer 
incidence by histological subtype: 
Adenocarcinoma stabilizing in men 
but still increasing in women
Lortet-Tieulent J, 
Soerjomataram I, 
Ferlay J, 
Rutherford M, 
Weiderpass E, 
Bray F
Lung Cancer 84 (2014) 13–22
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aBSTRaCT
Objectives: Trends in overall lung cancer incidence in different countries reflect the 
maturity of the smoking epidemic. Further understanding of the underlying causes for 
trends over time can be gained by assessing the trends by sex and histological sub-
type. We provide a temporal analysis of lung cancer incidence in 12 populations (11 
countries), with a focus on cohort-specific trends for the main histological subtypes 
(squamous cell carcinomas (SCC), adenocarcinomas (AdC), and small cell carcinoma). 
Material and Methods: We restrict the analysis to population-based registry data of 
sufficient quality to provide meaningful interpretation, using data in Europe, North 
America and Oceania, extracted from successive Cancer Incidence in Five Continents 
Volumes. Poorly specified morphologies were reallocated to a specified grouping on a 
population, 5-year period and age group basis. 
Results: In men, lung cancer rates have been declining overall and by subtype, since 
the beginning of the study period, except for AdC. AdC incidence rates have risen 
and surpassed those of SCC (historically the most frequent subtype) in the majority 
of these populations, but started to stabilize during the mid-1980s in North America, 
Australia and Iceland. In women, AdC has been historically the most frequent subtype 
and rates continue to increase in most populations studied. Early signs of a decline in 
AdC can however be observed in Canada, Denmark and Australia among very recent 
female cohorts, born after 1950. 
Conclusions: The continuing rise in lung cancer among women in many countries re-
inforces the need for targeted smoking cessation efforts alongside preventive actions.
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InTRODuCTIOn
With 1.6 million new cases and 1.4 million deaths in 2008, lung cancer remains the 
most frequent cause of cancer worldwide and the leading cause of cancer death in 
men and women in 91 and 17 countries respectively, with the lifetime cumulative 
risk (ages<75) over 7% in men in several Eastern European countries [1]. Lung 
cancer patterns are largely determined by past exposure to tobacco smoking; pooled 
estimates indicate over 90% of cases are due to smoking among men and over 80% 
among women [2], although there is considerable variation by world region. 
By 1930, decades after smoking had become common among men, the tobacco indus-
try began to capitalize on changing social attitudes, promoting smoking as a symbol 
of women empowerment [3]. As a consequence of uptake of the habit, the incidence 
of female lung cancer began increasing in the 1970’s in Western countries such as in 
the U.S. [4] and in Europe [5]. Declines in lung cancer incidence among men tended 
to follow the earlier uptake and cessation in those U.S. and European populations and 
for which rates have historically been highest [4] [5]. 
Lung cancer trends are more complex on stratification by histological subtype, and 
insight may be gained by assessing trends according to the well-established etiology 
by histology [2;6]. Smoking increases risk of all subtypes of lung cancer, with the 
risk greater for squamous cell and small cell carcinomas than for adenocarcinomas. 
Adenocarcinoma is consistently more frequent in women than men (in both smokers 
and non-smokers), with increasing rates of this subtype observed in both sexes in 
many high income settings [7;8]. 
We provide a temporal analysis of lung cancer incidence in 11 countries across three 
continents, with a focus on cohort-specific trends by histological subtype and sex. 
The results are discussed according to current etiological evidence regarding smoking 
and risk by subtype, alongside differences reported in tobacco consumption in these 
populations.
MaTERIaLS anD METHODS
Data Sources
New cases of lung cancer (ICD-10 C33-34) were extracted by histology, year of diag-
nosis, sex and age from population-based cancer registries for the period 1973-2002 
contained within CI5Plus Detailed [9], a database of successive volumes of the Cancer 
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incidence in Five Continents (CI5) series. The specific inclusion requirement was at 
least 15 consecutive years of data and compilation in the last volume of the CI5 series 
(volume IX, covering the period 1998-2002), a criterion indicative of each registry’s 
data quality over time. 
We further restricted analysis to registries that met all of the following criteria (based 
on the mean percentages across each CI5 volume for each registry): ≥80% of micro-
scopically-verified cases, ≤5% of cases reported by death certificates only and ≤25% 
of cases recorded with morphology poorly specified (as defined as either unspecified 
lung cancers or unspecified lung carcinomas). Registry datasets in 11 countries (two 
populations in the USA: Blacks and Whites) met all of the above conditions; with 
national registry data available for two countries (Denmark and Iceland). For the 
remaining countries, regional registries were aggregated to obtain a proxy of national 
incidence (36 regional registries in total, see Table 1, footnote). The varying start-up 
and final years available for each registry by country led to a pragmatic selection of 
registries that sought to maximise both the number of included registries and the 
length of period of study. The time span of observations by country varied from 15 
to 30 years (Table 1). Corresponding population data were obtained from the same 
sources as incidence. 
Reallocation of unspecified morphologies over specified subtypes
The data were extracted based on the ICD-O-2 groupings [10] [11] [12]: (1) Carci-
noma partitioned into the following sub-groups: (1.1) Squamous-cell carcinoma, (1.2) 
Adenocarcinoma, (1.3) Small cell carcinoma, (1.4) Large cell carcinoma, (1.5) Other 
specified carcinoma, (1.6) Unspecified carcinoma; (2) Sarcoma; (3) Other specified 
cancer; (4) Unspecified cancer. 
To enable comparisons of rates by subtype, we first reallocated those lung cancer 
cases with unspecified morphologies. Lung cancer cases were partitioned into three 
age groups (35-54, 55-64 and 65-74 years) and the proportion of each histological 
group on a registry, 5-year period and age group basis calculated and used to and 
then proportionally reallocate cases with unspecified cancer (4) to the three speci-
fied groups (1), (2) and (3). Secondly, we reallocated unspecified carcinoma cases 
(1.6) to specified carcinoma cases (1.1), (1.2), (1.3), (1.4) and (1.5). The results are 
presented for lung cancer and for the four major histologies: squamous-cell carcinoma 
(SCC), adenocarcinoma (AdC), small cell carcinoma and large cell carcinoma.
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Statistical methods
Cases were stratified by sex and 5-year age group and analyses restricted to the ages 
35-74. Truncated age-standardized incidence rates (ASR) per 100,000 were estimated 
using the world standard [13]. Ten-year cohorts were obtained on subtracting the 
midpoints of 5-year age groups and 5-year calendar periods. The trends are presented 
as rates versus birth cohort by age for each sex and subtype. We selected eight 
populations with sufficiently large numbers of cases and at least a 20-year data span, 
to ensure meaningful analyses and interpretation. 
Assuming incidence rates were constant within 5-year age and periods, an age-period-
cohort (APC) model was fitted on assuming the number of cases followed a Poisson 
random variable with the logarithm of the person-years at risk specified as an offset:
log(λ(a, p)) = αa + βp + γc
where λ refers to the rate, αa, βp and γc are functions of age a, period p and birth 
cohort c. Birth cohorts c are computed as c = p - a. The effects were estimated and 
presented using the full APC model. The relative simplicity of fitting APC models belies 
difficulties in providing an informed presentation of the model parameters, given the 
irresolvable issue of non-identifiability. In order to provide a unique, non-arbitrary 
solution, we constrained the linear component of the period effect to have zero slope, 
and therefore assumed that the linear changes in trends were cohort-related. This 
was considered reasonable given the overwhelming evidence that exposure to tobacco 
and changes in its prevalence are influenced by societal and peer-related factors, 
placing successive generations of men and women at higher (or lower) risk of lung 
cancer. As the solution presented is entirely dependent on choice of allocation of the 
trend (drift) [14], caution is needed when interpreting the results. The model analysis 
and presentation was performed using APCfit [15] in Stata [16]. We used the default 
number of internal knots for each of the spline bases for the three variables (a, p and 
c), i.e. 4, and hence the knots were placed at each quintile (except for Australia, where 
we used 3 knots over the period). The vertical lines indicate the specific cohorts for 
which the male and female cohorts reach their maximum risk, by subtype. 
RESuLTS
Trends in overall lung cancer incidence: age-adjusted rates in 1973-2002 by sex
The ASR of lung cancer incidence (ages 35-74) have changed markedly from the 
1970s in all studied countries, with major variations in the sex-specific scale of the 
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burden and the direction and magnitude of trends (Figure 1). Rates are higher in men 
than women, with incidence trends among men declining at variable periods, except 
in Spain, where increases continue to be observed. In contrast, female rates steadily 
increased over the study period, and only in those countries where burden is now 
relatively high (the U.S., possibly Australia, Canada, Denmark), have rates showed 
signs of a plateau. The most recent rates among men vary 2.5-fold, from 176.9 (per 
100 000), among U.S. Blacks, to 73.6 in Iceland (Table 1). The U.S. black population 
have the highest female rates (91.7) compared with low-risk Spain (17.0). 
Trends in lung cancer incidence by histological type: age-adjusted rates in 
1973-2002 by sex
Among men, SCC has been the most frequent subtype in all studied countries, with 
incidence rates decreasing over the study period (Figure 1). Adenocarcinoma (AdC) 
rates started to stabilize during the mid-1980s in North America, Australia and Ice-
land, yet was the most common subtype in recent years in all countries except France, 
Spain and The Netherlands. Small cell carcinoma rates are also in decline, largely in 
parallel with SCC. Large cell carcinoma is the least frequent subtype in both sexes. 
Two notable facts emerge when examining female lung cancer trends by subtype. AdC 
has been rising steadily in all countries, irrespective of trends of the other subtypes. 
The subtype has predominated in every population in the last decade (with the excep-
tion of The Netherlands) with the rate of change in AdC often greater than those 
observed for the other subtypes with calendar time. 
Trends in lung cancer incidence by histological type: rates vs. birth cohort
Figures 2a and 2b illustrate the SCC and AdC trends versus birth cohort by age in eight 
countries by sex. The parallelism of the curves indicates the influence of generation 
on risk of both SCC and AdC. The peak incidence of SCC among men has occurred 
in all eight populations, with rates uniformly decreasing in generations born after 
1930, or even earlier (circa 1915) in Australia. The generational declines in AdC cases 
started later than SCC, among men born during WWII in North America, Denmark and 
Australia. Conversely, the male rates are uniformly rising in successive generations 
born up to and including the 1960s cohorts in France and Spain. 
In women, the marked cohort-specific declines in SCC in North America, Denmark 
and Australia began in cohorts born around WWII, the same generation for which a 
decrease in AdC was observed in men. The trends elsewhere are less easy to interpret 
given the random variation inherent due to small numbers. AdC rates among women 
rose in successive generations in each population, with an stabilization of incidence 
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Figure 1.Lung cancer age-adjusted (World standard) incidence rates over time, by popu-
lation and sex, by morphological subtype, for ages 35-74. 
The black line represents all morphologies combined.
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trends in Canada, Denmark and Australia among recent cohorts, born in the 1950s or 
thereafter. 
age-period-cohort analyses: comparisons of cohort trends in SCC and adC by 
sex
Figure 3 summarizes the observed histological subtype- and sex-specific trends by 
population. The peak in risk of SCC consistently precedes that of AdC (except in 
Spain), in both sexes. The highest risk of SCC in men occurs during the beginning 
of the observation period, among cohorts born early in the 20th century, while the 
corresponding peak in women is found in cohorts born 20 to 55 years later. The time 
lag between maximum rate ratios of the two subtypes varies greatly across countries, 
from zero to 60 years. The maximum risk of AdC among women is observed in the 
most recent cohorts – in all populations except US Whites and Australia – affect-
ing generations born after 1960, and in selected populations in men (France, The 
Netherlands). Of note are the uniformly increasing rates among female birth cohorts 
in France and Spain, with few signs of recent stabilization, irrespective of subtype. 
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Figure 3. Cohort parameters form the APC model based on the assumption of a zero 
slope (drift taken up entirely by cohort) by population, subtype and sex. 
The vertical lines indicate the specific cohorts for which the male and female cohorts reach their maximum risk, by 
subtype.
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DISCuSSIOn
This study reports the variation in lung cancer patterns and trends across subtypes 
by sex in 11 countries worldwide and serves to illustrate the varying phases of the 
tobacco epidemic and subsequent temporal development and impact of the lung can-
cer epidemic by histology in each population[17]. The overall lung cancer trends are 
largely the product of changing prevalence in smoking (the proportion of the population 
who smoke regularly) and patterns of tobacco consumption (e.g. the amount smoked 
and composition of the cigarette). In North America, Australia and Denmark, where 
rates have been elevated, decreasing lung cancer trends in men have been observed 
for a number of decades, while rates have now begun to level off among women. 
In a second group of countries (Austria, France, Iceland, Italy, the Netherlands and 
Switzerland), male rates have been declining in contrast to the rising rates in women. 
Spain is perhaps the exception in that increasing rates are observed in both men and 
women. 
The trends by subtype present a somewhat different picture. Among men, in most 
countries that we studied, AdC was the most predominant subtype of lung cancer in 
1998-2002, as compared to 20 years before when SCC represented the most frequent 
of all subtypes (except in Iceland). This shift from SCC to AdC had already been 
observed in previously published studies at national level (in the US [18], Japan [19], 
Lithuanian men [20] and international level [2;7;8]. Not only did women start smoking 
cigarettes later, they also smoked lower-tar brands [21] and consequently developed 
a somewhat different profile of histological subtypes compared with men. In women, 
AdC was the most frequent subtype of lung cancer throughout the study period, with 
few exceptions (before the 1990s in France, in 1980 in Spain and in 1975 in The Neth-
erlands). In our study, a stabilization or decline in AdC rates are seen among younger 
women and recent cohorts, among US Whites, and in Canada, Denmark and Australia. 
The emerging predominance of AdC can be related to three factors. Firstly, the change 
in cigarette manufacturing; the rise of filtered, lower tar- and nicotine-containing 
cigarettes, smokers have tended to satiate nicotine needs by inhaling deeper [21], 
leading to a more peripheral distribution of tobacco smoke in the lung. This promotes 
a shift from central tumors (SCC and small cell carcinomas) to peripheral tumors (AdC 
and large cell carcinomas). Other changes in cigarette composition and design could 
partially explain the surge in AdC. including the decrease in polycyclic aromatic hydro-
carbons in manufactured cigarettes which are SCC inducers, alongside the increase in 
tobacco-specific N-nitrosamines, which are AdC inducers [4]. Tobacco companies have 
introduced products marketed in a manner that implies they are “safer”, yet research 
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indicates that there is no completely safe form of tobacco [22]. The results presented 
here show that the shift to filtered/low-tar cigarettes has merely altered the type of 
lung cancer. 
Secondly, the risk of SCC and small cell carcinoma lung cancers increases more rapidly 
with increasing smoking duration than AdC [23]. Hence SCC is the first subtype to 
develop, and then AdC appears later. Thirdly, while the relative risk of all types of 
lung cancer decreases after quitting smoking, the risk of small cell carcinoma and SCC 
decrease more rapidly after cessation than for AdC [23]. The high risk of AdC for a lon-
ger period after quitting is in line with the higher exposure required for inducing AdC 
compared with SCC (deeper inhalation and longer exposure). SCC is more strongly 
related to smoking, while AdC is seen both in smokers and non-smokers, and is the 
most common type in never-smokers [2;4;23]. Since the risk of AdC decreases less 
rapidly after smoking cessation than for small cell carcinoma and SCC, the reduction 
in AdC (commonly the predominant subtype presently) will likely be seen later than 
for SCC where tobacco cessation is observed generationally. 
Additional explanations for the distinct SCC and AdC trends could include the impact 
of the atmospheric pollution, as it has been estimated that 3% of lung cancer deaths 
are due to urban air pollution in high-income countries [24]. Air pollution, particularly 
oxides of nitrogen, had been suggested to increase AdC, but the absence of change 
in AdC rates among never smokers makes this hypothesis less tangible [25]. While 
indoor smoke from solid fuel use and limited ventilation is a known risk factor for lung 
cancer [24], it would have a limited impact in our study, given this study excluded all 
but high-income countries where such household use is very infrequent. Few stud-
ies have investigated occupational risk in relation to specific histological subtypes 
[26;27]. Given a maximum of 10% of lung cancer deaths among men and 5% among 
women worldwide have been estimated to be attributable to exposure of eight oc-
cupational lung carcinogens [4], such changes alone are unlikely to explain the shift 
in subtypes that we observe. In a large Nordic study [28] occupational risk patterns 
were quite similar in all main histological subtypes of lung cancer, although earlier 
case-control studies in British Columbia and Turkey had reported histology-specific as-
sociations [26;27]. Change in classification and coding, including improved diagnostic 
methods for peripheral tumors may partially explain such changes, although as Burns 
[25] has stated for the U.S., while changes in histological classification and diagnostic 
techniques may have contributed to the increase in adenocarcinoma of the lung, they 
are unlikely to explain the magnitude of the observed change.
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Several limitations warrant mention. First, the data are somewhat limited as they cap-
ture trends only to 2002, although such availability is in line with studies to comparing 
incidence trends by histological subtype in several countries ([7] [8] [29]). 
Only two registries had national coverage (Iceland and Denmark). For the other 
countries, we used regional data and assumed the regional registry datatset(s) were 
nationally representative. 
The extent to which poorly-specified histology (morphology unspecified or specified 
only as carcinoma) impacts on the interpretation of the trends is an obvious concern. 
The reallocation procedure has been shown to perform robustly in previous analyses 
[7], and as in that study, we restricted analysis to populations with 25% or fewer 
cases with poorly-specified morphologies. Further, in the Appendix, we noted that 
temporal trends based on the original and the reallocated rates were very similar, and 
in terms of the relative frequency and ranking of subtypes across calendar periods. 
The strict inclusion criteria narrowed our study to 12 long-term high-quality registry 
populations, all of them representing highly developed countries. 
In APC modeling, it is not possible to identify the linear trends attributable to period 
or birth cohort. As tobacco uptake and cessation is largely a cohort-related behavior 
– most users begin as young adults and carry the habit through adulthood – the 
incidence rate ratios are presented assuming that the linear trend is entirely due to 
birth cohort. We cannot however exclude the possibility of some underlying period-
based linear trends, driven, for example, by a gradual increasing awareness of health 
hazards of smoking supported by emerging tobacco control laws. 
The continuing increases in lung cancer and the concomitant increase in AdC, par-
ticularly among women, are of concern. Recent tobacco control policies may further 
reduce the burden in the longer term given laws that prohibit smoking in public places 
(e.g. Ireland in 2004 and Italy in 2005), or prohibit sales to minors (e.g. France in 
2011, Hungary in 2013) are quite new. Smoking cessation and prevention actions 
against smoking initiation are evidently still needed, and careful monitoring of trends 
in tobacco and tobacco-related diseases is one of the key requirements in planning 
and evaluating tobacco control [30]. Therefore, this dissemination of detailed trends 
in lung cancer should provide key information on priorities for targeting the primary 
prevention of many tobacco-related cancers and other noncommunicable diseases.
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aPPEnDIx
Comparison of the incidence rates in each histological subtype before and after real-
location of the unspecified morphology cases, the unspecified carcinoma cases and 
the non-small cell carcinoma cases. Men in Italy had the most important proportion 
of poorly specified morphologies (i.e. the sum of the unspecified lung cancers and 
unspecified lung cancer carcinomas). No cases of non-small cell carcinomas were 
diagnosed in this population.
It was noted that following the introduction of the ICD-O-3 classification in 2000 [12], 
a new code had been introduced for non-small cell carcinoma (8046M), while minor 
changes had also been implemented in grouping histological codes. Because the ICD-
O-3 classification had been used by some registries for the last period studied (1998-
2002), we extracted the data directly from the last volume of CI5 (volume IX). We 
then made the back-conversion from ICD-O-3 to ICD-O-2 using the SEER conversion 
program (http://seer.cancer.gov/tools/conversion). Thus, after having performed the 
reallocation of unspecified morphologies over specified subtypes, we also proportion-
ally reallocated non-small cell carcinoma (8046M, affecting data from volume IX only) 
to the lung carcinoma sub-groups: (1.1), (1.2) and (1.4). The temporal trends based 
on the original and the reallocated rates were very similar (see Appendix Figure). The 
relative frequency of each subtype remained unchanged across calendar periods (the 
ranking in the subtypes was preserved). 
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Appendix Figure 1
Lung cancer age-adjusted (World standard) incidence rates over time, in Italian registries, in men, by morphological 
subtype, for ages 35-74, before and after the reallocation of ill-defined morphological subtypes.
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aBSTRaCT
Introduction: In the U.S., people of different races/ethnicities have differences in 
cancer incidence, mortality, survival, stage at diagnosis, and receipt of treatment, 
resulting in variances in cancer burden. The burden of cancer in 2011 was assessed by 
race/ethnicity for 24 cancers using disability-adjusted life years (DALYs).
Methods: In 2014–2015, DALYs and their two components were estimated (years of 
life lost [YLLs] and years lived with disability) by race/ethnicity using population-based 
cancer registry data collected in 2013, vital statistics, and literature reviews.
Results: A total of 9.8 million DALYs (91% YLLs) were lost to cancer. Half of DALYs were 
due to lung (24%), breast (10%), colorectal (9%), and pancreatic (6%) cancers. Age-
standardized DALY rate (ASR) ratios of non-Hispanic blacks (NHBs) over non-Hispanic 
whites (NHWs) for “all cancers” were 1.3 (95% CI:1.2, 1.4) times higher in men and 
1.2 (95% CI:1.2, 1.3) times higher in women (ASR in NHBs 4,003 per 100,000 in 
men and 3,329 in women vs 3,088 and 2,758 in NHWs, respectively); ASRs were 
also higher in NHB for 15 cancers. Compared with NHWs, Hispanics and non-Hispanic 
Asians exhibited lower ASR for “all cancers” and common cancers, contrasting with a 
higher ASR for infection-related cancers (stomach, liver, cervix).
Conclusions: The cancer burden was highest in NHBs, followed by NHWs, Hispan-
ics, and non- Hispanic Asians. In all races/ethnicities, the cancer burden was largely 
driven by YLLs, highlighting the need to prevent death at middle age through broad 
implementation of structural and behavioral measures of primary prevention, early 
detection, and treatment.
3The smoking share of the cancer burden in the United States 113
InTRODuCTIOn
Mortality is considered the best measure for monitoring progress against cancer, for 
ranking burden of disease, and for assessing racial/socioeconomic disparities between 
populations.1 However, this measure is limited by its inability to consider life years 
lost due to premature death or decreased quality of life associated with the disease. 
Disability-Adjusted Life Years (DALYs) overcome these limitations by combining mor-
tality, incidence, survival and quality of life into a summary indicator.2 It allows easy 
comparison of burdens across diseases and populations. DALYs have two components: 
Years of Life Lost (YLLs) due to premature death and Years Lived with Disability (YLDs), 
i.e. diminished health due to the disease or its treatment. One DALY is equivalent to 
the loss of one healthy year. DALYs represent a health gap, measuring the state of a 
population’s health compared to a normative goal of living the life expectancy in full 
health. They have been commonly used for assessing the burden of several diseases3,4 
across the world5,6 since the early 1990s.2
Recent cancer DALY estimates for the US include 12.4 million healthy years lost in 
2010 (Global Burden of Disease (GBD) 2010),7 14.9 million in 2012 (WHO)8 and 13.0 
million in 2013 (GBD2013).9 Only one previous study,10 in 1996, provided estimates 
by race for select cancers. However, DALYs for the US from this study and all following 
studies were based on modeled data, rather than observed data. Herein are provided 
DALYs in the US in 2011 for all cancers combined and for the 24 most common can-
cers by race/ethnicity and sex, using observed nationwide cancer incidence, survival, 
mortality and treatment data.
METHODS
Data sources and computation methods are described below and in the Supplement. 
Incidence data of tumors with a malignant behavior were extracted by sex and race/
ethnicity for the 24 most common cancers (with an age-standardized incidence rate 
>1 per 100,000 in 2011),11 and for “all other cancers” (Table S1) collected in 2013. 
Race/ethnicity was grouped as: Non-Hispanic White (NHW), Non-Hispanic Black 
(NHB), Hispanic, and Non-Hispanic Asian (NHA) (Asian or Pacific Islander). Other races 
(American Indian/Alaska Native and unknown race) were not presented separately 
(2.0% of cases) but were included in “all races/ethnicities”. “Unknown ethnicity” (992 
or 0.06% of cases) was excluded. Age was stratified into nineteen groups (0-1, 1-4, 
5-9, . . . 80–84, ≥85).12
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Data Sources and Statistical analysis
DALYs, the sum of YLLs and YLDs, were calculated by cancer, race/ethnicity and sex. 
YLLs were estimated by multiplying the number of deaths at each age group by the 
life expectancy at the mid-point for each age group, using the 2011 mortality data 
from the National Center for Health Statistics (NCHS)13 extracted via SEER*Stat ver-
sion 8.2.1, and the 2011 US life table14 (life expectancy [LE] of 76.3 years for males 
and 81.1 for females). YLDs were estimated as the incidence of disease phase or 
disease sequela by age group, multiplied by the disability weight for that phase or 
sequela, multiplied by the phase duration15 (Figure S1). The computational details 
are presented in Supplement 2, and the list of the disease phases and sequelae with 
disability weights in Table S2. For the YLDs, data from the North American Association 
of Central Cancer Registries (NAACCR) database were extracted for incidence; the 
Surveillance, Epidemiology and End Results (SEER)12 database for proportion cured, 
proportion of people treated (vs. proportion not treated, Table S3), and median time 
to death (Table S4); and SEER and a literature review for proportion of sequelae 
among patients. Disability weights issued by the GBD 2013 study were used,16 which 
establish the loss of health associated with disability related to various health states 
including cancer. These weights were based on household surveys in nine countries 
and a worldwide online survey. In total, about 17% of the participants lived in the US. 
A prior GBD study had reported high consistency in the disability weight of a health 
outcome between countries, highlighting a broad social understanding of the relative 
importance of aspects of health.17 
The burden of cancer was also assessed with age-standardized DALY rates (ASR) 
per 100,000 persons, based on the 2000 US standard population,18 for all cancers 
combined, 24 selected cancers, and all other cancers. All analyses were performed in 
2014-2015, using SAS 9.4 and Stata 13 software. ASR ratios were calculated as the 
ratios of ASR in NHB, Hispanics or NHA versus ASR in NHW. Age-specific rates were 
calculated as the number of DALYs in an age group divided by the population size, 
multiplied by 100,000.
All 95% confidence intervals (CI) were estimated via simulation (Supplement 3).19 This 
study used previously collected data without patient identifiers, and was determined to 
be exempt from full review of the NAACCR Institutional Review Board. 
RESuLTS 
The US burden of cancer in 2011 was estimated to be over 9.8 million DALYs (Figure 
1) in both sexes combined, equally shared among men (4.9 million DALYs) and women 
(4.9 million DALYs) (Table S5). Lung cancer was by far the largest contributor to loss 
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of health due to cancer, with 24% of all DALYs (2.4 million DALYs). Four cancers caused 
about half of all DALYs: lung, breast (10%), colorectum (9%) and pancreas (6%). 
Notably, 91% of the overall DALYs were due to YLLs alone. 
The ASRs for all cancers were 3,046 per 100,000 persons for men and 2,694 for women 
(Table S6). ASRs were higher in men than in women for most of the cancers, except 
for breast, thyroid and gallbladder. The highest ASRs were found for lung cancer, both 
in men (780) and women (600). In men, prostate ranked second (325), followed by 
colorectum (293), pancreas (174) and liver cancer (152). In women, breast cancer 
had the second highest ASR (554), followed by colorectum (234), pancreas (144) and 
ovary (139). 
For both sexes combined, in each race/ethnicity group, lung, breast and colorectal 
cancers were the top three cancers for DALYs, although lung cancer contributed fewer 
DALYs among Hispanics (12%) and NHA (18%) than among NHW (26%) and NHB 
(22%) (Figure 2). Breast and colorectal cancers each accounted for around 10% of all 
DALYs in each race/ethnic group. Liver cancer represented 7% of DALYs in Hispanics 
and 9% in NHA, ranking fourth in both races/ethnicities (Table S5). The share of 
Lung 24%
Breast 10%
Colorectum
9%
Pancreas 6%Prostate 5%
Leukemia 4%
Liver 4%
Brain & NS 3%
NHL 3%
Ovary 3%
All other 
cancers 28%
All races and ethnicities 
9.8 million DALYs
Figure 1. Proportion of Disability-Adjusted Life Years (DALYs) from each cancer over all 
DALYs (detailed for top 10 cancers), all races/ethnicities, in 2011
NHL: Non-Hodgkin Lymphoma; NS: nervous system
Black: Top 3 cancers for DALYs, Gray: Top 4-10 cancers, White: all other
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leukemia and stomach cancer (5-6%) in the burden of cancer was also higher among 
Hispanics and NHA. 
Figure 3 shows ASRs for both sexes combined, by cancer, and race/ethnicity separated 
into YLL and YLD components. Only for a few cancers did YLDs make up over 20% of 
DALYs: melanoma of the skin and breast, and especially for men with prostate cancer 
(45%) and women with thyroid cancer (49%) (Table S6). 
Compared to NHW, NHB had significantly higher ASRs for all cancers combined (1.3 
[95% CI: 1.2-1.4]) times higher in men and 1.2 [95% CI: 1.2-1.3] times higher in 
26%
2%
2%
3%
3%
5%
6%
7%
11%
13%
22%
All other cancers
NHL
Myeloma
Stomach
Leukemia
Liver
Pancreas
Prostate
Colorectum
Breast
Lung
B. NonWHispanic Black
30%
4%
4%
5%
5%
6%
6%
7%
10%
11%
12%
All other cancers
NHL
Brain & NS
Stomach
Prostate
Pancreas
Leukemia
Liver
Colorectum
Breast
Lung
C. Hispanic
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NHL
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6%
9%
10%
26%
All other cancers
Ovary
Liver
NHL
Brain & NS
Leukemia
Prostate
Pancreas
Colorectum
Breast
Lung
A. NonWHispanic White
NHL: NonWHodgkin Lymphoma; NS: nervous system
28%
Figure 2. Proportion of Disability-Adjusted Life Years (DALYs) from each cancer over all 
DALYs (detailed for top 10 cancers), by race/ethnicity in 2011.
Black: Top 3 cancers for DALYs, Gray: Top 4-10 cancers, White: all other cancers
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women), and for 15 of the 24 cancers (Figures 4), including common cancers (pros-
tate, female breast and colorectal cancers) and infection-related cancers (stomach, 
liver and cervix uteri). In both sexes, compared to NHW, the excess burden among 
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Hispanics and NHA was largely confined to liver, stomach and cervical cancers. Com-
pared to NHW men, ASRs in stomach cancer were 2.6 (95% CI: 2.4-2.8) times higher 
in NHB, 2.0 (95% CI:1.8-2.2) times higher in Hispanics and 2.0 (95% CI: 1.8-2.2) 
times higher in NHA. The male ASRs in liver cancer were 1.8 (95% CI: 1.7-2.0) times 
higher in NHB, 1.6 (95% CI: 1.5-1.8) times higher in Hispanics, and 1.9 (95% CI: 
1.8-2.1) times higher in NHA compared with NHW. 
ASRs in cervical cancer in NHB women were about twice as high (111) as in any other 
race/ethnicity (66 in NHW, 74 in Hispanics and 52 in NHA) (Table S7). Notwithstanding 
the higher ASRs for infection-related cancers and a few other cancers, Hispanics and 
NHA had lower ASRs for all cancers combined (2,165 and 1,873 in men and 1,851 and 
1,751 in women, in Hispanics and NHA, respectively) than did NHW (3,088 in men and 
2,758 in women), for commonly diagnosed cancers (breast, colorectum, pancreas), 
and smoking-related cancers such as lung, laryngeal, bladder, esophageal and oral 
cavity cancer.20 NHW had the highest ASR for ovarian cancer (148), melanoma (100 
in men and 59 in women), brain and nervous system (129 in men and 97 in women) 
and bladder (men) (100) cancers.
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Figure 4A. Age-standardized (US 2000 standard population) Disability-Adjusted Life 
Years (DALYs) rate ratio for 24 cancers and for all cancers combined, in 2011, for men.
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Age-specific DALY rates were higher in the oldest age groups, starting at 50-54 
years (Figure S2). In each sex, at each age group, NHB had the highest all cancers 
age-specific rates (prostate cancers in men, and breast and corpus uteri in women 
contributed most to those differences), followed by NHW, Hispanics and Asians. 
Figure S3 presents the number of years lost due to premature death per person dying 
from cancer (YLLs per person). Each person dying from any cancer lost, on average, 
16 years (95% CI: 15-16), with estimates markedly varying across races/ethnicities: 
from 15 years (95% CI: 14-15) for NHW to 19 years (95% CI:18-19) in Hispanics 
(Figure S4). The differences in YLLs per person by race/ethnicity were even greater 
for female breast cancer (NHW: 18 years [95% CI: 17-18]; NHB: 23 [95% CI: 22-23]; 
Hispanics: 23 [95% CI: 22-24]; NHA: 23 [95% CI: 22-25]). Of note, the average YLLs 
per person in all races/ethnicities contributed by testicular cancer in men (35 years 
[95% CI: 31-39]) and cervical cancer in women (26 years [95% CI: 25-27]) were the 
highest of any of these 24 causes of cancer death, though each represented at most 
1% of all YLLs.
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Figure 4B. Age-standardized (US 2000 standard population) Disability-Adjusted Life 
Years (DALYs) rate ratio for 24 cancers and for all cancers combined, in 2011, for women.
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DISCuSSIOn 
These results estimate that 9.8 million DALYs were lost in 2011 due to cancer— equiva-
lent to losing 3.1% of a healthy life year, or about 2 healthy weeks (11 days) per US 
resident—representing 11% of the 89 million9 DALYs from all causes in the country. 
YLLs represented >90% of the total DALYs, underscoring the importance of preventing 
premature mortality. However, YLDs accounted for a substantial proportion of the 
DALYs, particularly for thyroid and prostate cancers, due to their high survival rates. 
ASRs varied greatly across race/ethnicities; NHB had the highest ASRs of all races/
ethnicities for all cancers combined and for most common cancers, whereas Hispanics 
and NHA had the lowest ASRs for all cancers and common cancers, but high ASRs for 
liver, stomach, cervix uteri and gallbladder. 
Health disparities usually arise from a complex combination of several factors, includ-
ing socioeconomic aspects, behavior, biology21 and structural barriers. Compared to 
NHW, NHB and Hispanics are disproportionately represented in the poor22 and unin-
sured23 segments of the US population. Low- Socioeconomic Status (SES) groups are 
more likely to engage or persist in unhealthy behaviors;24 to be without a usual source 
of care (22% in NHB versus 16% in NHW)22 for primary prevention, early detection, 
timely treatment; and to have a higher number of comorbidities.25 They also more 
often reside in neighborhoods unsafe for physical activity,26 with poor access to super-
markets and healthful food.27 While differences in smoking rates could (partly) explain 
the higher lung cancer rates in black men compared with white men,28 differences in 
receipt of screening and lower survival rates might account for over half of the black-
white disparities in mortality from colorectal cancer.29 In contrast, the higher breast 
cancer mortality rates among black women compared with white women, despite their 
lower incidence rates, largely reflect differences in stage at diagnosis and disease 
biology.30
 Previous studies31,32 reported that Hispanics had lower incidence rates for all cancers 
combined and common cancers, but higher rates for infection-related cancers (i.e. 
liver and stomach cancers), compared to NHW. These patterns are largely thought 
to reflect the burden in their countries of origin,33 since over 35% of Hispanics in the 
US are foreign-born.34 Similar to their countries of origin, Hispanics in the US have 
higher prevalence of cancer-related infections (e.g., Hepatitis B virus,35 Helicobacter 
pylori)36 and lower prevalence of smoking37 than the US population. Furthermore, they 
consume more plant-based food,38 which is associated with lower risk of several can-
cers.39 However, cancer rates for Hispanics as a group mask substantial variation by 
country of origin because of differences in length of stay and degree of acculturation. 
A study in Florida40 reported that the low cancer rates in Hispanics compared to NHW 
were limited to Mexicans, who immigrated more recently. Cubans —who immigrated 
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earlier and achieved higher SES— and Puerto Ricans (US citizens) showed rates similar 
to those of NHW. Likewise, cancer rates among Asians in the US substantially vary by 
country of origin. For example, cervical cancer incidence rate in Vietnamese women 
(recent migrants) is about twice as high as in Japanese women, who have been in the 
US for generations and have similar rate as NHW.41 Notably, colorectal cancer rates in 
Japanese have exceeded the rates in NHW in part because of increased adoption of US 
lifestyle in subsequent generations of immigrants.41,42
Although ASRs for all cancers combined are substantially lower in women, total DALYs 
are comparable between women and men. This is due to the higher life expectancy of 
women compared to men43 and higher cancer mortality rates in middle-aged women 
(30-54).11 Female breast cancer is the largest contributor to YLLs in middle ages. 
Cervical, ovarian, and corpus uteri cancers (only in ages 45-54 for the latter) also 
contribute to higher YLLs in middle-aged women. The higher ASRs in men reflects 
differences in prevalence of known risk factors — such as smoking20— as well as 
biological differences.44,45
These findings of 9.8 million DALYs are lower than those of the GBD 2013 (13.0 
million),9 possibly due to differences in age at death and a rising number of deaths 
between 2011 counts and 2013 projections, and the fact that GBD modeled prevalence 
of disabilities while this study used observed incidence. The YLLs computed by SEER 
in 2011 (9.1 million years)11 were slightly higher than in the present study (8.9 mil-
lion years) because SEER used 1-year age groups. However, none of these studies 
presented estimates by race/ethnicity. 
YLLs constitute 91% of the cancer burden, stressing the need to direct efforts to prevent 
premature death from cancer, particularly at middle ages. A substantial proportion of 
DALYs due to cancer could be avoided with primary prevention, screening and early 
detection. Eleven of the top 15 cancers for DALYs are related to two preventable risk 
factors: smoking and alcohol.36 The majority of colorectal and cervical cancers (9% 
and 1% of cancer DALYs, respectively) can be prevented through screening, as can 
most future cervical cancer through vaccination. Furthermore, breast (10% of cancer 
DALYs), colorectal and cervical cancers can be detected early, through screening and 
clinical manifestation, when treatment is more effective. Screening for lung cancer 
among high-risk individuals could potentially avert approximately 12,000 deaths per 
year46 (80,400 YLLs based on a median age at death of 72 years).11 
The GBD2010 study showed that, in the US, cancer had the highest YLL fraction of 
DALY (94%) compared with other major diseases with high burden, including ischemic 
heart disease (91%), cerebrovascular disease (75%) and COPD (47%).7 
Although the overall YLDs accounts for only 9% of ASRs for all cancers combined, it 
represents a substantial proportion of the burden in several cancers. Moreover, the YLD 
share is expected to increase in the future as survival improves because of advances 
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in early detection and treatment for many cancers. Cured patients contributed most 
to the total YLDs (76%); those who died from cancer despite of (curative) treatment 
contributed 20% of YLDs; those offered palliative treatment or diagnosed upon death 
contributed the least (4%). This highlights the need to: 
- prevent or manage treatment side effects (incontinence, impotence, dyspareunia, 
etc.)47-50
- improve quality of life51 among the ever-growing number of cancer survivors.52 
The strength of this study, besides as a contemporary burden of cancer study according 
to DALYs by race is, for the first time, its report of outcomes by ethnicity; secondarily, 
the frequency of the disabilities – necessary for YLD estimation – is largely based on 
observed data from population-based registries.
Limitations
The limitations of this study are mainly related to the availability and quality of data. 
These may have prevented full capture of the total spectrum of disabilities associ-
ated with cancer, hereby underestimating the YLDs in several ways. First, data on 
the prevalence of disabilities among cancer patients, particularly late effects, and in 
the community remain rare. Furthermore, they vary widely due to discrepancies in 
studied populations, definitions, outcome measures, and overall study design. All too 
often, the prevalence of a disability is estimated in a small and restricted population 
(specific stage, mode of treatment or age group). In addition, not all cancer-related 
disabilities can be accounted for due to the lack of information on prevalence of dis-
abilities (although common, major depression in cancer patients is not systematically 
diagnosed).53 The second limitation is the lack of corresponding disability weight. For 
instance, there are no disability weights for fecal incontinence –affecting almost 40% 
of rectal cancer patients treated with total mesorectal excision54 and >10% of women 
with hysterectomy for cervical cancer–49 nor for bone-health issues, cognitive func-
tion decrements, peripheral neuropathy, or fatigue, which affect cancer survivors at 
different levels.55 Finally, only one disability weight exists for “Diagnosis and primary 
therapy” for all cancers, while treatment varies by cancer type and stage. However, 
the loss of health was differentiated during this disease phase by using cancer-specific 
durations (from 1 month for melanoma to >1 year for colorectal cancer). The overall 
underestimation of YLDs may contribute to the high proportion of YLLs in DALYs.
COnCLuSIOnS
For all cancers, YLLs constituted the majority of the cancer burden, irrespective of 
race/ethnicity. This stresses the need to direct efforts to prevent premature death, 
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particularly at middle ages, through broad implementation of known effective inter-
ventions from primary prevention, to early detection and treatment.
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SuPPLEMEnTaRY MaTERIaL 
Supplement 1 Cancers selected
Data for 24 cancers with age-standardized incidence >1 per 100,000 in 2011 were 
extracted, “All other cancers” and “All cancers”. “All other cancers” were deducted 
based on “All cancers” and the sum of each specified cancer. Only cases with malignant 
behavior were extracted (see Table S1 for ICD-9 codes). 
Table S1. Cancers selected and corresponding International Classification of Diseases-9 
codes (ICD-9)
Cancer ICD-9
All cancers 140-208, 238.6
Oral cavity and pharynx 140-149
Esophagus 150
Stomach 151
Colorectum and anus 153-154.8, 159.0
Liver and intrahepatic bile ducts 155.0-155.2
Gallbladder and other biliary 156.0-156.9
Pancreas 157
Larynx 161
Trachea, mediastinum and other respiratory organs, 
bronchus and lung
162, 164, 165
Melanoma of skin 172
Breast 174-175
Cervix uteri 180
Corpus and uterus, not otherwise specified 179, 182
Ovary 183.0
Prostate 185
Testis 186
Kidney, renal pelvis and ureter 189.0-189.2
Bladder 188
Brain and other nervous system 191, 192
Thyroid 193
Hodgkin lymphoma 201
Non-Hodgkin lymphoma 200, 202.0-202.2, 202.8-202.9
Myeloma 203.0, 238.6
Leukemia 204-208
All other cancers those not abovementioned but included in 
140-208, 238.6
Source:44 
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Supplement 2 Computation of Years of Life Lived with Disabilities (YLDs)
Years of Life Lived with Disabilities (YLDs) were computed as the incidence i of disease 
phase or disease sequelae y at age group x, multiplied by the disability weight dw for 
that phase or sequela, multiplied by the phase duration d.
75 
 
1.7 Supplementary material 
Supplement 1 Cancers selected 
Data for 24 cancers with age-standardized incidence >1 per 100,000 in 2011 were extracted, 
“All other cancers” and “All cancers”. “All other cancers” were deducted based on “All 
cancers” and the sum of each specified cancer. Only cases with malignant behavior were 
extracted (see Table S1 for ICD-9 codes).  
 
 Supplement 2 Computation of Years of Life Lived with Disabilities (YLDs) 
 
Years of Life Lived with Disabilities (YLDs) were computed as the incidence i of disease 
phase or disease sequelae y at age group x, multiplied by the disability weight dw for that 
phase or sequela, multiplied by the phase duration d. 
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A four-stage natural disease history for cancer was followed, as presented in Figure S1, to 
determine the number of patients in each disease phase. Figure S1 only presents the disease 
phases that trigger disabilities and does not aim to represent the whole the cancer continuum. 
The details of the method that was adapted and its validation were described by 
Soerjomataram et al.1 and Global Burden of Disease Study 2013 Collaborators.2,3 A summary 
of the sources of data4-28 are presented in context, in Table S2. In this study, four possible 
pathways for newly-diagnosed patients were assumed, based on the cancer history:  
1) Those diagnosed, treated with curative intent (p) and cured (s) from cancer (red path on 
Figure S1). They underwent a period of disability during the diagnosis and primary therapy 
phase (LD), and the control phase (LC1) during which patients underwent intensive follow-up 
and, for some of them, light treatment. Those patients, considered as cured, will live on their 
life expectancy. A fraction of those patients suffer from sequelae, either from the disease or 
from its treatment. The sequelae were accounted for since time of “diagnosis and primary 
therapy”; 
2) Those who died after treatment and a (shorter) control phase (p-s) (purple path). They 
underwent a period of disability during the diagnosis and primary therapy phase (LD), the 
control phase (LC2), then the metastatic (LM1) and terminal (LT) phases. A fraction of those 
patients suffer from sequelae, either from the disease or from its treatment, starting at the 
time of “diagnosis and primary therapy”; 
3) Those who did not receive curative treatment (1-p) and underwent a period of disability 
during metastatic phase (with medication) (LM1) and terminal phase (LT) (orange path). Those 
patients can receive some palliative treatment;  
4) Those diagnosed upon their death (“death certificate only” and autopsy) underwent a 
metastatic phase (without medication) (LM2) and a terminal phase (LT) (black path). 
A four-stage natural disease his ory for cancer was followed, as presented in Figure S1, 
to determine the number of patients in each disease phase. Figure S1 only presents 
the disease phases that trigger disabilities and does not aim to represent the whole 
the cancer continuum. The details of the method that was adapted and its validation 
were described by Soerjomataram et al.1 and Global Burden of Disease Study 2013 
Collaborators.2,3 A summary of the sources of data4-28 are presented in context, in 
Table S2. In this study, four possible pathways for newly-diagnosed patients were 
assumed, based on the cancer history: 
 
Note: 
p = proportion treated with curative intent, s = proportion cured 
LD = time in diagnosis and primary therapy phase, LC = time in control and remission phase, 
LM = time in metastatic cancer phase, LT = time in terminal cancer phase 
DCO = death certificate only 
Every step of the cancer continuum in a rectangle, black or blue, has a corresponding disability weight. 
Long-term sequelae also affect the patients who are treated with curative therapy but eventually die of 
cancer, during metastatic and terminal phases (not depicted on the figure for clarity). 
Adapted from Soerjomataram I, Lortet-Tieulent J, Ferlay J et al. Estimating and validating disability-
adjusted life years at the global level: a methodological framework for cancer. BMC Med Res Methodol. 
2012;12:125. 
 
Cancer 
Incidence, 
no DCO 
Diagnosis and 
primary (curative) 
therapy 
LD 
Metastatic      
 LM 
Control 
LC1 
Control 
LC2 
Terminal         
(medication)        
LT 
Cancer 
death 
Cure 
p 
1-p 
s 
p-s 
DCO 
Metastatic     
LM 
Terminal             
(no medication)   
LT 
Long-term sequelae: 
Mastectomy, Stoma, Urinary 
incontinence, Impotence, 
Dyspareunia, Infertility, 
Disfigurement, Speech problems 
Patients treated with curative intent and cured 
Patients treated with curative intent but who later died from cancer 
Patients diagnosed at metastatic stage, who will die from cancer after palliative treatment 
Patients diagnosed upon their death, who never got treated 
Figure S1. Disabilities in a four-stage natural disease history for cancer
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1) Those diagnosed, treated with curative intent (p) and cured (s) from cancer (red 
path on Figure S1). They underwent a period of disability during the diagnosis 
and primary therapy phase (LD), and the control phase (LC1) during which patients 
underwent intensive follow-up and, for some of them, light treatment. Those pa-
tients, considered as cured, will live on their life expectancy. A fraction of those 
patients suffer from sequelae, either from the disease or from its treatment. The 
sequelae were accounted for since time of “diagnosis and primary therapy”;
2) Those who died after treatment and a (shorter) control phase (p-s) (purple path). 
They underwent a period of disability during the diagnosis and primary therapy 
phase (LD), the control phase (LC2), then the metastatic (LM1) and terminal (LT) 
phases. A fraction of those patients suffer from sequelae, either from the disease 
or from its treatment, starting at the time of “diagnosis and primary therapy”;
3) Those who did not receive curative treatment (1-p) and underwent a period of 
disability during metastatic phase (with medication) (LM1) and terminal phase (LT) 
(orange path). Those patients can receive some palliative treatment; 
4) Those diagnosed upon their death (“death certificate only” and autopsy) underwent 
a metastatic phase (without medication) (LM2) and a terminal phase (LT) (black 
path).
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Figure S2. Age-specific DALY rate, by race/ethnicity and sex
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How to determine the number of cancer patients?
Cancer incidence
To estimate the number of patients diagnosed in 2011, access to incidence data 
from the North American Association of Central Cancer Registries (NAACCR)4 cover-
ing 95.4% of the total population for 2011 was obtained. Data was extracted using 
SEER*Stat version 8.2.1. Incidence was corrected for partial population coverage, 
and adjusted for delayed reporting using SEER cancer-, gender-, race- (All/White/
Black) and age- (<50/50-64/65+) ratios provided by Surveillance, Epidemiology and 
End Results (SEER) at http://surveillance.cancer.gov/delay/canques.html. The “All 
cancers” delay ratio was applied to “Gallbladder cancer” and “All races” to Hispanic 
and NHA data because no delay ratios were provided for Gallbladder nor Hispanics and 
NHA. Adjusting for delayed reporting augmented the number of new cases by 2.1%.
The number of patients who are diagnosed with cancer upon their death (black path), 
also known as DCO (death certificates only) is indicated in the NAACCR file.
How to determine the number of patients treated (red and purple paths) and the number not 
treated with curative intent (orange path)?
Proportion treated (p) and proportion not treated (1-p)
To compute the proportion of patients treated with curative intent (p), the first step was 
to estimate the proportion of patients not treated with curative intent (1-p) (those pa-
tients will have some palliative treatment). For almost all cancers, those patients were 
assumed to be the average annual number of patients diagnosed in 2010-2011 at stage 
IV and who did not receive curative surgery nor curative radiotherapy, in SEER18.29 
For a few cancers (myeloma, leukemia, lymphoma), patients are primarily treated with 
chemotherapy (not available in the SEER database). To estimate the number of those 
patients not treated, a literature review (details in Table S3) was conducted.30,31
To obtain the number of patients treated and the number not treated, the number of 
patients diagnosed with cancer (excluding DCO) was then multiplied by the proportion 
treated and the proportion not treated.
How to determine the number of patients cured from cancer (red path on Figure S1) and the 
number not cured (purple path)?
Proportion cured (s)
To determine the number of patients cured, among the patients treated, the cure 
fraction was used. Proportion cured (s), or cure fraction, is defined as the propor-
tion of patients who survived the disease and no longer experience excess mortality 
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rate. Survival time of patients diagnosed in 1992-2007 and followed through end of 
2012, was used, as reported in SEER1332, excluding DCO (death certificate only) and 
autopsy and patients with unknown survival time. Patients with multiple primaries 
were included. Data by cancer were extracted, by race/ethnicity, and by large age 
group (0-39, 40-64 and 65+ years), for both sexes combined. As the study includes 
racial minorities and ethnicity, for which life tables were available only recently, cause-
specific survival was used, as recommended by Howlader.33 CanSurv (http://srab.
cancer.gov/cansurv) version 1.3, a Windows program was used to obtain the cure 
fraction, with a lognormal distribution to model survival time in a mixture cure model. 
A mixture model assumes that a fraction of patients will die from their cancer, while 
another fraction will eventually be considered as cured. The mixture cure model as-
sumes that the survival function S(t)=c+(1-c) G(t;µ,σ), and the cure fraction c is the 
value of the survival function when the time t goes to infinity. Screen shots of the 
model specification in CanSurv and software output are presented in Figure S5. 
For five cancers (esophageal, pancreas, liver, gallbladder in most racial/ethnic groups 
and lung), the cure fraction was determined to be <1%. In those instances, the 
10-year relative survival rates were used (patients diagnosed in 2002, followed-up 
through end of 2012), all races combined, both sexes combined, all ages combined, 
in SEER9.34 Cause-specific survival estimates are not available in SEER Statistics for 
gallbladder for “American Indians and Unknown race”. Also, the numbers for the cure 
fraction for NHW for gallbladder were too small for the model to converge. So the cure 
fraction of all races/ethnicities combined, by large age group, was used for gallbladder 
for NHW and for “American Indians and Unknown race”.
To obtain the number of patients cured, the number of patients treated was then 
multiplied by the proportion cured (s) (red path). To determine the number of patient 
Table S3. Estimated proportion of cancer patients without curative treatment or treat-
ment to significantly prolong life
Cancer Patients receiving no curative treatment
All cancers (excluding basal and squamous skin cancer), Oral cavity 
and pharynx, Esophagus, Stomach, Colorectum and anus, Liver and 
intrahepatic bile ducts, Gallbladder and other biliary, Pancreas, Larynx, 
Trachea, mediastinum and other respiratory organs, bronchus and lung, 
Melanoma of skin, Breast, Cervix uteri, Corpus and Uterus Not Otherwise 
Specified, Ovary, Prostate, Testis, Kidney, renal pelvis and ureter, Bladder, 
Brain and other nervous system, Thyroid
Stage IV and no radiotherapy or 
surgery in SEER1832
Hodgkin lymphoma 19%30
Non-Hodgkin lymphoma 16%30
Myeloma 0%31
Leukemia 50% of patients 70+ years30
Note: All patients with Myeloma are treated with the intent to significantly prolong life, yet for now the disease is not 
considered as curable.31
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not cured, the number of patients treated was multiplied by the proportion not cured 
(1-s) (purple path).
How to determine the number of patients who have sequelae due to cancer or its treatment 
(red path and purple path)?
Proportion of survivors with sequelae (s)
The proportion of survivors with sequelae was either derived from the surgical proce-
dure (e.g., 100% of cervical cancer patients are infertile after radical hysterectomy) or 
determined through a literature review in PubMed (e.g. 46% of female rectal cancer 
patients suffer from dyspareunia),20 or a combination of the two (91% of bladder 
cancer patients have a stoma after radical cystectomy). 9 The review was conducted 
using the combination of the following MESH terms: disability, sequela, complication, 
sexual health or function, side-effects, the list of disabilities and of cancers. The aver-
age annual number of surgical procedures over the 2010-2011 period was obtained 
from SEER1829 and later divided by the number of patients over the same period, on 
a sex-, age group-, cancer- and race/ethnicity-basis (excluding death certificates only 
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Figure S3. Average Years of Life Lost (YLLs) per person dying of cancer, all races/ethnici-
ties, both sexes, and contribution (%) of the YLLs of each cancer in total YLLs
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and autopsies) to find the proportion of patients with some sequelae. The average 
proportions by cancer are listed in Table S2. 
Some disabling conditions are also found in the cancer-free population; the proportion 
of some disabilities in some cancer patients was therefore reduced. The risk of some 
disabilities, such as impotence, increases with age.35 Among young patients, any dis-
ability would be due to the treatment. Conversely, the frequency of some disabilities 
in the older general population would be equivalent or higher to the frequency of the 
disability due to cancer or its treatment. Hence, firstly the impact of some disabilities 
was restricted to some age groups (e.g. 20-39 for female infertility), and secondly a 
small discount was applied to the youngest age group (i.e. considering the majority of 
the disability in these age groups is due to cancer), up to a large discount to the eldest 
age group (i.e. a smaller fraction of the disability in those age groups is actually due 
to cancer). On average, a mean discount of 22% (from 11% for ages 15-19 to 51% for 
ages 70-74, based on the distribution of impotence in the MALES study)35 was applied 
on the proportion of men affected by cancer-related impotence, 5% from dyspareu-
nia36 (2% to 8% for ages classes 15-19 to 70-74, respectively), 6% (3% to 9%) from 
male and 10% (6% to 14%) in female urinary incontinence,37 and discounted 15%38 
(10% for ages 20-24 up to 20% for the last age-group) from the surgical procedures 
causing infertility. The discounts are presented by age group and disability in Table S8.
For the sequelae of melanoma, two levels of disfigurement were used, depending on 
the location of the lesion, based melanoma incidence in 2011 at national level (NAACCR 
file).4 The average frequency of melanoma location (“on the face or overlapping lesion” 
for disfigurement level 2, and “not on the face nor overlapping” for disfigurement level 
1) over 2010-20114 was computed on an age-, race-, ethnicity- and sex-basis, and 
applied the distribution of lesion location to the 2011 new cases.
To obtain the number of patients with sequelea, the number of patients cured was 
multiplied by the proportion of patients with sequelea, for each sequela (red path). To 
determine the number of patients who are treated with curative intent but eventually 
die from their cancer who also experience sequelae, the number of those patients was 
multiplied by the proportion of patients with sequelae (purple path).
How long does each patient live in each disease phase or sequela phase?
DuRaTIOn Of DISEaSE PHaSES
Diagnosis and primary therapy LD
The duration of the diagnosis and primary therapy phase LD was obtained from a prior 
cancer study.7
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Control phase LC1 in patients who were cured
The control phase was assumed to end 5 years (10 years for breast and prostate 
cancer patients)6 after the diagnosis. The cancer-specific “Diagnosis and primary 
treatment” duration LD was deducted from 5 years (or 10 years) to obtain the Control 
phase duration LC1.
Metastatic LM and Terminal phases LT
The Metastatic phase LM was set to last for 3 months8 and the Terminal phase LT, 
where patients are at the final stage of living, was uniformly set to 1 month.8 Those 
metastatic and terminal phases are used only for patients who will die from cancer and 
do not apply to all patients diagnosed at metastatic phase. 
Control phase LC2 in patients who are treated with curative intent, then die
The median survival time was first obtained, by cancer, from patients who died from 
their cancer (cause of death is “attributable to this cancer diagnosis”), diagnosed over 
the 1992-2006 period, followed-up through December 2011, from SEER1329 (Table 
S4), extracted through the SEER*Stat “Case list session” module. DCO patients and 
autopsies were excluded as they were counted in the fourth possible pathway for pa-
tients. The Metastatic LM1 and Terminal phases LT (4 months in total), and the (cancer-
specific) Diagnosis and primary therapy phase LD were deducted from the median 
survival time, to obtain the duration of the Control phase LC2. When the survival time 
was shorter than the sum LD + LM1 + LT, the time in Diagnosis and primary treatment 
phase LD were reduced accordingly. Since the people who were treated for liver or 
pancreas cancer and died from the cancer had a median survival time of 3 months, the 
duration of the Metastatic phase LM1 was also reduced to 2 months.
Sequelae phase
Sequelae were assumed to start with the Diagnosis and primary therapy phase and 
lasted until the end of life (corresponding to the life expectancy at age at diagnosis), 
or until the end of the disability period (infertility was counted until age 39 for women 
and age 59 for men, dyspareunia and impotence until the age of 74), or the end of life 
for those who died of cancer.
When the same patients had several possible sequelae (e.g. urinary incontinence, 
impotence and infertility for prostate cancer patients), each disability was counted 
separately and then added. 
The case of active surveillance prostate cancer patients 
A fraction of prostate cancer patients will not undergo an intensive curative therapy; 
rather, they will get “active surveillance”. According to the National Comprehensive 
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Cancer Network (NCCN) guidelines,39 this is the management of choice for low-risk 
prostate cancer patients with life expectancy of ≥20 years. It involves biopsies and PSA 
testing at least every 6 months. The NCCN defines the low-risk group as patients with 
tumors stage T1 to T2a, low Gleason score and PSA levels. In a retrospective study 
from Hoffman, 20% of patients age 66 years and older were not treated with up-front 
treatment.40 The proportion of patients diagnosed at T1-T2a stage, in 2010-2011, in 
SEER18 was computed; and applied 20% of it to all prostate cancer patients age 65+ 
in the NAACCR dataset to estimate the number of low-risk patients at national level 
who would go through active surveillance. The disability weights for “Control phase” 
was used in lieu of the “Diagnosis and Primary therapy phase” for those patients 
throughout their life expectancy.
Disability weights issued by the GBD 2013 study41 which establish the loss of health 
associated with disability related to various health states including cancer (Table S2) 
were used. Due to unavailability of disability weight for dyspareunia in women with 
bladder, breast, cervical, corpus uteri and rectal cancers, the disability weight of 
impotence in men was applied. Also, because the definition of “mastectomy” in the 
GBD 2013 focuses on lymphedema, which is as frequently experienced by men as by 
women,42 this disability weight was applied to both women and men. 
Supplement 3 Calculation of the confidence intervals on DaLYs
The 95% confidence intervals for the estimates of DALYs, YLLs, YLDs and rate ratios 
were determined using a simulation method in which random numbers were gener-
ated for all the parameters.43 In detail, random numbers were generated within each 
sex, race/ethnicity, cancer and age group for: the number of cases, the proportion of 
patients treated, the proportion of prostate cancer patients diagnosed at early stage, 
the cure fraction, life expectancy, each disability weight, the proportion of patients in 
each disease phase or with a disability, and the duration of each disease phase or 
disability. Case counts and duration of disease phase or disability were assumed to 
follow a Poisson distribution. For each Poisson distribution, the mean of the parameter 
was specified. The Normal distribution was used for the cure fraction, life expectancy, 
frequency of early stage at diagnosis in prostate cancer patients and frequency of 
disabilities. The means and the standard deviations of the Normal distributions were 
specified. Confidence intervals for disability weights were available at their source.41 The 
few values randomly generated for proportions and disability weights that were outside 
[0;1] were replaced by 0 when negative and replaced by 1 when greater than 1. The 
few negative values generated for life expectancies were replaced by 0. The simulation 
process was replicated 1,000 times, a large enough number of replications that allowed 
the confidence intervals to be stable when the whole simulation process was repeated.
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Figure S4. Average Years of Life Lost (YLLs) per person dying of cancer, by race/ethnic-
ity, both sexes, and contribution (%) of the YLLs of each cancer in total YLLs 
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A. Model specification in CanSurv to compute cure fractions 
 
B. Cure fraction plots for colon and rectum, for ages 65 years and above, all races/ethnicities, both sexes 
 
  Figure S5. Model specification and cure fraction output in CanSurv software, with the 
example of colon and rectum cancer, ages 65 years and above in all races/ethnicities.
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Table S4. Median time to death for those who die of cancer, by cancer
Cancer Time to death (months)
Liver 3
Pancreas 3
Gallbladder 5
Stomach 6
Lung 6
Esophagus 7
All Other cancers 7
Brain, nervous system 8
Leukemia 9
Kidney, renal pelvis and ureter 11
Non-Hodgkin lymphoma 11
Testis 14
Oral cavity and pharynx 16
Cervix uteri 17
Corpus and uterus not otherwise specified 18
Bladder 18
Ovary 19
Colorectum and anus 19
Hodgkin lymphoma 20
Thyroid 21
Larynx 22
Myeloma 22
Melanoma of skin 30
Breast 42
Prostate 53
Source: SEER13 1992-201129
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Table S5A. Number of Disability-Adjusted Life Years (DALYs), with 95% confidence in-
terval, rank of cancer, and proportion of Years of Life Lost (YLLs) in DALYs, in All races/
ethnicities and Non-Hispanic Asians, in 2011
MEN
Cancer All races/ethnicities Non-Hispanic Asians
DALYs Rank % YLLs DALYs Rank %YLLs
All cancers a
4905310 
(4779980;5036390) 90
128530 
(124250;132920) 91
Lung
1268410 
(1230110;1307090) (1) 98
27280 
(25690;28880) (1) 98
Prostate
514980 
(490630;541860) (2) 51 9100 (8310;9860) (4) 46
Colorectum
469520 
(456320;483220) (3) 88
14540 
(13480;15720) (3) 84
Pancreas
284460 
(274960;294640) (4) 99 7480 (6740;8240) (5) 99
Liver
262430 
(253870;270960) (5) 99
17870 
(16560;19240) (2) 99
Leukemia
210460 
(203640;217640) (6) 96 6960 (6010;7970) (6) 97
Esophagus
188360 
(182070;195190) (7) 98 3080 (2590;3560) (11) 98
Brain & NS
179570 
(174320;185460) (8) 98 4060 (3310;4830) (10) 98
NHL 173320 (167290;179350) (9) 93 4520 (3970;5150) (9) 92
Kidney
147860 
(142480;153060) (10) 93 3000 (2520;3520) (12) 92
Bladder
138250 
(132610;144490) (11) 85 1760 (1500;2090) (13) 81
Oral cavity
126940 
(122770;131580) (12) 84 4610 (3980;5230) (8) 87
Melanoma of 
skin
122390 
(118160;127060) (13) 79 360 (210;540) (18) 86
Stomach
105510 
(101510;109510) (14) 97 6860 (6110;7680) (7) 97
Myeloma 86400 (82640;89940) (15) 93 1760 (1440;2130) (14) 92
Larynx 51260 (48960;53620) (16) 92 720 (520;960) (17) 91
Gallbladder 20690 (19370;22010) (17) 96 1270 (960;1610) (15) 96
Hodgkin 
lymphoma 17420 (15990;18930) (18) 88 340 (170;590) (19) 86
Testis 15960 (14410;17520) (19) 83 190 (70;360) (20) 67
Thyroid 15820 (14730;16970) (20) 76 800 (590;1040) (16) 77
Breast 8750 (8030;9600) (21) 76 150 (80;240) (21) 72
All Other 
cancers
495040 
(481220;509890) — 98
11630 
(10560;12840) — 98
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Table S5A. Number of Disability-Adjusted Life Years (DALYs), with 95% confidence in-
terval, rank of cancer, and proportion of Years of Life Lost (YLLs) in DALYs, in All races/
ethnicities and Non-Hispanic Asians, in 2011 (continued)
WOMEN
Cancer All races/ethnicities Non-Hispanic Asians
DALYs Rank % YLLs DALYs Rank %YLLs
All cancers a
4924790 
(4799120;5061220) 91
149640 
(144570;154690) 90
Lung
1125180 
(1090890;1161010) (1) 98
23510 
(22020;25060) (2) 98
Breast
992330 
(963990;1019620) (2) 77
30960 
(28990;32910) (1) 72
Colorectum
431760 
(418280;446460) (3) 88
14960 
(13870;16130) (3) 86
Pancreas
271080 
(260880;280570) (4) 99 8890 (8010;9720) (4) 99
Ovary
256500 
(248860;264850) (5) 97 8860 (7920;9960) (5) 96
Leukemia
167830 
(161600;174350) (6) 96 5850 (5040;6740) (9) 97
Corpus uteri
167610 
(161890;173230) (7) 87 5990 (5300;6800) (8) 87
Brain & NS
144810 
(139850;150020) (8) 98 3730 (3050;4510) (12) 98
NHL 132740 (127500;138070) (9) 92 4350 (3780;5000) (11) 92
Cervix uteri
116580 
(112630;121150) (10) 91 4670 (3970;5470) (10) 92
Liver
113380 
(108780;117980) (11) 99 7720 (6870;8570) (6) 99
Kidney 83880 (80160;87340) (12) 92 2050 (1630;2540) (13) 93
Melanoma of 
skin 77160 (73860;80590) (13) 76 470 (310;700) (20) 85
Myeloma 77090 (73740;80770) (14) 94 1890 (1520;2300) (15) 94
Stomach 74500 (71390;78220) (15) 98 6340 (5540;7130) (7) 98
Bladder 58710 (55450;61780) (16) 88 800 (600;1020) (18) 83
Oral cavity 49590 (47230;52010) (17) 83 2040 (1660;2500) (14) 84
Esophagus 47150 (44680;49530) (18) 98 780 (560;1040) (19) 98
Gallbladder 32400 (30450;34370) (19) 97 1500 (1150;1860) (17) 96
Thyroid 25670 (24070;27320) (20) 54 1720 (1390;2060) (16) 61
Larynx 15020 (13940;16170) (21) 93 60 (10;140) (22) 82
Hodgkin 
lymphoma 12360 (11170;13560) (22) 87 180 (60;350) (21) 79
All Other 
cancers
452400 
(438400;468150) — 97
12110 
(10970;13300) — 97
a Excludes basal and squamous skin cancers
Note: NS: nervous system; NHL: Non-Hodgkin lymphoma
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Table S5B. Number of Disability-Adjusted Life Years (DALYs), with 95% confidence inter-
val, rank of cancer, and proportion of Years of Life Lost (YLLs) in DALYs, in Non-Hispanic 
Whites, Non-Hispanic Blacks and Hispanics, in 2011
MEN
Cancer Non-Hispanic White Non-Hispanic Black Hispanic
DALYs Rank % YLLs DALYs Rank % YLLs DALYs Rank % YLLs
All cancers a
3760310 
(3656360;3877550) 90
630570 
(611150;646130) 91
335590 
(326990;344700) 91
Lung
1024650 
(992630;1059420) (1) 98
161160 
(155550;166940) (1) 98
47560 
(45390;49960) (1) 98
Prostate
369340 
(347280;394290) (2) 52
91120 
(86340;96220) (2) 57
32560 
(30590;34740) (4) 50
Colorectum
345430 
(334490;356330) (3) 88
68460 
(65510;71350) (3) 91
36070 
(34200;38030) (2) 86
Pancreas
220020 
(212610;227600) (4) 99
35130 
(33140;36890) (5) 99
19810 
(18520;21210) (6) 99
Liver
165420 
(159610;171050) (5) 99
42350 
(40000;44520) (4) 99
33930 
(32100;35840) (3) 99
Esophagus
157250 
(152020;162680) (6) 98
17830 
(16610;19230) (9) 98 9350 (8480;10360) (11) 98
Leukemia
156360 
(150150;162310) (7) 96
22270 
(20700;24000) (6) 97
23420 
(21620;25430) (5) 96
Brain & NS
145130 
(139610;150130) (8) 98
13300 
(11990;14720) (13) 98
15530 
(13990;17110) (8) 98
NHL 136120 (130340;141100) (9) 93
17260 
(15970;18650) (10) 94
14190 
(13100;15360) (9) 92
Bladder
120130 
(114870;125410) (10) 85
9870 
(9040;10770) (15) 90 5340 (4760;5900) (14) 84
Melanoma of 
skin
116140 
(112060;120900) (11) 80 1090 (800;1390) (19) 92 3120 (2620;3680) (17) 87
Kidney
115850 
(111430;120300) (12) 93
15100 
(13950;16380) (12) 92
12560 
(11470;13760) (10) 92
Oral cavity
96050 
(92570;99940) (13) 83
18090 
(16790;19490) (8) 92 6750 (6040;7500) (12) 83
Myeloma
62300 
(59640;65250) (14) 93
15370 
(14160;16490) (11) 94 6260 (5600;6960) (13) 93
Stomach
60990 
(58170;63930) (15) 97
20090 
(18790;21420) (7) 98
16530 
(15220;17870) (7) 98
Larynx
36610 
(34700;38560) (16) 91
10070 
(9130;11000) (14) 94 3450 (2970;3990) (16) 92
Gallbladder
14510 
(13540;15590) (17) 96 2270 (1840;2690) (17) 97 2300 (1890;2790) (19) 96
Thyroid
12380 
(11460;13360) (18) 76 950 (720;1230) (20) 79 1490 (1190;1840) (20) 77
Hodgkin 
lymphoma
11930 
(10810;13090) (19) 88 2410 (1900;2980) (16) 90 2640 (2090;3180) (18) 90
Testis 10710 (9630;12010) (20) 80 740 (460;1090) (21) 87 4090 (3340;5040) (15) 89
Breast 6600 (5940;7310) (21) 75 1470 (1130;1820) (18) 84 480 (310;690) (21) 72
All Other 
cancers
378960 
(366880;392580) — 98
63330 
(60570;66190) — 98
37690 
(35370;39950) — 98
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Table S5B. Number of Disability-Adjusted Life Years (DALYs), with 95% confidence inter-
val, rank of cancer, and proportion of Years of Life Lost (YLLs) in DALYs, in Non-Hispanic 
Whites, Non-Hispanic Blacks and Hispanics, in 2011 (continued)
WOMEN
Cancer Non-Hispanic White Non-Hispanic Black Hispanic
DALYs Rank % YLLs DALYs Rank % YLLs DALYs Rank % YLLs
All cancers a
3719660 
(3615390;3831560) 91
675370 
(658950;692080) 93
339360 
(330390;349090) 89
Lung
936960 
(907780;966210) (1) 98
126050 
(121260;130950) (2) 98
32070 
(30290;33880) (2) 97
Breast
716370 
(690900;740460) (2) 76
162820 
(157210;168290) (1) 85
73670 
(70230;77060) (1) 75
Colorectum
312970 
(301900;323460) (3) 88
69410 
(66430;72480) (3) 91
30310 
(28540;32040) (3) 87
Pancreas
204580 
(196840;212940) (4) 99
38180 
(35910;40180) (4) 99
17680 
(16470;19060) (6) 99
Ovary
202350 
(195250;209070) (5) 97
25330 
(23710;26960) (6) 97
18330 
(16970;19690) (5) 96
Leukemia
121660 
(116920;126720) (6) 96
19250 
(17740;20840) (8) 97
19720 
(17960;21660) (4) 97
Brain & NS
116350 
(111970;120710) (7) 98
11770 
(10470;13230) (13) 98
11850 
(10410;13410) (11) 98
Corpus uteri
116160 
(112030;120790) (8) 86
30200 
(28420;32070) (5) 93
13850 
(12730;14980) (9) 86
NHL 102130 (97160;106810) (9) 92
13720 
(12510;14940) (12) 94
11570 
(10490;12790) (12) 92
Cervix uteri
72720 
(69590;76120) (10) 90
22420 
(20760;24220) (7) 95
15420 
(14080;16830) (7) 87
Liver
72600 
(69500;76260) (11) 99
17880 
(16400;19300) (9) 99
13820 
(12730;15050) (10) 99
Melanoma of 
skin
70880 
(67720;73970) (12) 77
1450 
(1110;1840) (22) 92 2980 (2450;3520) (17) 80
Kidney
62810 
(59790;65810) (13) 92
10720 
(9700;11800) (14) 92 7330 (6500;8220) (13) 91
Myeloma
51560 
(48860;54310) (14) 94
17010 
(15740;18320) (10) 94 6100 (5400;6830) (14) 93
Bladder
46980 
(44170;49700) (15) 87
7600 
(6860;8380) (15) 92 2830 (2380;3300) (18) 88
Stomach
38570 
(36510;40740) (16) 97
14290 
(13140;15500) (11) 98
14540 
(13320;15850) (8) 98
Oral cavity
37780 
(35730;39870) (17) 83
6260 
(5510;7040) (17) 89 2790 (2320;3320) (19) 81
Esophagus
36270 
(34450;38390) (18) 98
7530 
(6710;8380) (16) 98 2130 (1720;2570) (20) 98
Gallbladder
20450 
(19170;21930) (19) 97
5050 
(4420;5700) (18) 98 4920 (4250;5570) (15) 97
Thyroid
17960 
(16580;19470) (20) 52
2730 
(2320;3130) (19) 63 2990 (2600;3410) (16) 51
Larynx
11700 
(10700;12740) (21) 92
2380 
(1920;2880) (20) 93 650 (420;930) (22) 91
Hodgkin 
lymphoma 8810 (7900;9830) (22) 87
1870 
(1380;2390) (21) 89 1360 (1000;1820) (21) 86
All Other 
cancers
342350 
(330400;354580) — 97
61580 
(59030;64440) — 98
32550 
(30450;34390) — 97
a Excludes basal and squamous skin cancers
Notes: NS: nervous system; NHL: Non-Hodgkin lymphoma
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Table S6. Disability-Adjusted Life Years (DALYs) age-standardized rates (ASR) per 
100,000, with 95% confidence intervals, rank of cancer, and proportion of Years of Life 
Lost (YLLs) rate in ASR, in All races/ethnicities, in 2011
Cancer MEN WOMEN BOTH SEXES
ASR Rank %YLLs ASR Rank %YLLs ASR Rank %YLLs
All cancers a
3046 
(2962;3130) 90
2694 
(2632;2763) 91
2842 
(2791;2894) 91
Lung 780 (755;805) (1) 98 600 (582;619) (1) 98
682 
(666;696) (1) 98
Breast 5 (5;6) (21) 76 554 (539;568) (2) 77
294 
(286;302) (2) 77
Colorectum 293 (284;302) (3) 88 234 (227;241) (3) 88
262 
(256;267) (3) 88
Pancreas 174 (168;180) (4) 99 144 (138;149) (4) 99
158 
(154;162) (4) 99
Prostate 325 (310;342) (2) 55 — — —
145 
(139;153) (5) 53
Leukemia 137 (132;142) (6) 96 96 (93;100) (6) 96
115 
(112;118) (6) 96
Liver 152 (147;157) (5) 99 61 (59;63) (11) 99
104 
(102;107) (7) 99
Brain & NS 112 (109;116) (8) 98 84 (81;87) (8) 98 97 (95;100) (8) 98
NHL 111 (107;116) (9) 93 72 (69;75) (9) 92 90 (88;93) (9) 92
Ovary — — — 139 (135;143) (5) 97 74 (72;76) (10) 97
Kidney 91 (87;94) (10) 93 45 (43;47) (12) 92 66 (64;68) (11) 92
Esophagus 113 (109;117) (7) 98 25 (24;26) (18) 98 66 (64;68) (12) 98
Melanoma of 
skin 77 (74;80) (12) 79 44 (42;46) (13) 76 59 (58;61) (13) 78
Bladder 91 (86;95) (11) 85 31 (30;33) (16) 88 57 (55;59) (14) 86
Stomach 67 (64;69) (14) 97 42 (40;44) (14) 98 53 (52;55) (15) 97
Oral cavity 75 (73;78) (13) 84 27 (26;28) (17) 83 50 (49;51) (16) 84
Corpus uteri — — — 89 (86;92) (7) 87 47 (46;49) (17) 87
Myeloma 55 (53;57) (15) 93 41 (39;43) (15) 94 47 (46;49) (18) 94
Cervix uteri — — — 71 (69;74) (10) 90 37 (35;38) (19) 90
Larynx 30 (29;32) (16) 91 8 (7;9) (21) 93 18 (18;19) (20) 92
Gallbladder 13 (12;14) (17) 96 17 (16;18) (19) 97 15 (15;16) (21) 97
Thyroid 10 (9;10) (20) 75 15 (14;16) (20) 51 12 (12;13) (22) 60
Hodgkin 
lymphoma 11 (10;12) (18) 88 8 (7;8) (22) 87 9 (9;10) (23) 88
Testis 10 (9;11) (19) 82 — — — 5 (5;6) (24) 82
All Other 
cancers 311 (302;321) — 98 249 (242;257) — 97
278 
(271;284) — 98
a Excludes basal and squamous skin cancers 
Notes: NS: nervous system; NHL: Non-Hodgkin lymphoma
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Table S7A. Disability-Adjusted Life Years (DALYs) age-standardized rates (ASR) per 
100,000, with 95% confidence intervals, rank of cancer, and proportion of Years of Life 
Lost (YLLs) rate in ASR, in Non-Hispanic Whites and Non-Hispanic Blacks, in 2011
MEN
Cancer Non-Hispanic White Non-Hispanic Black
ASR Rank %YLLs ASR Rank %YLLs
All cancers a 3088 (3000;3183) 91 4003 (3868;4114) 91
Lung 817 (790;847) (1) 98 1031 (994;1069) (1) 98
Prostate 298 (281;316) (2) 55 650 (616;688) (2) 64
Colorectum 288 (278;297) (3) 88 436 (417;454) (3) 91
Pancreas 176 (169;182) (4) 99 221 (209;232) (5) 99
Leukemia 138 (132;144) (5) 96 137 (127;146) (6) 97
Brain & NS 129 (124;134) (6) 98 72 (65;79) (13) 98
Liver 128 (123;132) (7) 99 234 (222;247) (4) 99
Esophagus 125 (121;129) (8) 98 107 (100;115) (8) 98
NHL 116 (111;120) (9) 93 106 (99;114) (9) 94
Bladder 100 (95;104) (10) 85 69 (64;75) (14) 89
Melanoma of 
skin 100 (96;104) (11) 80 7 (5;9) (19) 92
Kidney 94 (90;98) (12) 93 94 (87;101) (12) 92
Oral cavity 76 (74;79) (13) 83 105 (97;112) (10) 92
Myeloma 51 (49;54) (14) 93 104 (96;111) (11) 93
Stomach 51 (48;53) (15) 97 131 (123;139) (7) 98
Larynx 29 (27;30) (16) 91 61 (56;66) (15) 94
Gallbladder 12 (11;13) (17) 96 16 (13;18) (16) 96
Hodgkin 
lymphoma 12 (10;13) (18) 88 14 (11;17) (17) 90
Testis 11 (10;13) (19) 80 4 (3;6) (21) 87
Thyroid 10 (9;11) (20) 74 6 (5;7) (20) 79
Breast 5 (5;6) (21) 75 10 (7;12) (18) 82
All Other 
cancers 322 (311;333) — 98 385 (369;403) — 98
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Table S7A. Disability-Adjusted Life Years (DALYs) age-standardized rates (ASR) per 
100,000, with 95% confidence intervals, rank of cancer, and proportion of Years of 
Life Lost (YLLs) rate in ASR, in Non-Hispanic Whites and Non-Hispanic Blacks, in 2011 
(continued)
WOMEN
Cancer Non-Hispanic White Non-Hispanic Black
ASR Rank % YLLs ASR Rank %YLLs
All cancers a 2758 (2686;2829) 91 3329 (3248;3415) 93
Lung 665 (644;686) (1) 98 620 (597;645) (2) 98
Breast 550 (530;569) (2) 76 793 (766;821) (1) 85
Colorectum 228 (222;236) (3) 88 342 (327;356) (3) 91
Ovary 148 (143;153) (4) 97 126 (118;134) (6) 97
Pancreas 143 (138;149) (5) 99 193 (182;203) (4) 99
Brain & NS 97 (93;100) (6) 98 57 (51;64) (13) 98
Leukemia 96 (92;100) (7) 96 97 (90;105) (8) 97
Corpus uteri 83 (80;86) (8) 86 149 (140;158) (5) 93
NHL 73 (70;77) (9) 92 69 (63;75) (12) 94
Cervix uteri 66 (63;69) (10) 89 111 (103;120) (7) 95
Melanoma of 
skin 59 (56;61) (11) 76 8 (6;10) (22) 92
Liver 53 (50;55) (12) 99 86 (79;93) (9) 99
Kidney 45 (43;47) (13) 92 53 (48;58) (14) 92
Myeloma 36 (34;38) (14) 94 86 (80;93) (10) 94
Bladder 32 (31;34) (15) 87 39 (36;43) (15) 92
Stomach 28 (27;30) (16) 98 73 (68;80) (11) 97
Oral cavity 28 (27;30) (17) 82 30 (26;33) (17) 89
Esophagus 26 (25;28) (18) 98 36 (32;40) (16) 98
Thyroid 15 (13;16) (19) 47 13 (11;15) (19) 63
Gallbladder 14 (13;15) (20) 97 25 (22;28) (18) 97
Larynx 8 (8;9) (21) 92 11 (9;14) (20) 93
Hodgkin 
lymphoma 8 (7;9) (22) 86 9 (7;11) (21) 89
All Other 
cancers 258 (250;267) — 97 304 (291;319) — 98
a Excludes basal and squamous skin cancers
Note: NS: nervous system; NHL: Non-Hodgkin lymphoma
150 Chapter 3.1
Table S7B. Disability-Adjusted Life Years (DALYs) age-standardized rates (ASR) per 
100,000, with 95% confidence intervals, rank of cancer, and proportion of Years of Life 
Lost (YLLs) rate in ASR, in Hispanics and Non-Hispanic Asians, in 2011
MEN
Cancer Hispanic Non-Hispanic Asian
ASR Rank %YLLs ASR Rank %YLLs
All cancers a 2165 (2096;2235) 90 1873 (1804;1939) 91
Lung 355 (338;373) (1) 97 417 (392;441) (1) 98
Prostate 264 (248;281) (2) 57 148 (135;160) (4) 52
Colorectum 235 (224;247) (3) 86 208 (194;224) (3) 83
Liver 209 (199;221) (4) 99 242 (225;259) (2) 99
Pancreas 136 (127;146) (5) 99 112 (102;123) (5) 99
Leukemia 111 (104;118) (6) 96 96 (83;109) (7) 97
Stomach 102 (95;110) (7) 97 100 (90;112) (6) 97
NHL 91 (84;97) (8) 92 68 (61;76) (8) 92
Kidney 79 (72;85) (9) 92 42 (36;49) (12) 91
Brain & NS 72 (66;78) (10) 98 52 (43;62) (10) 98
Esophagus 63 (57;69) (11) 98 42 (36;49) (11) 98
Myeloma 47 (42;51) (12) 92 28 (23;33) (14) 92
Bladder 44 (40;49) (13) 83 30 (26;35) (13) 82
Oral cavity 42 (38;46) (14) 83 61 (53;70) (9) 87
Larynx 24 (21;28) (15) 91 11 (8;14) (17) 90
Melanoma of 
skin 18 (16;21) (16) 86 6 (3;8) (18) 87
Gallbladder 16 (13;18) (17) 95 19 (15;23) (15) 96
Testis 14 (11;17) (18) 89 2 (1;4) (21) 69
Hodgkin 
lymphoma 13 (11;15) (19) 91 5 (2;8) (19) 86
Thyroid 9 (7;11) (20) 79 11 (9;15) (16) 78
Breast 3 (2;4) (21) 73 2 (1;4) (20) 73
All Other 
cancers 218 (206;231) — 97 165 (150;181) — 98
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Table S7B. Disability-Adjusted Life Years (DALYs) age-standardized rates (ASR) per 
100,000, with 95% confidence intervals, rank of cancer, and proportion of Years of Life 
Lost (YLLs) rate in ASR, in Hispanics and Non-Hispanic Asians, in 2011 (continued)
WOMEN
Cancer Hispanic Non-Hispanic Asian
ASR Rank % YLLs ASR Rank %YLLs
All cancers a 1851 (1798;1911) 90 1751 (1692;1812) 90
Breast 385 (368;402) (1) 75 344 (323;365) (1) 72
Lung 197 (187;208) (2) 97 284 (267;303) (2) 98
Colorectum 173 (164;183) (3) 87 176 (164;189) (3) 86
Pancreas 109 (102;117) (4) 99 109 (99;119) (4) 99
Ovary 100 (93;108) (5) 96 99 (89;111) (5) 96
Leukemia 88 (81;95) (6) 97 70 (61;81) (8) 97
Liver 84 (77;91) (7) 99 94 (84;104) (6) 99
Stomach 77 (71;83) (8) 98 74 (65;83) (7) 98
Corpus uteri 77 (71;82) (9) 87 66 (59;74) (9) 87
Cervix uteri 74 (67;80) (10) 88 52 (45;61) (11) 92
NHL 67 (61;73) (11) 92 54 (47;61) (10) 92
Brain & NS 53 (47;59) (12) 98 43 (34;52) (12) 98
Kidney 41 (37;46) (13) 91 24 (20;30) (13) 93
Myeloma 38 (34;42) (14) 93 24 (19;29) (14) 94
Gallbladder 29 (25;33) (15) 97 18 (14;23) (17) 97
Bladder 18 (15;21) (16) 88 11 (8;13) (18) 84
Thyroid 16 (14;19) (17) 58 20 (16;23) (16) 63
Melanoma of 
skin 15 (13;18) (18) 81 6 (4;8) (20) 86
Oral cavity 15 (13;18) (19) 82 24 (19;29) (15) 84
Esophagus 13 (10;15) (20) 98 9 (7;12) (19) 98
Hodgkin 
lymphoma 7 (5;9) (21) 87 2 (1;4) (21) 79
Larynx 4 (3;5) (22) 91 1 (0;2) (22) 81
All Other 
cancers 174 (163;183) — 97 144 (131;158) — 97
a Excludes basal and squamous skin cancers
Note: NS: nervous system; NHL: Non-Hodgkin lymphoma
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Table S8. Discounts applied to the frequency of disabilities to account for prevalence in 
the general population
Age 
(years)
Impotence 
men (%)
Dyspareunia 
women (%)
Incontinence 
men (%)
Incontinence 
women (%)
Infertility 
men (%)
Infertility 
women (%)
0 3 6
1-4 3 6
5-9 3 6
10-14 3 6
15-19 11 2 3 6
20-24 11 2 3 6 10 10
25-29 11 2 3 6 10 15
30-34 15 3.5 3 6 10 15
35-39 15 3.5 3 6 15 20
40-44 21 4.5 6 10 15
45-49 21 4.5 6 10 20
50-54 30 5.5 6 10 20
55-59 30 5.5 6 10 20
60-64 41 6.5 6 10
65-69 41 6.5 9 14
70-74 51 8 9 14
75-79 9 14
80-84 9 14
85+ 9 14
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aBSTRaCT
Cigarette smoking is a leading preventable cause of death and disability from cancer 
in the US. We estimated smoking-attributable Disability-Adjusted Life Years (DALYs) 
lost, overall and within racial/ethnic groups, using published DALY estimates, smoking 
prevalence from survey data, and relative risks from large cohort studies. In 2011, 2.6 
million DALYs were lost to cancer due to cigarette smoking (27% of all DALYs lost to 
cancer). Smoking-attributable DALY rates were higher in men (968 per 100,000 people 
[95% confidence interval: 943–992]) than women (557 [540–574]). In combined sex 
analyses, DALY rates were higher in non-Hispanic Blacks (960 [934–983]) and non-
Hispanic Whites (786 [768–802]) than in Hispanics (409 [399–421]) and non-Hispanic 
Asians (335 [320–350]). However, smoking-attributable cancer burden is substantial 
in all racial and ethnic groups, underscoring the need for intensified tobacco cessation 
in all populations.
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BRIEf COMMunICaTIOn
Cigarette smoking remains a leading preventable cause of cancer death [1] and the 
second leading cause of overall Disability-Adjusted Life Years (DALYs) lost in the 
US.[2] Previous study estimated that smoking causes over 160,000 cancer deaths 
each year nationwide [3-5] and accounts for 21% of cancer deaths in Hispanics, 26% 
in non-Hispanic Whites (NHW), and 27% in non-Hispanic Blacks (NHB).[5] However, 
these estimates did not consider life years lost due to premature death and disability, 
measured by DALYs. We report estimates of cigarette smoking-attributable DALYs for 
the US overall and by race/ethnicity, to document smoking-related racial/ethnic health 
disparities.
The number of smoking-attributable DALYs lost to cancer was calculated as the sum 
of smoking-attributable Years of Life Lost (YLL) and smoking-attributable Years Lived 
with Disabilities (YLD). The smoking-attributable YLL and YLD were computed by 
multiplying the overall YLL and YLD for cancer previously calculated [6] for 2011, for 
adults 35 and older, by the population attributable fraction (PAF) for cigarette smoking, 
computed with the standard formula [7] for multi-category exposure. This formula 
incorporated smoking prevalence (never, former, current) and relative risks (RRs) for 
cancer death and occurrence. Smoking prevalence in 2009-2011, by race/ethnicity, 
sex, and age group was obtained from the National Health Interview Survey.[8] Race/
ethnicity was grouped as: NHW, NHB, Hispanic, and non-Hispanic Asian (NHA). Other 
races (American Indian/Alaska Native and unknown race) are not presented but are 
included in “All races/ethnicities”. We used RRs from large US prospective studies for 
death from, or occurrence of, 12 cancers caused by smoking according to the US Sur-
geon General:[9] cancers of the lip, oral cavity, and pharynx; esophagus; stomach; 
colon and rectum; liver; pancreas; larynx; trachea, lung and bronchus; cervix uteri; 
kidney and renal pelvis; urinary bladder; and acute myeloid leukemia. Specifically, we 
used RRs for cancer death by age group and sex for the 12 cancers combined, [4] and 
RRs for cancer occurrence by specific cancer and sex.[10]
The proportion of all DALYs lost to cancer that was attributable to smoking was cal-
culated by dividing the number of smoking-attributable DALYs lost from cancer in 
people ages 35 and over, by the total number of DALYs lost to cancer for all ages. 
Age-standardized rates (ASRs) of DALYs were calculated using the US 2000 standard 
population. The 95% confidence intervals (CI) were estimated via a bootstrap method.
[11]
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Overall, 2.6 million DALYs (95% confidence interval 2.6–2.7 million) lost to cancer were 
lost to cigarette smoking in 2011 in the US, representing 27% of DALYs (26%–27%) 
lost to cancer (Figure 1). The smoking-attributable cancer burden was higher in men 
(1.6 million DALYs [1.5–1.6 million]) than in women (1.0 million DALYs [1.0–1.1 mil-
lion]), and varied substantially by race/ethnicity, ranging from 10-12% in NHA and 
Hispanic women to 33-34% in NHW and NHB men. 
The smoking-attributable cancer burden, measured by DALY ASRs, was highest in NHB 
and NHW men (1,331 [1286–1372] and 994 [965–1021] DALYs per 100,000 people, 
respectively) (Figure 2). ASRs were about 40% lower in NHA and Hispanic men than 
in NHW men. Similarly, in women, the smoking-attributable ASRs were highest in NHB 
and NHW (679 [654–703] and 604 [584–624], respectively), and about two-thirds 
lower in NHA and Hispanics. 
The large variations in smoking-attributable cancer burden by sex and race/ethnicity 
reflect differences in current and past cigarette smoking prevalence. Smoking preva-
lence has traditionally been higher in men than in women in every racial and ethnic 
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Figure 1 Proportion and number (in millions) of Disablity-Adjusted Life Years (DALYs) 
due to cancer attributable to cigarette smoking by sex and race/ethnicity
Black: smoking-attributable DALYs. White: not smoking-attributable DALYs
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group, and in Blacks and Whites than in Hispanics or Asians. Among men, NHB used 
to have the highest smoking prevalence of all racial/ethnic groups [12] but have now 
almost matched the smoking prevalence of NHW (22% in NHB vs. 19% in NHW).[13] 
Reasons for high smoking prevalence among NHB include targeted marketing from the 
tobacco industry [14] and higher proportion of people with low socioeconomic status 
(SES), [15, 16] a characteristic strongly associated with smoking.[13] In contrast, 
smoking prevalence in Asians (10%) and Hispanics (11%) [13] is lower, despite a high 
frequency of low SES among Hispanics. This may in part reflect the high proportion of 
Asian and Hispanic migrants and the lower smoking prevalence in their countries of 
origin.[17, 18] 
This is the first study to detail the cancer burden attributable to smoking in the US us-
ing DALYs, both overall and within racial/ethnic groups. These estimates are valuable 
for tobacco control program to document and evaluate changes in smoking-related 
racial/ethnic health disparities. However, the limitations of the study must be borne 
in mind. RRs for both cancer occurrence and death were derived from large cohort 
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studies including predominantly white participants, as sufficiently precise RRs from 
prospective studies for specific racial/ethnic groups in the US are not available. These 
RRs may not accurately reflect the risk in Hispanics and Asians, who have lower 
smoking duration and intensity.[17] In addition, we estimated only the cancer burden 
attributable to cigarette smoking; our estimate does not include cancer burden from 
secondhand smoke, or use of pipes, cigars or smokeless tobacco.
In conclusion, despite substantial declines in smoking prevalence over the past five 
decades, cigarette smoking accounted for close to 3 out of the 10 million healthy life 
years lost to cancer per year in the US. Although the share of the smoking-attributable 
cancer burden is largest in NHB and NHW, the burden is substantial in Hispanics and 
Asians as well, underscoring the need for intensified tobacco cessation in all popu-
lations to reduce the burden of smoking-related cancer and other smoking-related 
diseases.
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aBSTRaCT
Importance: State-specific information about the health burden of smoking is valuable 
because state-level initiatives are at the forefront of tobacco control. Smoking-attrib-
utable cancer mortality estimates are currently available nationally and by cancer, but 
not by state. 
Objective: To calculate the proportion of cancer deaths among adults 35 years and 
older that were attributable to cigarette smoking in 2014 in each state and the District 
of Columbia. 
Design: The population attributable fraction (PAF) of cancer deaths due to cigarette 
smoking was computed using relative risks for twelve smoking-related cancers from 
large US prospective studies and state-specific smoking prevalence data from the 
Behavioral Risk Factor Surveillance System. 
Results: We estimate at least 167,133 cancer deaths in 2014 (28.6% of all cancer 
deaths, 95% confidence interval 28.2%–28.8%) were attributable to cigarette smok-
ing. Among men, the proportion of cancer deaths attributable to smoking ranged from 
a low of 21.8% in Utah (19.9%–23.5%) to a high of 39.5% in Arkansas (36.9%–
41.7%), but was ≥30% in every state except Utah. Among women, the proportion 
ranged from 11.1% in Utah (9.6%–12.3%) to 29.0% in Kentucky (27.2%–30.7%) and 
was ≥20% in all states except Utah, California, and Hawaii. Nine of the top ten ranked 
states for men and six of the top ten states for women were located in the South. In 
men, smoking explained nearly 40% of cancer deaths in the top five ranked states 
(Arkansas, Louisiana, Tennessee, West Virginia, and Kentucky). In women, smoking 
explained more than 26% of all cancer deaths in the top five ranked states, which 
included three Southern states (Kentucky, Arkansas and Tennessee), and two Western 
states (Alaska and Nevada). 
Conclusions and relevance: The proportion of cancer deaths attributable to cigarette 
smoking varies substantially across states and is highest in the South, where up to 
40% of cancer deaths in men are caused by smoking. Increasing tobacco control 
funding, implementing innovative new strategies, and strengthening tobacco control 
policies and programs, federally and in all states and localities would further increase 
smoking cessation, decrease initiation, and reduce the future burden of morbidity and 
mortality associated with smoking-related cancers.
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InTRODuCTIOn
Smoking prevalence in the US has been more than halved since the release of the 
first Surgeon General’s Report on the health hazards of cigarette smoking in 1964, as 
a result of increased awareness and implementation of public health policies against 
smoking.1 Nevertheless, there are still 40 million current adult cigarette smokers, 
and smoking remains the largest preventable cause of death from cancer and other 
diseases.2 Cigarette smoking accounted for an estimated 28.7% of all cancer deaths 
in US adults 35 years and older in 2010.3 However, there are no such estimates by 
state, despite substantial geographic variation in smoking prevalence.4 State-specific 
smoking-attributable mortality is particularly valuable for public health advocates and 
policy-makers because state-level initiatives are at the forefront of tobacco control 
efforts. Herein, we estimate the proportion of all cancer deaths explained by cigarette 
smoking in adults aged ≥35 years in each of the 50 states and the District of Columbia 
(DC). For convenience, we refer to DC as a state hereafter.
METHODS
We estimated the state-specific proportion of cigarette smoking-attributable cancer 
mortality (SACM) using methods similar to those of the 2014 Surgeon General’s 
Report,1 based on 12 cancers caused by cigarette smoking (acute myeloid leukemia 
and cancers of the oral cavity and pharynx; esophagus; stomach; colorectum; liver; 
pancreas; larynx; trachea, lung, and bronchus; cervix uteri; kidney and renal pelvis; 
and urinary bladder). To avoid potential bias, we calculated the overall population 
attributable fraction (PAF) for cancer deaths in each state using the weighted sums 
method.5 Specifically, we first calculated the PAF for each sex and age group (35-49, 
50-54, 55-59, … 85+) in each state, using the standard formula for multi-category 
exposure:6 
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3.3 Methods
We estima ed state-specific proportion of cigarette smoking-attributable cancer mortality 
(SACM) using methods simil r to those of the 2014 Surgeon General’s Report,1 based on 12 
cancers caused by cigarette smoki  ( cute myeloid l ukemia and cancers of the oral cavity 
and pharynx; esophagus; stomach; col rectum; liver; pancreas; larynx; trachea, lung, and 
bronchus; cervix uteri; kidney and renal pelvis; and urinary bladder). To avoid potential bias, 
we calculated the overall population attributable fraction (PAF) for cancer deaths in each 
state using the weighted sums method.5 Specifically, we first calculated the PAF for each sex 
and age group (35-49, 50-54, 55-59, … 85+) in each state, using the standard formula for 
multi-category exposure:6  
𝑃𝑃𝑃𝑃𝑃𝑃𝑠𝑠 = (𝑝𝑝0,𝑠𝑠 +  𝑝𝑝1,𝑠𝑠(𝑅𝑅𝑅𝑅1,𝑠𝑠) + 𝑝𝑝2,𝑠𝑠(𝑅𝑅𝑅𝑅2,𝑠𝑠)) − 1
𝑝𝑝0,𝑠𝑠 +  𝑝𝑝1,𝑠𝑠(𝑅𝑅𝑅𝑅1,𝑠𝑠) +  𝑝𝑝2,𝑠𝑠(𝑅𝑅𝑅𝑅2,𝑠𝑠)  
where s = age; p0, p1, p2 = proportion of never, former, and current smokers, respectively; and 
RR1, RR2 = relative risk for former and current smokers, respectively, compared with never 
smokers. 
Age-, sex- and state-specific smoking prevalence (never, former, or current) were calculated 
based on data from the 2014 Behavioral Risk Factor Surveillance System survey (BRFSS), 
which is the only national survey designed to provide reliable state-level estimates of health 
behaviors.4 Smoking prevalence estimates were based on 372,759 survey participants 35 
where s = age; p0, p1, p2 = proportion of never, former, and current smokers, re-
spectively; and RR1, RR2 = relative risk for former and current smokers, respectively, 
compared with never smokers.
Age-, sex- and state-specific smoking prevalence (never, former, or current) were 
calculated based on data from the 2014 Behavioral Risk Factor Surveillance System 
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survey (BRFSS), which is the only national survey designed to provide reliable state-
level estimates of health behaviors.4 Smoking prevalence estimates were based on 
372,759 survey participants 35 years and older who provided information on smoking 
status. These smoking prevalence estimates were generated from the weighted public 
data provided by the Centers for Disease Control and Prevention (CDC). Weighting was 
based on characteristics such as sex, age, race and ethnicity, education, and marital 
status to adjust for nonresponse bias and ensure that the sample was representative.7 
Age- and sex-specific (but not state-specific) relative risks for death for current and 
former smoking status were those for a composite outcome of any of the 12 smoking-
related cancers as reported from analyses of the Cancer Prevention Study-II (442,960 
participants) and Pooled Contemporary Cohort (954,029 participants).3 
For each state, the number of smoking-attributable cancer deaths in each age and sex 
group was calculated by multiplying the age- and sex-specific PAFs by the correspond-
ing observed 2014 cancer death counts obtained from the National Center for Health 
Statistics.8 The total number of smoking-attributable cancer deaths in each state was 
then calculated by summing across all age and sex groups. Finally, the overall SACM 
in each state was calculated by dividing the number of estimated smoking-attributable 
cancer deaths by the total number of cancer deaths among persons 35 year and 
older in each state. The 95% confidence intervals on the SACM were estimated via a 
bootstrap method,9 with 5,000 simulations.
To illustrate the geographic variation in SACM, we mapped the results grouping states 
by number rank (1 being the highest SACM). 
Differences in SACM between states may be partly due to differences between states 
in racial and ethnic composition because smoking prevalence substantially varies by 
race/ethnicity.2 To compare a measure of SACM between states that was not influ-
enced by racial and ethnic composition, we calculated SACM by state for non-Hispanic 
White (NHW) men. We then assessed whether variation in SACM across states in 
NHW men was similar to that for all races/ethnicities combined using Spearman’s 
correlation. Sparse data precluded similar comparison for other racial/ethnic and sex 
groups. However, we also calculated national SACM estimates for NHW, non-Hispanic 
blacks (NHB), and Hispanics using smoking prevalence from in the National Health 
Interview Survey (NHIS, 51,637 participants 35 years and older) during 2013–201410 
and relative risks of cancer death as described above. 
Finally, as a sensitivity analysis, we compared the SACM in four regions (South, Mid-
west, West, and Northeast according to the Bureau of Census classification)11 using 
smoking prevalence from the NHIS with that estimated using smoking prevalence 
from the BRFSS.
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RESuLTS
In 2014, at least 167,133 cancer deaths (28.6% of all cancer deaths) in persons 
aged ≥35 years in the US were attributable to cigarette smoking, with 103,609 of 
these deaths occurring in men (62.0%) and 63,524 in women (38.0%) (Table 1). The 
proportion of SACM ranged from 21.8% in Utah to 39.5% in Arkansas among men, 
and from 11.1% in Utah to 29.0% in Kentucky among women. Many of the states 
with the highest proportions of SACM were located in the South, including nine of 
the top ten states for men (Arkansas, Louisiana, Tennessee, West Virginia, Kentucky, 
Alabama, Mississippi, North Carolina and Oklahoma) (Figure 1). Notably, smoking ex-
plained nearly 40% of adult male cancer deaths in five of these states. Southern states 
dominated the top ten SACM states among women as well, but the second and third 
ranked states were Alaska (27.5%) and Nevada (27.1%) — which ranked 18th and 
20th, respectively, in men. For both sexes combined, seven of the top ten states were 
located in the South, two in the West (Alaska and Nevada) and one in the Midwest 
(Missouri). While California had the lowest SACM after Utah, it had the highest number 
of deaths explained by smoking, because of its large population.
A. Men
Figure 1A. Rank and proportion of cancer mortality attributable to cigarette smoking, for 
men (A), women (B), and both sexes (C) in 2014
Footnote: States are ranked by the proportion of cancer deaths attributable to cigarette smoking, from highest (1) 
to lowest (51). States were categorized into four groups (group 1, states ranked 1-10; group 2, those ranked 11-40; 
group 3, those ranked 41-50; and group 4, Utah alone as the proportion was substantially lower than in any other 
state). The color of the state indicates the proportion of cancer deaths attributable to cigarette smoking. 
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B. Women
B. Women
Figure 1B. Rank and proportion of cancer mortality attributable to cigarette smoking, for 
men (A), women (B), and both sexes (C) in 2014
Footnote: States are ranked by the proportion of cancer deaths attributable to cigarette smoking, from highest (1) 
to lowest (51). States were categorized into four groups (group 1, states ranked 1-10; group 2, those ranked 11-40; 
group 3, those ranked 41-50; and group 4, Utah alone as the proportion was substantially lower than in any other 
state). The color of the state indicates the proportion of cancer deaths attributable to cigarette smoking. 
C. Both sexes
C. Both sexes
Figure 1C. Rank and proportion of cancer mortality attributable to cigarette smoking, for 
men (A), women (B), and both sexes (C) in 2014
Footnote: States are ranked by the proportion of cancer deaths attributable to cigarette smoking, from highest (1) 
to lowest (51). States were categorized into four groups (group 1, states ranked 1-10; group 2, those ranked 11-40; 
group 3, those ranked 41-50; and group 4, Utah alone as the proportion was substantially lower than in any other 
state). The color of the state indicates the proportion of cancer deaths attributable to cigarette smoking. 
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State-specifi c rankings for NHW men were generally similar to those for all raceraces/
ethnicities combined (Spearman’s correlation coeffi  cient = 0.91, p<0.001), with the 
notable exception of DC (SACM of 18.5% in NHW men vs. 33.3% in men overall) (eFig-
ure 1). Nationally, NHBs had the highest SACM (26.9%), followed by NHWs (25.5%) 
and Hispanics (20.5%) (Figure 2). Finally, estimates of SACM at the regional level 
using smoking prevalence from the NHIS were equivalent to those estimated using 
smoking prevalence from BRFSS (eTable 1).
DISCuSSIOn
In most states, about a third of cancer deaths in men and a quarter in women are ex-
plained by cigarette smoking. However, consistent with smoking-attributable all-cause 
mortality,12 cancer deaths are associated with cigarette smoking less often in Western 
states and more often in the South, particularly among men. For example, smoking 
accounted for nearly 40% of cancer deaths among men in fi ve Southern states. The 
larger burden of SACM in men than in women likely refl ects a lower prevalence of 
smoking among women than men in the older birth cohorts.13,14 However, gender 
diff erences in SACM may diminish in the future because smoking histories and risk of 
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Figure 2. National proportion of cancer deaths attributable to cigarette smoking, by race 
and ethnicity, with 95% confi dence intervals, in 2014
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mortality from smoking-related diseases are comparable for men and women in more 
recent birth cohorts.15 In fact, female smoking prevalence recently surpassed male 
smoking prevalence in South Dakota, Montana, and Arkansas.16 
Higher SACM in the South is driven by higher historic smoking prevalence, which has 
prevailed in large part due to weaker tobacco control policies and programs. Policy 
initiatives are heavily influenced by the tobacco industry in all states,17,18 especially 
those in the South,19 where 95% of the US tobacco crop is grown.20 Although spending 
on tobacco control is inversely associated with smoking prevalence,21,22 only five states 
spent at least 50% of the amount recommended by the Centers of Disease Control and 
Prevention (CDC) in 2016.23 In particular, eight of the 21 states that spend less than 
10% of the CDC recommended amount are located in the South (Alabama, Georgia, 
Kentucky, North Carolina, South Carolina, Tennessee, Texas, and Virginia). Tobacco 
control spending by all states combined was under $500 million in 2016, far less than 
the $10 billion spent annually by the tobacco industry on marketing.24 
Public smoking restrictions and high cigarette prices (through excise taxes, price 
promotion restrictions, and minimum price laws)25 are among the most effective to-
bacco control policies,26,27 and both are primarily legislated by states. Again, the least 
restrictive public smoking policies and most affordable cigarettes are in the South. 
Nine of fourteen states with the least comprehensive smoke-free indoor air laws are 
in this region28 and the average cigarette excise tax is $0.49 in major tobacco states, 
compared with $1.80 in other states (and as high as $4.35 in New York).29 However, 
there are signs that the tobacco industry’s influence has waned somewhat in Southern 
tobacco-growing states in recent years, facilitating improvement in tobacco control 
policies30 and highlighting the opportunity for more rapid progress in the future.
The higher SACM in Southern states may also be due in part to disproportionately high 
levels of low socioeconomic status, which is associated with higher smoking preva-
lence2 and lower smoking cessation rates.31 Smoking prevalence among adults with 
a high school education or less are two to four times those among college graduates2 
and people with a lower educational attainment have a lower awareness of the health 
hazards of smoking.32 Only half (50%) of adults in Kentucky have more than a high 
school education, compared with 68% in Colorado.31 In addition, racial differences in 
smoking prevalence and population distribution may account for some variation in the 
SACM by state. For example, black men have a higher SACM and a higher proportion 
of smoking-attributable all-cause mortality,33 reflecting historically higher smoking 
prevalence compared with white men.34 In some Southern states (e.g. Louisiana, Mis-
sissippi), blacks account for more than 30% of the population compared with less than 
5% in many Western and Northern states (e.g. Utah, Connecticut).35 Conversely, some 
states, such as California and Texas, are disproportionately populated by Hispanics,35 
among whom SACM is lower. Nevertheless, the SACM by state for NHW men is gener-
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ally similar to that of all men, indicating that variation in racial composition is unlikely 
to be the driving factor for state differences in SACM. Of note, DC showed the lowest 
SACM for NHW men, reflecting the large proportion of highly educated men (85% with 
a Bachelor’s degree or more)31 in whom awareness about the health hazards of smok-
ing is highest.32 The comparatively low SACM in Utah reflects the religious prohibition 
of smoking among Mormons.36
In addition to Southern states, Alaska and Nevada had particularly high SACM, es-
pecially among women. In Alaska, which had the second highest SACM in women, 
smoking prevalence was the same in men and women in 2009, in contrast to most 
states where it was 10% to 60% higher in men.16 Nevada is one of a handful of non-
Southern states that still allows smoking in bars and casinos.37 A previous study of 
smoking-attributable all-cause mortality found that Nevada had the highest fraction 
of deaths explained by smoking of any state.38 Missouri is another non-Southern state 
with high SACM, ranking seventh for both sexes combined. It has the lowest cigarette 
excise tax ($0.17) of any state, 90% lower than the national average of $1.65.29
Tobacco control has been credited with preventing about 8 million premature deaths in 
the US over the past five decades, equivalent to 157 million years of life saved.39 Our 
data shows that there remains the potential to avert many more premature deaths in 
light of suboptimal funding for tobacco control programs, not only in the South, but in 
all states. As of 2016, two-thirds of states lack 100% smoke-free laws in public places 
to protect the general public from second hand smoke;40 no state41 has a cigarette 
excise tax that accounts for at least for 70% of the retail price, as recommended by 
the WHO;42 and only one state (North Dakota) funds its tobacco control programs 
at the level recommended by the CDC.23 The Affordable Care Act includes coverage 
of cessation treatments without cost-sharing for the privately and Medicare-insured. 
However, for Medicaid enrollees – who are twice as likely to smoke2 – coverage is 
state-governed, and only seven states provide comprehensive coverage (Connecticut, 
Indiana, Massachusetts, Minnesota, Nevada, Pennsylvania, Vermont).43 Although 
there has generally been a stagnation in the adoption of traditional comprehensive 
tobacco control,44 some states and localities have implemented innovative approaches 
to fight the tobacco epidemic. For instance, California, Hawaii, and 145 smaller locali-
ties have raised the tobacco sales age to 2145 —a measure supported by the Institute 
of Medicine.46 Likewise, communities across the US have passed laws that limit or 
prohibit smoking in multi-family housing.47 The federal government can do much more 
to accelerate cessation and discourage initiation, including requiring manufacturers of 
tobacco products to reduce nicotine content to nonaddictive levels,48 raising federal 
tobacco taxes, and maintaining funding of anti-smoking campaigns.49 With fully one-
third of tobacco-related cancer deaths in men and one-quarter in women preventable 
with current knowledge, tobacco control should spearhead the Cancer Moonshot initia-
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tive to accelerate progress against cancer. However, it is important to realize that 
given the lag time between tobacco use and cancer diagnosis,50 the impact of today’s 
policies will be most evident on the future cancer burden. 
Our study likely underestimated deaths caused by tobacco use for several reasons. 
First, only 12 cancers were included for consistency with the Surgeon General’s report;1 
however, cigarette smoking is associated with excess mortality for additional cancers.3,51 
Second, self-reported data are known to underestimate smoking prevalence.52 Third, 
deaths caused by tobacco exposures other than active cigarette smoking, including 
second hand smoke, pipes, hookahs, cigars, smokeless tobacco, and electronic nico-
tine delivery systems, were not included in our analysis. Due to changing patterns of 
tobacco use,53 products other than cigarettes may account for a greater proportion of 
all tobacco-related cancer deaths in the future. Finally, confidence intervals for SACM 
in some states were relatively wide due to limited precision of smoking prevalence 
estimates available from BRFSS in some age groups. However, the BRFSS is the only 
national survey designed to provide estimates of state-level smoking status. Although 
the response rate for the BRFSS is lower (47%) than that for the NHIS (61%),10 the 
surveys report generally comparable smoking prevalence estimates54 which generate 
remarkably similar SACM when compared at the regional level. Notably, higher SACM 
was less apparent in the Census Bureau-defined Southern region because it includes 
states such as Maryland, which has exceptionally low smoking prevalence (16.4% 
in 2013),55 and Texas, which has a large lower-smoking Hispanic population.56 This 
illustrates the high variability of smoking-attributable disease within regions and sup-
ports the value of state-specific analyses.
COnCLuSIOn
The proportion of cancer deaths attributable to cigarette smoking varies substantially 
across states and is highest in the South, where up to 40% of cancer deaths in men 
are caused by smoking. However, the human costs of cigarette smoking are staggering 
in all states, regardless of ranking. Increasing tobacco control funding, implementing 
innovative new strategies, and strengthening tobacco control policies and programs, 
federally and in all states and localities would further increase smoking cessation, 
decrease initiation, and reduce the future burden of smoking-related cancers.
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eTable 1. Number and proportion of cancer deaths attributable by US region to smoking 
using smoking prevalence from the Behavioral Risk Factor Surveillance System (BRFSS) 
and the National Health Interview Survey (NHIS)
Cancer deaths attributable to smoking
and 95% confidence interval
Proportion of cancer deaths attributable to 
smoking (%) and 95% confidence interval
BRFSS NHIS BRFSS NHIS
Northeast 29698 32312 27.3 (25.9;28.6) 28.2 (26.4;29.8)
Midwest 40164 40235 29.3 (27.9;30.6) 29.5 (27.9;30.9)
South 66069 65375 29.8 (28.4;31.1) 30.3 (29.0;31.5)
West 32037 30543 26.4 (25.0;27.8) 27.3 (25.7;28.7)
US 167968 168465 28.7 (27.8;29.2) 28.8 (28.2;30.2)
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aBSTRaCT
Background: Chronic obstructive pulmonary disease (COPD) and lung cancer are com-
mon among smokers, often overlapping in the same patients. Our objectives were to 
present international patterns and trends of COPD mortality —in some countries for 
the first time— and to tease out the contribution of smoking in COPD mortality, using 
lung cancer as indirect indicator of the accumulated hazards of smoking.
Methods: Death counts in adults 35 years and older for each condition, for 1994–2013, 
were extracted from the WHO mortality database, for 46 countries with data span ≥11 
years, and 13 countries for shorter periods. Age-standardized mortality rates, average 
annual percentage change in rates, mean age at death, and future death counts, by 
sex, cause of death, and country were reported.
Findings: Since around 2003, mortality rates declined or were stable in men in both 
COPD and lung cancer in 45 out of 46 countries, and in 40 countries in women in COPD. 
In contrast, female lung cancer increased in half of the countries. The declines were 
greater in COPD than lung cancer. Meanwhile, the number of deaths increased in both 
conditions, largely for demographic reasons. Around 2011–2013, rates for both men 
and women in high-income countries were up to ten times higher in lung cancer than 
COPD. In contrast, in most middle-income countries in Latin America and Asia, COPD 
rates were up to five times higher than lung cancer rates. Despite favorable declining 
trends, future deaths counts will not drop because of population growth and ageing.
Interpretation: The higher COPD than lung cancer rates in middle-income Latin Ameri-
can and Asian countries highlight the role of risk factors beyond smoking in COPD 
death, including poverty, air pollution, respiratory infections, and asthma in those 
countries. 
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InTRODuCTIOn
Chronic obstructive pulmonary disease (COPD) and lung cancer (lung cancer) are 
major causes of mortality worldwide. In 2015, COPD was the fourth-leading cause 
of death (5·6% of deaths) and lung cancer the seventh (2·9% of deaths), with large 
regional variations.1 Since the beginning of their rise at the turn of the twentieth 
century, international trends in lung cancer mortality have been extensively reported 
in industrialized countries.2-4 Lung cancer etiology is well-studied and largely follows 
the trend and pattern of tobacco smoking prevalence with a 20–30-year lag time. 
However, lung cancer is also frequent in never-smoking women in Asia, in part due to 
genetic susceptibility and indoor air pollution. 
Contrary to lung cancer, the research on COPD is more recent. Lung cancer and COPD 
share several etiological factors, and in particular tobacco smoking.5 Accordingly, pa-
tients are often affected by both diseases (e.g. 20% of lung cancer patients in Europe6, 7 
and 50% of lung cancer patients in New Zealand).8 It has been postulated that the 
epidemiology of lung cancer and COPD mirror each other,9 but with different courses. 
On the one hand, lung cancer is mostly diagnosed after prolonged exposure to tobacco 
smoke. On the other hand, and although the condition becomes clinically apparent 
around the age of 40–50 years, the causes of COPD –other than smoking– can be 
traced back early in life, through insults to the lung (e.g. respiratory tract infections, 
exposure to maternal smoking, and air pollution) or sub-optimal lung development 
(due to undernourishment).10 The proportion of smoking-attributable deaths in each 
condition varies by country and by sex. In 2000, around 90% of lung cancer and 85% 
of COPD deaths in men in high-income countries (HICs) were attributed to smoking, 
and 80% and 60% in low- and middle-income countries (LMICs), respectively.11 The 
proportions were lower in women in HICs (around 78% of lung cancer and 70% of 
COPD deaths attributable to smoking) and in LMICs (50% and 34%, respectively).
Observed data from HICs5, 9, 12-17 and modeled data in a global study18 have reported 
declines in COPD mortality rates since the 1990s or the 2000s, depending on the 
country. Yet, little is known about trends in COPD mortality in LMICs, in Latin America, 
and more recently in Asia. Our first objective was to describe the most up-to-date 
trends in COPD mortality, including in Latin America and Asia, and by income group. 
Our second objective was to tease out the contribution of smoking in COPD mortality. 
As long-term annual smoking prevalence is not available for all countries, lung cancer 
mortality was used as an indirect indicator of the accumulated hazards of smoking.19 
Our hypothesis was that if smoking had the same impact on COPD and lung cancer 
mortality, then trends and patterns in lung cancer and COPD mortality rates would 
fairly match within one country and one sex. Finally, we reported the change in death 
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counts of these two conditions in high-income and middle-income countries over the 
last ten years and provided insight on their future burdens based on historical trends.
METHODS
Death counts for ages 35 and older –to focus on the effects of smoking– were extracted 
from the World Health Organization (WHO) mortality database20 by sex and 5-year age 
group. Underlying cause of death ICD-10 codes J40-44 for COPD (chronic bronchitis 
[J40-J42], emphysema [J43], and other COPD [J44]),17 and C33-C34 for trachea, 
bronchus and lung cancer were extracted for 1994–2013 (varying by country). No 
imputation of ill-defined codes was performed. Data from countries with at least 
70% of national population coverage and less than 20% of ill-defined cause of death 
since 1995, with the most recent year available after 2005 and a national population 
≥300 000 inhabitants in 2010 were selected. Sixty-one countries met the criteria, with 
46 of them providing ≥11 years of continuous data —the minimum number of years 
required for trend analysis. Only years with less than 10% of deaths from COPD at 
unknown age were analyzed. Corresponding population data were obtained from the 
same database, and completed with United Nations (UN) population 2015 revision 
estimates. Countries were grouped into regions according to the UN classification, 
and into income group (41 HICs and 20 middle-income countries [MICs]) according 
to the World Bank classification. Notably, no low-income country passed the selec-
tion process. Specifically, there were no representative data from sub-Saharan Africa, 
India and China.
Age-standardized mortality rates were computed using the world standard popula-
tion. COPD and lung cancer rates for the last two years (around 2011–2013) were 
compared to depict the most recent mortality burden. To assess changes in trends, 
the annual percent change (APC) and the average annual percentage change (AAPC) 
for the last ten available years of data were computed, using a Joinpoint regression 
analysis (details in Supplement). Details of the mean age at death computation are in 
the Supplement.
Relatively simple models were used to predict 2016 and 2030 premature (ages 35– 69) 
mortality burdens, by sex, condition, and country income group. National mortality 
trends over the last 10 years were assumed to continue until 2030, and future rates 
were applied to UN forecasted national populations.
Role of the funding source
The study sponsor had no role in study design; in the collection, analysis, and inter-
pretation of data; in the writing of the report; and in the decision to submit the paper 
for publication.
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RESuLTS
Over the whole study period, in most of the countries selected for trend analysis, rates 
have been declining —generally steadily— or remained stable, in both sexes in COPD, 
and in male lung cancer (Figure 1 and Supplement Tables 2 and 3A). In contrast, 
female lung cancer rates have been increasing in half of the countries (Supplement 
Table 3B). For instance, in the Netherlands, over 1996–2013, COPD rates remained 
stable in women but were halved in men. Meanwhile, female lung cancer rates doubled 
and male rates declined by a third.
Over the last ten years (since around 2003), male rates declined or were stable in 
both conditions in all countries and across income levels except for three populations 
(COPD rates increased in Paraguay and Czech Republic, as well as lung cancer rates 
in Paraguay and Romania) (Figure 2A). The declines were greater in COPD than lung 
cancer rates, and very large in some countries (≥6% annual decline in The Republic 
of Moldova, Kyrgyzstan, Slovenia, and Malta). Female COPD rates also declined or 
levelled off in all countries except six HICs European countries (Luxembourg, Czech 
Republic, Hungary, Norway, Croatia, and Germany). In contrast, female lung cancer 
rates were modestly declining or stable in about half of the countries (in America, Asia, 
Northern Europe, Republic of Moldova, Luxembourg, Malta and New Zealand) while 
they were increasing in five South American countries, Israel, 15 European countries, 
and Australia (Figure 2B). Declines in lung cancer rates were greater in men than 
in women. As a result, male and female trends have been converging in 25 of 46 
countries in COPD (in Northern, Central and South America, Northern, Southern and 
Western Europe, and Oceania) and 40 of 46 countries in lung cancer.
Recent mortality rates (around 2011–2013) varied around 18-fold between the coun-
tries with the lowest and the highest rates in men in both COPD and lung cancer, and 
25- and ten-fold in women, respectively (Figure 3 and Supplement Tables 1A and 1B). 
The lowest COPD mortality rates were observed in Kuwait and Japan, in both men 
and women (around ten and two deaths per 100 000 person-years, respectively). The 
highest COPD rates were observed in Kyrgyzstan and the Philippines in men (around 
120), and in Kyrgyzstan and Denmark in women (around 50). Female COPD rates were 
usually lower than male rates, but nearly matched in Sweden, Iceland, Denmark and 
the USA. The lowest lung cancer mortality rates (≤30 in men and ≤15 in women) were 
observed in MICs in Latin America, the Caribbean and Asia; the highest rates were 
observed in HICs, all over Europe in men (≥100) and Northern and Western Europe, 
and Canada in women (≥60). Hungary exhibited the highest lung cancer rates in both 
men and women (178 and 73, respectively). In both sexes, mortality COPD rates were 
generally higher than lung cancer rates in MICs, and always lower than lung cancer 
rates in HICs (except in Venezuelan women). 
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Figure 1A Trends in age-standardized mortality rates in chronic obstructive pulmonary 
disease (COPD) and lung cancer, for ages 35 and older
Portugal had no data for 2004–2006, Trinidad and Tobago had no data for 2003. Age-standardized rates from coun-
tries with fewer than 1 million inhabitants (Bahamas, Belize, Iceland, and Malta) were smoothed with a moving aver-
age of 50% of the annual values.
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Figure 1B Trends in age-standardized mortality rates in chronic obstructive pulmonary 
disease (COPD) and lung cancer, for ages 35 and older
Portugal had no data for 2004–2006, Trinidad and Tobago had no data for 2003. Age-standardized rates from coun-
tries with fewer than 1 million inhabitants (Bahamas, Belize, Iceland, and Malta) were smoothed with a moving aver-
age of 50% of the annual values.
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Figure 1C Trends in age-standardized mortality rates in chronic obstructive pulmonary 
disease (COPD) and lung cancer, for ages 35 and older
Portugal had no data for 2004–2006, Trinidad and Tobago had no data for 2003. Age-standardized rates from coun-
tries with fewer than 1 million inhabitants (Bahamas, Belize, Iceland, and Malta) were smoothed with a moving aver-
age of 50% of the annual values.
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Figure 1D Trends in age-standardized mortality rates in chronic obstructive pulmonary 
disease (COPD) and lung cancer, for ages 35 and older
Portugal had no data for 2004–2006, Trinidad and Tobago had no data for 2003. Age-standardized rates from coun-
tries with fewer than 1 million inhabitants (Bahamas, Belize, Iceland, and Malta) were smoothed with a moving aver-
age of 50% of the annual values.
198 Chapter 4.1
DO DP DG V G P O
Average annual percent change in mortality rate (%)
H
ig
hD
in
co
m
e
M
id
dl
eD
in
co
m
e
Malta
Slovenia
Lithuania
Republic of Korea
New Zealand
Netherlands
Spain
Belgium
Australia
Luxembourg
Canada
Finland
Austria
Israel
Japan
France
Denmark
Slovakia
Uruguay
Sweden
USA
United Kingdom
Chile
Bahamas
Norway
Latvia
Venezuela
Germany
Estonia
Iceland
Hungary
Croatia
Czech Republic
Kyrgyzstan
Republic of Moldova
Panama
Costa Rica
Brazil
Romania
Mexico
Colombia
Serbia
Cuba
Belize
Ecuador
Paraguay
A. Men
COPD COPD, no significant change
Lung Cancer Lung cancer, no significant change
6.8
-7.1
-6.6
-8.1
-8.5
-9.4
Figure 2A Average annual percent change over the last ten years (since around 2003) 
in chronic obstructive pulmonary disease (COPD) and lung cancer mortality rates, for 
ages 35 and older, in men
Values are sorted by decreasing average annual percent (AAPC) change in COPD mortality rate, within income group.
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Figure 2B Average annual percent change over the last ten years (since around 2003) 
in chronic obstructive pulmonary disease (COPD) and lung cancer mortality rates, for 
ages 35 and older, in women
Values are sorted by decreasing average annual percent (AAPC) change in COPD mortality rate, within income group.
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Figure 3A Mean age-standardized mortality rate in chronic obstructive pulmonary dis-
ease (COPD) and lung cancer, for ages 35 and older, over the last two years of data 
(around 2011–2013), in men
Values are sorted by decreasing age-standardized mortality rate in COPD, within income group.
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Figure 3B Mean age-standardized mortality rate in chronic obstructive pulmonary dis-
ease (COPD) and lung cancer, for ages 35 and older, over the last two years of data 
(around 2011–2013), in women
Values are sorted by decreasing age-standardized mortality rate in COPD, within income group.
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The number of COPD and lung cancer deaths increased over the last ten years in most 
of the countries (Table 1). This increase was greater in women than in men (21% 
increase in deaths in COPD and 24% lung cancer in women, vs. 13% and 6% in men, 
respectively) and greater in MICs than in HICs. During the last two years of data, 
almost 438 000 people (44% women), aged 35 years and older, died from COPD annu-
ally, in the 61 countries studied (Table 1). Meanwhile, 577 000 died from lung cancer 
(36% women). However, COPD deaths exceeded lung cancer deaths, in the majority of 
countries (all MICs) in Latin America (such as Brazil, Colombia, and Mexico) and some 
Asian countries (Kyrgyzstan, Uzbekistan, and the Philippines). Additionally, more 
women died from COPD than lung cancer in seven HICs: Chile, Denmark, Norway, 
Portugal, USA, Uruguay and Venezuela. Of note, the number of COPD deaths among 
women surpassed that of men in Northern Europe (Denmark, Iceland, and Sweden) 
and in the USA, and was identical in Norway. 
Table 1A. Chronic obstructive pulmonary disease (COPD) and lung cancer (LC) deaths, 
during the last two years of available data, proportional change in death counts, mean 
age at death, in middle-income countries
Men Women
Mean annual 
deaths
Change in 
deaths over 
the last 10 
years (%)
Mean age 
at death 
(years)
Mean 
annual 
deaths
Change in 
deaths over 
the last 10 
years (%)
Mean 
age at 
death 
(years)
Region Country Study period COPD LC COPD LC COPD LC COPD LC COPD LC COPD LC
Africa
Mauritius 2005–2013 70 107 * * 76 68 20 42 * * 82 69
Latin America and the Caribbean
Belize 2002–2012 19 15 † † 72 66 8 4 † † 73 66
Brazil 1996–2012 22719 13861 13% 29% 76 68 16456 8880 31% 75% 76 67
Colombia 1997–2011 5824 2341 29% 25% 79 70 5017 1577 39% 37% 81 70
Costa Rica 1997–2012 416 197 12% 22% 82 71 341 88 3% 12% 84 72
Cuba 2001–2012 1721 3235 29% 14% 77 70 1309 1812 40% 38% 75 70
Ecuador 1997–2012 707 424 83% 35% 83 73 510 303 78% 76% 84 71
Guatemala 2005–2012 414 176 * * 78 70 410 141 * * 78 69
Jamaica 2000–2006 303 286 * * 75 66 59 78 * * 79 70
Mexico 1998–2012 11986 4072 22% -9% 79 71 9769 2252 31% 8% 81 70
Panama 1998–2012 206 178 -10% 15% 81 71 178 78 9% 10% 83 70
Paraguay 1996–2012 297 355 236% 47% 75 69 71 102 131% 69% 80 68
Asia
Kyrgyzstan 2000–2013 769 335 -48% 1% 73 64 545 98 -49% 3% 79 65
Philippines 1999–2008 9467 5686 68% 35% 71 64 2803 2051 27% 44% 74 65
Uzbekistan 2004–2005 1052 691 * * 69 62 953 227 * * 72 61
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Premature COPD deaths (ages 35–69) were estimated to decrease by 10% in the 13 
MICs, and to increase by 2% in the 33 HICs with trend analyses, between 2016 and 
2030. Contrariwise, lung cancer premature deaths were projected to increase by 12% 
in MICs while decreasing by 14% in HICs (Supplemental Figure 1).
In the studied countries, over the most recent two years, among people 35 years and 
older, the mean age at death due to COPD was 78 years in men, and 79 in women 
(two to three years lower in MICs than in HICs) (Table 1). This was seven years older 
than the mean age at death from lung cancer (five years lower in MICs than in HICs).
Supplemental Figure 2 displays the frequency of each of the ICD-10 codes used to 
report COPD deaths, in the last two years. “Other COPD” was the most frequently 
reported condition, causing 84% of COPD deaths. However, emphysema was reported 
to be responsible for more than a third of deaths in Austrian, Japanese, Latvian, and 
Paraguayan men, and Uzbek women.
Table 1A. Chronic obstructive pulmonary disease (COPD) and lung cancer (LC) deaths, 
during the last two years of available data, proportional change in death counts, mean 
age at death, in middle-income countries (continued)
Men Women
Mean annual 
deaths
Change in 
deaths over 
the last 10 
years (%)
Mean age 
at death 
(years)
Mean 
annual 
deaths
Change in 
deaths over 
the last 10 
years (%)
Mean 
age at 
death 
(years)
Region Country Study period COPD LC COPD LC COPD LC COPD LC COPD LC COPD LC
Europe
Republic of 
Moldova 1996–2013 594 743 -39% 15% 73 63 314 190 -51% 15% 79 67
Romania 1999–2012 3691 7752 -10% 11% 75 66 1782 2057 -19 32 80 68
Serbia 1998–2013 1494 3767 6 12 75 66 865 1386 23 43 77 66
TFYR 
Macedonia 2006–2010 196 662 * * 74 65 116 135 * * 75 64
Oceania
Fiji 2006–2012 36 23 † † 69 66 11 16 † † 69 63
Middle-income 61975 44901 23% 23% 76 67 41531 21512 29% 51% 78 68
Mean annual deaths were calculated by averaging the reported two last years of data. The proportional change in 
death counts over the last ten years is the difference between average death count for the most recent two years and 
average death count nine and ten years prior, divided by the average death count nine and ten years prior.
* Percentages not presented due to less than ten years of data 
† Percentages not presented due to fewer than 50 mean deaths per year in the most recent two years, separately 
for each sex.
Totals may not sum up due to rounding. Data from countries with less than 50 deaths in one sex are included in the 
percentage change in death counts for Middle-income countries, High-income countries and grand total.
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Table 1B. Chronic obstructive pulmonary disease (COPD) and lung cancer (LC) deaths, 
during the last two years of available data, proportional change in death counts, mean 
age at death, in high-income countries
Men Women
Mean annual 
deaths
Change in 
deaths over 
the last 10 
years (%)
Mean age 
at death 
(years)
Mean annual 
deaths
Change in 
deaths over 
the last 10 
years (%)
Mean age 
at death 
(years)
Region Country
Study 
period
COPD LC COPD LC COPD LC COPD LC COPD LC COPD LC
Latin America and the Caribbean
Bahamas 1999–2010 14 22 † † 70 64 4 12 † † 79 69
Chile 1997–2012 1591 1694 21% 28% 80 70 1392 1109 27% 58% 82 71
Trinidad and 
Tobago 1999–2009 67 95 -26% 18% 73 65 14 31 † † 76 71
Uruguay 1997–2010 769 992 -7% -2% 77 69 265 244 24% 50% 79 69
Venezuela 1996–2009 1705 1838 30% 42% 75 66 1473 1191 42% 55% 78 66
Northern America
Canada 2000–2011 5389 10515 2% 5% 79 72 5164 8737 26% 28% 80 72
USA 1999–2013 67294 86124 16% -4% 77 71 74395 70571 21% 3% 78 72
Asia
Brunei 
Darussalam 2011–2012 22 26 † † 78 69 13 21 † † 79 68
Cyprus 2004–2012 70 191 * * 81 70 24 48 * * 83 69
Israel 1998–2012 636 1180 11% 23% 79 71 490 616 9% 44% 82 72
Japan 1995–2013 13137 51680 24% 21% 83 76 3739 20394 0% 32% 86 78
Kuwait 2012–2013 13 71 * * 76 68 5 25 * * 64 74
Republic of 
Korea 1995–2012 3823 11821 5% 28% 79 71 1746 4409 -20% 33% 83 73
Singapore 2012–2013 273 788 * * 77 71 65 404 * * 83 72
Europe
Austria 2002–2013 1514 2370 -2% 2% 77 70 1131 1320 -6% 28% 81 70
Belgium 1998–2012 2674 4721 -18% -6% 78 72 1733 1784 5% 51% 80 69
Croatia 1995–2013 989 2097 37% -1% 77 69 626 697 80% 34% 81 70
Czech 
Republic 1994–2013 1802 3789 67% -11% 74 69 1161 1715 82% 28% 78 70
Denmark 1994–2012 1528 1890 -5% 0% 78 72 1809 1763 5% 19% 79 72
Estonia 1997–2012 137 506 7% -11% 75 70 50 163 15% 28% 77 73
Finland 1996–2013 803 1468 13% 5% 77 72 342 726 39% 43% 77 73
France 2000–2011 5265 22279 10% 7% 80 69 2722 7510 23% 61% 84 69
Germany 1998–2013 16962 29682 20% 3% 77 71 13269 14924 40% 38% 80 71
Hungary 1996–2013 2844 5583 34% -4% 74 66 2218 3149 58% 33% 77 68
Iceland 1996–2009 42 63 † 11% 80 72 47 71 † 33% 81 73
Ireland 2007–2010 684 1012 * * 79 71 640 690 * * 81 73
Italy 2003–2012 12688 25043 -10% -3% 83 74 8155 8601 -1% 34% 86 73
Latvia 1996–2012 207 785 11% -10% 72 69 55 198 -20% 8% 74 71
Lithuania 1998–2012 532 1133 -24% -7% 75 69 168 238 -41% 13% 79 73
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DISCuSSIOn
This is the first study contrasting worldwide COPD and lung cancer mortality in mag-
nitude and over time. Sharp differences in COPD and lung cancer mortality existed 
between country, income level, and gender. Since around 2003, COPD mortality has 
declined in many countries –sometimes drastically– in HICs and as well as in MICs, 
both in men and in women. For instance, COPD rates were halved in only ten years 
in Slovenia and Kyrgyzstan. Meanwhile, lung cancer mortality has more uniformly 
declined, but to a lesser extent than COPD, with the notable exception of the increase 
in female rates in half of the countries (mostly HICs). Around 2011–2013, in HICs, 
COPD mortality rates were lower than lung cancer, while COPD rates were up to five 
times higher than lung cancer rates in MICs in Latin America and Asia. 
Table 1B. Chronic obstructive pulmonary disease (COPD) and lung cancer (LC) deaths, 
during the last two years of available data, proportional change in death counts, mean 
age at death, in high-income countries (continued)
Men Women
Mean annual 
deaths
Change in 
deaths over 
the last 10 
years (%)
Mean age 
at death 
(years)
Mean annual 
deaths
Change in 
deaths over 
the last 10 
years (%)
Mean age 
at death 
(years)
Region Country
Study 
period
COPD LC COPD LC COPD LC COPD LC COPD LC COPD LC
Luxembourg 1998–2013 77 143 11% -4% 79 72 66 71 78% 39% 82 69
Malta 1995–2012 44 135 † 17% 79 73 12 35 † † 72 71
Netherlands 1996–2013 3660 6265 2% -1% 80 72 3054 4026 26% 45% 79 69
Norway 1996–2013 1026 1224 19% 3% 79 73 1026 947 41% 31% 79 72
Portugal 2002–2013 1719 3002 0% 17% 80 69 912 833 8% 46% 83 71
Slovakia 1994–2010 518 1588 6% -13% 74 67 223 495 0% 41% 75 68
Slovenia 1997–2010 262 768 -34% 4% 78 69 141 306 -29% 50% 81 70
Spain 1999–2013 11525 17607 -2% 6% 82 71 3177 3957 -4% 69% 85 69
Sweden 1997–2013 1289 1856 -1% 2% 80 73 1550 1746 29% 23% 80 73
United 
Kingdom 2001–2013 15534 19409 4% -1% 79 74 14924 16028 14% 18% 80 74
Oceania
Australia 1998–2011 3125 4940 -4% 6% 79 73 2521 3158 15% 29% 80 72
New Zealand 2000–2011 823 901 -11% 6% 80 72 736 765 -4% 28% 80 72
High-income 183066 327286 10% 4% 79 72 151247 183714 19% 21% 80 73
Middle- and high-income 245041 372187 13% 6% 78 71 192778 205226 21% 24% 79 72
Mean annual deaths were calculated by averaging the reported two last years of data. The proportional change in 
death counts over the last ten years is the difference between average death count for the most recent two years and 
average death count nine and ten years prior, divided by the average death count nine and ten years prior.
* Percentages not presented due to less than ten years of data 
† Percentages not presented due to fewer than 50 mean deaths per year in the most recent two years, separately 
for each sex.
Totals may not sum up due to rounding. Data from countries with less than 50 deaths in one sex are included in the 
percentage change in death counts for Middle-income countries, High-income countries and grand total.
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We report for the first time the inverse relationship between COPD and lung cancer 
mortality in MICs in Latin America and Asia. This suggests a distinct role of other 
risk factors for COPD, and probably also for lung cancer, in less wealthy nations as 
compared to wealthier ones. We had hypothesized that lung cancer mortality trends 
and patterns would, to some extent, be similar to the ones for COPD within one popu-
lation (country/sex). It turned out that, even in countries with low smoking prevalence 
(substantiated by low lung cancer rates), COPD mortality could be high. For example, 
circa 2012, female COPD rate in Kyrgyzstan was around 53 per 100 000, similar to 
that in Denmark. Yet, the female smoking prevalence in Kyrgyzstan was less than 
5%21 contrasting that observed in Denmark (39% in 1980 and 18% in 2012).22 Several 
reasons could explain this finding. First, in populations with low smoking prevalence 
(e.g. in women in some MICs), high COPD mortality might be driven by other risk 
factors such as asthma in childhood (e.g. prevalence around 23% in Brazilian teenag-
ers),23 bronchial hyper-reactivity,6 and most importantly the harming role of poverty 
on lungs.24, 25 Poverty acts through poor nutritional status, crowding, exposure to 
pollutants, second-hand exposure to smoking, early respiratory infections and poor 
access to health care.26 Contrariwise, the impact of high smoking prevalence in other 
populations (e.g. in women in some HICs) would surpass the impact of other risk 
factors, and, combined with genetic factors, lead to both high COPD and lung cancer 
mortality. Second, the magnitude of the two diseases could substantially differ by 
country and sex depending on differences in exposure to risk factors: occupational 
exposures (such as working in coal mines),27 indoor air pollution (solid fuel for cook-
ing is commonplace in Guatemala and the Philippines),28 outdoor air pollution, and 
respiratory infections (such as tuberculosis).29 Lastly, under-reporting —frequent in 
COPD—30 and differences in coding practices may partly explain this finding. 
The declines in the COPD rates in both sexes and male lung cancer rates in the highest 
income nations likely reflect declines in smoking prevalence. In addition, for COPD, 
recent progress in the diagnosis and management31 —most COPD patients die from 
another cause—32 in combination with declines in poverty24 in fast growing economies, 
such as in Latin America,18 probably also contribute. This is consistent with the result 
from a global study of modeled COPD mortality trends18 that age-specific COPD mor-
tality rates fall as country income rises.
The narrowing of the gender gap in COPD rates in half of the countries (most HICs) 
was previously reported in the most comprehensive population-based observational 
study in Europe.16 Equally, converging male and female lung cancer rates have been 
described before.4 In countries where women have been smoking as much and as 
long as men (e.g. USA, Denmark, and Sweden),22 female mortality from COPD and 
lung cancer were very similar to male mortality. If more women pick up the habit, in 
particular in LMICs, the gender gap will eventually close in other countries.
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While favorable declines in rates were observed in the majority of the countries under 
study, these two conditions still translated into a substantial number of adult deaths. 
Over the last ten-year period, the number of COPD and lung cancer deaths increased 
by 13% in men and 21% in women, and 6% and 24%, respectively —with greater 
increases in MICs than in HICs— as more people reached older ages. Even if those 
advantageous trends were to continue, the studied countries would not meet the 
Sustainable Development Goals (SDG) of the UN “to reduce by one third premature 
mortality from non-communicable diseases by 2030”, for COPD and lung cancer 
deaths. Population growth and ageing effects would overcome the declines in mortal-
ity rates. Further, we may see extra increases in deaths because of greater exposure 
to risk factors such as outdoor air pollution in the growing urban populations,26, 33 
and consequences of additional declines in mortality from cardio-vascular disease and 
acute infection. 
So what steps can be taken to curtail this future burden? First, stopping smoking 
remains the most important intervention affecting the development and the prognosis 
of COPD6, 34 and lung cancer,35 as well as avoiding any smoking uptake —particularly in 
countries in economic transition. Hence, expanding the implementation of the MPOWER 
measures from the WHO is essential. Second, poverty is a major risk factor for COPD 
in LMICs. The recent call to reduce the proportion of the population living in poverty 
by half by 2030 in the SDG will strengthen poverty eradication actions. Finally, COPD 
can be managed,36 and the observed success in the reduction of COPD death in many 
countries is partly due to management improvements. Therefore, access to diagnosis 
and treatment must be expanded to the remaining populations.
The strengths of this study include the extensive international coverage of COPD and 
lung cancer mortality, using up-to-date high-quality observed data. Nevertheless, 
several limitations of this study should be kept in mind. Firstly, under-diagnosis and 
underreporting of COPD are universal,30, 37, 38 probably more so in MICs and older 
people. However, the distribution of COPD ICD-10 codes in MICs is similar to that in 
HICs, and restricting the analysis to ages 35–69 revealed results (not shown) similar 
to the ones for ages 35 and older, supporting the robustness of our analysis on ages 
35 and older. Secondly, expanding the analysis to the contributing causes of death 
mentioned on the death certificates would give a better picture of the mortality at-
tributable to COPD and lung cancer,39 and should be pursued. For those reasons, 
this study most likely underestimates the true mortality burden of both conditions, 
particularly in COPD. Given the country selection process, the results may not be fully 
extrapolated to all HICs and MICs, and the lack of data from low-income countries 
hinders conclusions for those countries. Additional studies on the prevalence of COPD 
risk factors, in Latin America, Asia, and Africa could help interpret these results, and 
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further studies on COPD prevalence and lung cancer incidence in LMICs could discrimi-
nate the hypotheses for the high COPD rates in some countries.
In most of the countries studied, declines in COPD and lung cancer rates were ob-
served, except for lung cancer in females. While past smoking likely drove recent 
COPD mortality trends in HICs, other risk factors such as poverty, air pollution, respi-
ratory infections, and asthma likely played an added role causing high COPD mortality 
in MICs in Latin America and Asia. As such, regionally tailored strategies are needed 
to successfully further decrease COPD mortality. COPD and lung cancer deaths can be 
largely reduced through the reduction of exposure to risk factors, particularly smok-
ing, air pollution, harmful occupational exposure, respiratory infections, and through 
the reduction of poverty.
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SuPPLEMEnTaL MaTERIaL
average annual Percent Change
Average Annual Percent Change (AAPC) is a geometrically weighted average of the dif-
ferent annual percentage changes from the Joinpoint trend analysis, for which weights 
are equal to the length of each segment during the specified time interval.1 Logarith-
mic transformation of the rates and calculation of standard errors using the binomial 
approximation were chosen for the Joinpoint analysis. We depicted the relationship 
between COPD and lung cancer rates in Europe and Latin America (for which there 
were sufficient countries), by sex, with a weighted linear regression and weighted 
pairwise correlation coefficients.
Fifty countries had a data span of at least 11 years and were included in the trend 
analysis. However, Portugal had no data for 2004–2006, and Trinidad and Tobago 
had no data for 2003. Hence logarithmic transformation of null rates could not be 
performed. AAPC were not computed (figures 3A and 3B), however trends for those 
countries were presented on figure 2.
Joinpoint regression Program version 4.2.0.2 was used.
Mean age at death
Mean age at death was obtained by multiplying the number of deaths, after age 34, 
in each age group, by the age at the middle of the age group (e.g. 47.5 years for age 
group 45–49), and by 90 for age group 85+. The sum of the products was then divided 
by the total number of deaths. 
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Supplemental figure 1. Number of projected chronic obstructive pulmonary disease 
(COPD) and lung cancer premature (ages 35–69) deaths
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Supplemental figure 2A. Mean proportion of each condition within chronic obstructive 
pulmonary disease (COPD), over the last two years (around 2011–2013), for ages 35 
and older, in men
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Supplemental figure 2B. Mean proportion of each condition within chronic obstructive 
pulmonary disease (COPD), over the last two years (around 2011–2013), for ages 35 
and older, in women
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Supplement table 1A Mean age at death due to chronic obstructive pulmonary disease 
(COPD) and lung cancer (LC), over the last two years, in middle-income countries
Men Women
Ages 35 and 
above
Ages 35–69 Ages 35 and 
above
Ages 35–69
Region Country COPD LC COPD LC COPD LC COPD LC
Africa
Mauritius 63 60 76 68 62 59 82 69
Latin America and the Caribbean
Belize 59 56 72 66 48 57 73 66
Brazil 61 60 76 68 61 58 76 67
Colombia 62 60 79 70 62 59 81 70
Costa Rica 63 61 82 71 61 60 84 72
Cuba 62 61 77 70 62 60 75 70
Ecuador 61 59 83 73 61 58 84 71
Guatemala 60 59 78 70 60 57 78 69
Jamaica 61 58 75 66 63 58 79 70
Mexico 62 60 79 71 61 58 81 70
Panama 61 61 81 71 62 58 83 70
Paraguay 62 60 75 69 59 57 80 68
Asia
Kyrgyzstan 58 58 73 64 58 57 79 65
Philippines 61 59 71 64 60 58 74 65
Uzbekistan 59 57 69 62 60 55 72 61
Europe
Republic of 
Moldova 60 59 73 63 61 58 79 67
Romania 60 60 75 66 60 59 80 68
Serbia 62 60 75 66 62 59 77 66
TFYR Macedonia 62 59 74 65 60 58 75 64
Oceania
Fiji 59 58 69 66 61 57 69 63
Middle-
income 61 60 76 67 61 59 78 68
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Supplement table 1B Mean age at death due to chronic obstructive pulmonary disease 
(COPD) and lung cancer (LC), over the last two years, in high-income countries
Men Women
Ages 35 and 
above
Ages 35–69 Ages 35 and 
above
Ages 35–69
Region Country COPD LC COPD LC COPD LC COPD LC
Latin America and the Caribbean
Bahamas 61 58 70 64 68 63 79 69
Chile 63 61 80 70 63 60 82 71
Trinidad and 
Tobago 59 59 73 65 60 57 76 71
Uruguay 63 60 77 69 62 59 79 69
Venezuela 60 59 75 66 60 58 78 66
Northern America
Canada 63 62 79 72 63 61 80 72
USA 62 61 77 71 62 61 78 72
Asia
Brunei 
Darussalam 58 59 78 69 56 59 79 68
Cyprus 63 62 81 70 63 59 83 69
Israel 62 60 79 71 62 60 82 72
Japan 64 63 83 76 63 62 86 78
Kuwait 58 59 76 68 38 63 64 74
Republic of Korea 63 61 79 71 62 59 83 73
Singapore 62 60 77 71 64 59 83 72
Europe
Austria 63 61 77 70 63 61 81 70
Belgium 63 61 78 72 62 59 80 69
Croatia 62 61 77 69 61 60 81 70
Czech Republic 63 63 74 69 63 62 78 70
Denmark 63 63 78 72 63 62 79 72
Estonia 63 61 75 70 62 61 77 73
Finland 64 63 77 72 64 62 77 73
France 62 60 80 69 61 58 84 69
Germany 63 61 77 71 62 60 80 71
Hungary 61 61 74 66 61 60 77 68
Iceland 65 59 80 72 64 61 81 73
Ireland 64 61 79 71 64 61 81 73
Italy 63 62 83 74 63 60 86 73
Latvia 61 61 72 69 61 60 74 71
Lithuania 62 61 75 69 60 59 79 73
Luxembourg 63 60 79 72 65 59 82 69
Malta 64 63 79 73 61 61 72 71
Netherlands 63 62 80 72 62 60 79 69
Norway 64 63 79 73 64 62 79 72
Portugal 63 60 80 69 63 58 83 71
Slovakia 61 61 74 67 60 60 75 68
Slovenia 63 60 78 69 60 59 81 70
Spain 63 61 82 71 62 58 85 69
Sweden 64 63 80 73 64 63 80 73
United Kingdom 63 62 79 74 63 62 80 74
Oceania
Australia 63 61 79 73 62 61 80 72
New Zealand 63 62 80 72 63 60 80 72
High-income 63 61 79 72 62 61 80 73
Middle- and high-income 62 61 78 71 62 60 79 72
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5.1 gEnERaL DISCuSSIOn
When looking at the current burden of smoking-related diseases, we actually see the 
consequences of past smoking exposure, with a particularly long lag time of several 
decades for smoking-related cancers and COPD. Taking up and sustaining the habit 
of smoking is not only a personal choice but also the result of multiple factors includ-
ing influences of tobacco industry marketing, the addictive nature of tobacco, social 
norms, and tobacco control (or lack thereof). Therefore, smoking-related diseases, 
such as cancer and COPD, are now more frequent in some countries (in Bulgaria 
rather than in Sweden),1 in men than in women, in regions where tobacco is grown 
(the South of the US) or transformed (the southeastern part of the Netherlands).2 
Of course, tobacco marketing strategies and cigarettes change over time, and so do 
social norms —it is now acceptable for women to smoke in industrialized countries.3 In 
addition, as trade agreements opened new markets in developing countries, tobacco 
production and manufacturing shifted to these regions. 
The previous chapters contrasted the current burden of smoking-related cancer and 
COPD between (sub-)populations, and its evolution over time. In this discussion, the 
main findings and their interpretation are presented in the first part, followed by the 
limitations of studies in the second part. The third part describes the public health 
implications of this elevated burden, followed by the fourth part, which gives recom-
mendations on how to reduce it. 
MaIn EPIDEMIOLOgIC fInDIngS
Studies performed at IaRC, under the supervision of Dr. freddie Bray 
What is happening in the gender gap in smoking-related cancers?
•	 In which populations is the gender-specific incidence of smoking-related cancer 
still increasing in Europe?
Over the 1988–2007 period, in Europe, trends varied among the four major cancers 
related to tobacco smoking: cancer of the lung, oral cavity and pharynx, larynx, and 
esophagus (chapter 2.1).
In most of the countries, male lung cancer incidence rates had decreased since the early 
1990s. Increases in male lung cancer incidence were only observed in middle-aged 
French (35–64 years old) and in older Bulgarians (65–74 years old), a sign that the 
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lung cancer epidemic was still on its rise in France while fading in Bulgaria. In contrast, 
over the same period, lung cancer incidence continued to increase among middle-aged 
women in 19 out of the 26 countries, and in nine countries in the older female popula-
tions (Table 1). Since 2005 however, signs of stabilization were detected in women aged 
35–74 in central and eastern Europe, northern Europe, Switzerland and Malta. As for 
the other smoking related cancers such as oral cavity and pharyngeal cancer, incidence 
rate only increased in few countries among men (in the Czech Republic, Denmark [both 
in middle ages only], in Slovakia [among older ages only], UK, and Germany). Incidence 
also increased in these countries among women, as well as in Ireland, Norway (in older 
ages), and in the Netherlands in middle-aged populations. Bulgarian men was the only 
group with increasing laryngeal cancer incidence. Among women, the rates were very 
low, hence conclusion was difficult to draw. Finally, surges in esophageal cancer incidence 
in men were generally restricted to the northern half of Europe, whereas in women, 
increases appeared to occur in most countries in western, central and eastern Europe.
Table 1. Direction of the average annual percent change in incidence over 1998–2007, 
sorted by the direction of the trend in lung cancer incidence in men, then women
Country Lung Oral cavity Larynx Esophagus 
 Men Women Men Women Men Women Men Women
France ↗ ↗ ↘ ↔ ↘ ↔ ↘ ↔
Czech Republic ↘ ↗ ↗ ↗ ↔ ↔ ↔ ↔
United Kingdom ↘ ↗ ↗ ↗ ↔ ↘ ↗ ↘
Germany ↘ ↗ ↗ ↗ ↔ ↔ ↗ ↗
Poland ↘ ↗ ↘ ↔ ↘ ↔ ↔ ↔
Spain ↘ ↗ ↘ ↔ ↘ ↔ ↘ ↔
The Netherlands ↘ ↗ ↔ ↗ ↘ ↔ ↗ ↗
Slovakia ↘ ↗ ↔ ↗ ↔ ↔ ↔ ↔
Austria ↘ ↗ ↔ ↔ ↘ ↔ ↗ ↔
Belarus ↘ ↗ ↔ ↔ ↔ ↔ ↗ ↔
Russian Federation ↘ ↔ ↘ ↔ ↘ ↔ ↘ ↘
Italy ↘ ↔ ↘ ↔ ↘ ↔ ↘ ↔
Estonia ↘ ↔ ↘ ↔ ↔ ↔ ↔ ↔
Latvia ↘ ↔ ↔ ↔ ↔ ↔ ↔ ↔
Lithuania ↘ ↔ ↔ ↔ ↔ ↔ ↔ ↔
Denmark ↔ ↗ ↗ ↗ ↔ ↔ ↔ ↗
Croatia ↔ ↗ ↘ ↔ ↘ ↔ ↘ ↔
Slovenia ↔ ↗ ↘ ↔ ↔ ↔ ↔ ↔
Finland ↔ ↗ ↔ ↗ ↔ ↔ ↗ ↔
Ireland ↔ ↗ ↔ ↗ ↔ ↔ ↔ ↔
Bulgaria ↔ ↗ ↔ ↔ ↗ ↔ ↔ ↔
Norway ↔ ↗ ↔ ↔ ↔ ↔ ↔ ↔
Sweden ↔ ↗ ↔ ↔ ↔ ↔ ↔ ↔
Malta ↔ ↗ ↔ ↔ ↔ ↔ ↔ ↔
Switzerland ↔ ↔ ↘ ↔ ↘ ↔ ↔ ↔
Iceland ↔ ↔ ↔ ↔ ↘ ↔ ↔ ↗
Note: Changes in incidence trends for lung cancer are for ages 35–64 years, and ages 35-74 for the other cancers.
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Incidence generally declined among men in three cancers (lung, oral cavity and phar-
ynx, and larynx), while increased in women in two cancers (lung and oral cavity and 
pharynx). As a consequence, the gender gap in these smoking-related cancers nar-
rowed in Europe, the mark of the earlier declines in smoking prevalence among men 
contrasting with stable or increasing prevalence among women. The closing of the 
gender gap was most evident in lung cancer because of the high smoking-attributable 
fraction (≥80%).4 The fraction is as high in laryngeal cancer as in lung cancer, but the 
very low number of new cases in women hinders tangible conclusions on the direction 
of the trends. Differences in the prevalence and trends of additional risk factors —in 
particular obesity and alcohol consumption— may explain the apparent absence of 
convergence of male and female cancer incidence in some countries and in esophageal 
cancer incidence. 
•	 How does cigarette type influence lung cancer histology in men and in women?
Chapter 2.2 examined the lung cancer epidemic in eleven high-income countries, over 
the 1973–2002 period, by analyzing trends in new lung cancer cases by histological 
subtypes: adenocarcinoma (AdC), squamous cell carcinoma (SCC), small cell carci-
noma, large cell carcinoma, and other subtypes combined. It appeared that within the 
overall declining trends in lung cancer incidence in male, different trends emerged at 
the subtype level. SCC —the most frequently diagnosed subtype among men at the 
beginning of the study— rates declined over time and were ultimately exceeded by AdC 
rates in most countries starting around the 1990s. In contrast, among women, AdC 
was the dominant subtype throughout the whole period, and rates of AdC increased 
over time. As a consequence, at the end of the study period, the distribution of the 
cases’ subtypes in men was more similar to the distribution in women. The adoption of 
new cigarettes, first by women and later by men, around the 1950s (filtered cigarettes 
with lower nicotine and tar contents, less polycyclic aromatic hydrocarbons and more 
tobacco-specific N-nitrosamines) advertised as “safer cigarettes” (mild/light) probably 
explains the gender differences in the distribution of subtypes.5
In several high-income countries, the gender gap in smoking-related cancer incidence is 
narrowing because the younger female cohorts have smoked (age at initiation, type of 
cigarette smoked, quitting rates and total smoking years) more like their male counter-
parts than previous generations. While declines in smoking-related cancer incidence in 
men —as a result of tobacco control and rising awareness of the harms of tobacco— are 
welcome, in most of high-income countries, the number of new cases in women is still 
growing. This means that, in the past, tobacco control has, to a large extent, failed to 
prevent smoking initiation and to support smoking cessation among women. 
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Studies performed at the american Cancer Society, under the supervision of Dr. 
ahmedin Jemal
What is the burden of smoking-related cancers in the US? 
•	 Do non-Hispanic Blacks have a higher cancer burden and smoking-related cancer 
burden than other racial/ethnic groups in the US?
Chapter 3.1 described the burden of cancer in the US in 2011. DALY rates for all cancers 
combined were higher in non-Hispanic Blacks than in any other racial/ethnic group (30% 
higher than in non-Hispanic Whites, 80% higher than in Hispanics, and 100% higher 
than in non-Hispanic Asians). Chapter 3.2 examined the smoking-attributable fraction 
of the burden of 12 smoking-related cancers. The population attributable fraction (PAF) 
was substantial in every racial/ethnic group. It was highest in non-Hispanic Whites and 
non-Hispanic Blacks (27% and 28% of all DALYs due to cancer, respectively). The fraction 
was about two-thirds lower among non-Hispanic Asians and Hispanics (both at 19% of 
DALYs). Within each race/ethnicity, the burden was always higher in men than in women. 
Those differences in the smoking-attributable fraction of the cancer burden emerged 
because of differences in current and past smoking prevalence between races/ethnicities 
and genders. Variations in smoking prevalence reflect differences in social norms, socio-
economic status —tobacco use is higher among poor, less educated people— targeted 
tobacco marketing, and acculturation level among immigrants (recent Hispanic and 
Asian immigrants smoke as little as in their country of origin). The smoking-attributable 
fraction shows the theoretical health gains if tobacco smoking was eliminated: from 10% 
of the cancer burden in non-Hispanic Asian women to 34% in non-Hispanic Black men.
•	 Do people living in tobacco-growing states of the US have a higher burden of 
cancer mortality attributable to cigarette smoking?
Nowadays, 95% of US tobacco is grown in six southern states (North Carolina, 
Kentucky, Tennessee, Virginia, South Carolina, and Georgia). Kentucky exhibited the 
highest smoking-attributable proportion of cancer deaths (34%) out of the 51 states 
in the US, as estimated in Chapter 3.3. Besides Kentucky, the other main tobacco-
growing states were also confronted with high fractions of smoking-attributable cancer 
deaths (Tennessee 33%, North Carolina 31%, South Carolina 30%, and Georgia 29%). 
Virginia ranks the lowest (#30) of the tobacco-growing states, but still has 28% of 
its cancers deaths attributable to smoking. This high burden from smoking-related 
cancers is due to high past and current smoking prevalence, likely reflecting weaker 
tobacco control policies and social norms made possible by the large economic influ-
ence of the tobacco industry in those states. However, other factors also contribute. 
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Large poor and less educated populations —frequently smokers— can be found in 
those tobacco-growing states. Those large deprived populations are also common in 
the rest of the South, and the Appalachian region: Louisiana, Alabama, Mississippi, 
and West Virginia have 15%–18% of their population not graduating from high school 
(national average is 14%) and 16%–22% of their population living in poverty (national 
average is 15%).6 In these four states, at least 31% of cancer deaths explained are 
by smoking. The fraction is the lowest in California (26%), where tobacco control is 
strong and large non-smoking Hispanic populations live, and in Utah (17%) where 
social norms (55% of people are Mormons) proscribe smoking.
What is the impact of smoking on another important non-communicable disease: COPD?
Using lung cancer mortality as a marker of past and current smoking exposure, we 
investigated in 61 high- and middle-income countries whether COPD mortality was 
high where lung cancer mortality was high, and vice-versa, keeping in mind possible 
condition-specific lag times. It turned out that while lung cancer and COPD mortality 
where strongly correlated in high-income countries among women, they were only 
moderately correlated among men in both high- and middle-income countries. No 
correlation was found among women in middle-income countries. In fact, around 
2011–2013, lung cancer mortality rates were up to 10 times higher than COPD mortal-
ity rates in the majority of the countries, whereas in most of middle-income countries 
in Latin America and Asia, the reverse was true. Also, while both lung cancer and 
COPD were declining in men over the last 10 years (around 2002-2012), lung cancer 
was increasing in about half of the countries and COPD was increasing in six European 
countries in women. Progress in the diagnosis and treatment of COPD symptoms (as 
opposed to limited progress in lung cancer treatment) as well as declines in poverty 
—a major risk factor for COPD—further mitigated the association between smoking 
and COPD. In conclusion, while smoking had a major role in driving the COPD mortal-
ity rate in high-income countries, additional risk factors had to be also important (such 
as poverty and respiratory infections) in middle-income countries.
STuDY LIMITaTIOnS anD BIaSES
When interpreting our results, some limitations and biases must be taken into account —
beyond those specifically mentioned in the articles— related to the data or the methods.
Data
As previously mentioned in the introduction, incidence data coverage varies by region 
and only one in five low- and middle-income country has the data to assess the burden 
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of cancer. IARC has brought together international partners to launch the Global Initia-
tive for Cancer Registry Development (GICR).7 The GICR aims at implementing new 
population-based cancer registries in countries where there are none, and at improving 
the quality of existing ones. Likewise, only 20% of the countries worldwide have qual-
ity mortality data. Current efforts focus on improving death registration techniques, 
whether by developing verbal autopsy standards,8 or improving the surveys to collect 
mortality information.9 Having data for more countries would allow the surveillance of 
the burden of cancer, COPD and other diseases (mortality), in particular in low- and 
middle-income countries —for which information is now largely missing— where the 
smoking epidemic is at an earlier stage.
Furthermore, while cancer is most of the time accurately reported as cause of death (at 
least for lung cancer), COPD is underreported as cause of death for several reasons. 
1) it is largely underdiagnosed (e.g. 73% of underdiagnosis in Spain);10 
2) COPD may not be reported on death certificates in COPD patients (e.g. 42% of 
deaths certificates in COPD patients in TORCH trial did not mention COPD,11 or 55% 
in the Copenhagen City Heart Study);12 
3) COPD is not reported as secondary cause of death in most national mortality data-
sets which feed the WHO mortality database.
Even in countries with high-quality cancer registration as in the US, I was not able 
to study the burden of diseases of some minorities due to their under-representation 
in surveys and small population size. For instance, American Indians/Alaska Natives 
represent 1.2% of the US population.6 The small number of cases and deaths by age 
group and sex forbids the calculations of DALYs and smoking population attribut-
able fractions for this population. It is all the more important to examine the burden 
of diseases of American Indian/Alaska Natives than they have the highest smoking 
prevalence of all racial/ethnic groups (29% compared with 17% at national level).13 
Finally, smoking status is self-reported in those surveys. Self-reported smoking status 
is usually slightly underestimated,14 as are other socially undesirable behaviors. The 
degree of bias depends on the population examined. For example, among people 
in which smoking is seen as particularly undesirable, such as individuals who have 
smoking-related diseases, the discrepancy between measured and reported smoking 
rates can be high.
Methods
Disability weights
The estimation of the burden of diseases, with DALYs, involves many parameters. 
Among those parameters are disability weights, used for the YLD component —time 
spent in reduced health. The disability weights range from 0 (perfect health) to 1 (a 
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health equivalent to death). Having participated in two burden of cancer projects, us-
ing different sets of disability weights, I was able to witness their impact on the DALY 
estimates. The disability weights used in the 2008 Global burden of cancer15 project 
were derived from Dutch16 and Victorian17 burden of disease studies, as well as earlier 
estimates from the global burden of disease (GBD) project from 1996.18 The Victorian 
burden of disease study itself elaborated on the GBD1996 and the Dutch study. In 
all of these studies, the disability weights were estimated using a person trade-off 
method whereby a panel of experts (Dutch study) or health workers “from all regions 
of the world” (GBD 1996) were asked to value the severity of various conditions on 
a scale of 0 to 1 relative to a set of pre-determined weights of several conditions.19 
Meanwhile, the disability weights used in the 2011 US burden of cancer were published 
in 201220 and updated in 201521 by the Global Burden of Disease Study Collabora-
tors. These were established by conducting 30 000 online and household surveys in 
Bangladesh, Indonesia, Peru, Tanzania and the US. In the surveys, participants were 
given examples of two persons with two disabilities and were asked to choose which 
person was ‘the healthiest’. Consequently, some of the new cancer-related disability 
weights were lower than disability weights previously used19 (Table 2). 
Table 2. Comparison of cancer-related disability weights in the 2008 and the 2011 can-
cer burden projects 
Disability Disability weights used 
for 2008 Global cancer 
burden19
Disability weights 
used for 2011 US 
cancer burden21
Cancer: diagnosis and primary therapy 0.270 to 0.560 0.288
Cancer: follow-up 0.140 to 0.370 0.049
Cancer: metastatic – 0.451
Terminal phase: with medication 0.900 (pre-terminal) 0.930 0.540
Terminal phase: without medication – 0.569
Mastectomy 0.200 0.036
Stoma 0.211 0.095
Urinary incontinence 0.157 0.139
Impotence 0.195 0.017
Infertility: Primary (wants to have a child and has a fertile 
partner, but the couple cannot conceive)
0.180 0.008
Speech problems 0.200 0.051
Disfigurement level I (has a slight, visible physical deformity 
that others notice, which causes some worry and discomfort)
0.016 0.011
Disfigurement level II (has a visible physical deformity that 
causes others to stare and comment. As a result, the person 
is worried and has trouble sleeping and concentrating)
0.056 0.067
(0 is equivalent the best possible health; 1 is the worst possible health)
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Several inconsistencies between disability weights published in 2012 were noticed 
and reported by the WHO22 and others,23 some of which were addressed in the 2015 
update. Tackling the remaining issues for specific disability weights will largely need 
to await for further empirical research as it is likely that an important cause of these 
inconsistencies relates to the framing and wording of the lay descriptions.
In spite of differences in the methods applied to establish the disability weights used 
in 2008 Global burden of cancer and the 2011 US burden of cancer, the impact on 
the DALYs has been limited, as most of the burden ended up coming from premature 
mortality (YLL) (93% and 91%, respectively). Assessing the burden of a disease with 
high disabilities and low fatality (such as COPD) with the two sets of disability weights 
might have given a different picture.
Relative risk of former smokers
Two of my studies involved computing PAF using Relative Risk (RR, effect size linking 
smoking to cancer): the smoking-attributable cancer deaths by state study (chapter 
3.3) and the smoking-attributable burden of cancer by race/ethnicity study (chapter 
3.2). The RR of cancer diagnosis or death of former smokers is lower than the RR 
of current smokers. However, the RR should not be seen as discrete values, but as 
a continuously changing function of the risk of diagnosis, or death. It takes time for 
a smoker who quits smoking to acquire the diagnosis/mortality risk of the former 
smokers’ group.24 Time since tobacco quitting was not available in the datasets I 
used. Therefore, the results may be underestimated for recent quitters —who have 
a RR close to current smokers—and overestimated for long-time quitters —who have 
a RR close to never smokers. The RR were computed in a cohort study with a certain 
distribution of former smokers and given quitting durations, which might not apply 
well to other US populations.
Socioeconomic status
Our studies did not take into account socioeconomic status (SES), another key demo-
graphic factor for smoking besides race/ethnicity, and gender. Smoking started as a 
habit among higher SES. It also declined earlier in higher SES, while simultaneously 
rising in the lower SES groups. Smoking may be chosen by low SES people to cope 
with stress and deprivation,25 and due to social norms. Disadvantage increases the 
likelihood of smoking, and smoking makes circumstances worse (less money for es-
sential goods and services, greater financial stress, poorer health).26 It is a vicious 
circle (Figure 1). If the current trends in smoking prevalence continue (slower declines 
in the lowest SES group and greater declines in high SES group), inequality in health 
will increase (for example in lung cancer incidence).27 Studies have shown persisting 
socioeconomic disparities in mortality,28 in race/ethnicity,29 in smoking in high income 
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countries,13,30 as well as the contribution of smoking to socioeconomic inequalities in 
mortality.31 High smoking prevalence in low socioeconomic group is a marker of late 
phase of the smoking epidemic.32 Patterns of potential reduction in inequality differ by 
country or region and sex.33 Reducing smoking prevalence can reduce socioeconomic 
inequalities in health and mortality. Thus, studies on the burden of smoking-related 
diseases by socioeconomic should be pursued; they are critical to support the great 
need for tobacco control policies targeted at low SES.34
Descriptive studies
All the studies of this corpus are based on cancer registry and mortality datasets which 
do not report individual lifestyle data such as smoking status. Thus, the fraction of 
diagnosis and deaths which are attributable to smoking can only be inferred.
IMPLICaTIOnS
This research shows that the burden of smoking-related cancer and of COPD is large 
and still increasing in some populations. Cigarette consumption seems to have peaked 
at about 6 trillion cigarettes annually sometime after the turn of the twenty-first cen-
tury, but the deadly effects of this epidemic will still be felt for many decades even 
Tobacco impoverishes countries
Productivity loss and healthcare cost burdens undermine economic development
in many countries.
TANZANIA
$40M OF $50M REVENUE 
Tanzania earns $50 million per year from tobacco but spends $40 million for
tobacco­ related cancers alone.
UNITED STATES
$6000 EXCESS COST PER SMOKER 
US smokers cost their employers an excess of $6000 a year per smoker due to
lower on­the­job productivity, higher absences, and excess healthcare costs.
BRAZIL
100M REALS 
The cost to Brazil due to tobacco is approximately 100 million reals per thousand
smokers in lost productivity.
Development
Economics
Resources
Download Hi­Res Image
Sources
Menzin J, Marton JP, Menzin JA, Willke RJ, Woodward RM, Federico V. Lost
productivity due to premature mortality in developed and emerging countries: an
application to smoking cessation. BMC medical research methodology.
2012;12:87.
Berman M, Crane R, Seiber E, Munur M. Estimating the cost of a smoking
employee. Tobacco control. 2013.
Kagaruki LK. Environmental health impacts of tobacco farming: a review of the
literature. Invited commentary. Tobacco control. 2012;21(2):196­7.
Vicious cycle
Disadvantage increases smoking likelihood, and smoking increases likelihood of disadvantaged circumstances
Figure 1. The vicious circle of low socioeconomic status and smoking.
Source: 26 as in The Tobacco Atlas35
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if global use continues to decline.36 Furthermore, because of population growth and 
ageing, the number of smoking-related disease cases is anticipated to grow, even in 
areas where the risk of smoking-related disease has been declining.
So what can be done?
Lung cancer screening
Lung cancer is the most frequent smoking-related cancer. Lung cancer patients have 
high fatality rate, in part because few tumors are diagnosed at local stage (16% in 
the US,37 20–30% in the Netherlands)38 when survival rate is highest (55% 5-year 
survival in the US).37 Lung cancer screening using low-dose computed tomography 
(LDCT) —which came on the market during the late 1990’s—offered at least two ad-
vantages. First and foremost, if detected early, a tumor is easier to cure, surgically 
in the first place, because it is at lower stage and there are more treatment options 
available39 —including some of the promising immunotherapies.40 As a consequence, 
cure rate is higher and sequelae are less important. Second, earlier diagnosis means 
slightly younger patients, hence less likely to have co-morbidities and therefore, once 
again, more treatment options and better survival.
LDCT lung cancer screening is available in the US since 2013 for the current and 
former (who quitted less than 15 years ago) heavy-smokers (at least 30 pack years, a 
combined measure of the number of cigarettes smoked per day and the duration of the 
exposure), aged 55-80 years old. The decision made by the US Preventive Services 
Task Force to recommend annual lung cancer screening41 is based on the results of 
the National Lung Screening Trial (NLST) showing a 20% decrease in lung cancer 
mortality compared with screening with chest x-ray.42 In 2013, 8.4 million Americans 
met those criteria.43 There is concern that the favorable balance between the benefits 
and harms of screening observed in the idealized conditions of the NLST may be dif-
ficult to replicate when lung-cancer screening is introduced in diverse clinical practice 
settings.44 The US population eligible for lung cancer screening is probably less likely 
to benefit from early detection than NLST participants because they face a high risk of 
death from competing causes.43 
In Europe, the Dutch-Belgian NELSON lung cancer screening trial is investigating 
whether screening with LDCT can reduce lung cancer mortality by at least 25% 
compared with no screening, at 10 years of follow-up.45 The targeted population is 
individuals aged 50–75 years, who had a smoking history of at least 15 cigarettes 
per day for at least 25 years, or at least 10 cigarettes for at least 30 years, and were 
still smoking or had quit less than 10 years ago. The trial, which started in 2003 and 
includes around 16 000 participants,46 further aspires to establish guidelines for the 
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optimum patient management strategies, based on characteristics of detected nod-
ules.47 About half of people screened have one or more pulmonary nodules, but only 
a small percentage of these people has lung cancer. Nodules detected by screening 
are followed-up for size and growth rate to determine which nodules require additional 
diagnostic procedures. This protocol aims at reducing the number of additional proce-
dures for benign nodules.48
National screening is hard to implement, requires health services that only few coun-
tries can afford, and would have only a small impact on lung cancer mortality. A study 
estimated that LDCT could prevent approximately 12 000 lung cancer deaths per 
year in the US,49 or approximately 8% of the estimated 158 000 lung cancer deaths 
in 2016.37 In any case, current smokers should be advised to stop smoking at every 
screening visit,50 as screening is not a substitute for smoking cessation.44 Besides, 
smoking also increases the risk for other cancers51 and other diseases.52 As COPD and 
lung cancer share common pathogenic mechanisms,53 it has been proposed to offer 
lung cancer screening to both smoker54 and never smoker55 COPD patients. 
In conclusion, although relevant, for now there is some uncertainty whether lung can-
cer screening will have an impact at population level as large as the impact observed 
in the NLST trial. Moreover, more research is needed to decrease the frequency of 
false-positive tumors and to determine the optimal screening interval.56 Therefore, 
recommendation of population-wide screening should be done with caution. 
Improved COPD detection and treatment
COPD is universally underdiagnosed —80% of the participants in a survey in 27 
countries in Europe, Asia, South America, South Africa, Nigeria, and Canada had an 
undiagnosed COPD—57 even after years of multiple interventions such as population 
spirometry (a measure of lung function) and case finding. In the Netherlands, nearly 
600,000 people are diagnosed with COPD, and 300 000 are unaware they are at high 
risk for COPD.58 Apart from primary care as the central venue to screen for COPD, 
other options might be considered, such as voluntary testing of patients in pharma-
cies. In healthcare settings, given the rising number of COPD cases among women, 
spirometry should predominantly be performed not only among elderly male smokers 
but also among younger smoking women. 
If COPD was more often detected, patients could benefit of improved quality of life 
and decreased odds of emergency department visits and hospitalization59 owing to 
effective management strategies now available. Management of COPD includes both 
pharmacologic and non-pharmacologic treatments.60 Still, medications for COPD have 
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had variable, yet limited, successes in modifying the long-term decline in lung func-
tion, depending on the type (emphysema or bronchitis) and the delay in diagnosis. 
Better treatments are needed. Nevertheless, at all stages of COPD, regular physical 
activity and exercise can aid symptom control, improve quality of life, reduce rates 
of hospitalization, and improve morbidity and respiratory mortality.61 Higher numbers 
of cigarette pack years is associated with higher COPD mortality.62 Because of its 
long preclinical course, quitting early is needed to obtain reductions in morbidity and 
mortality due to COPD. 
Smoking cessation
Quitting smoking before the age of 40 eliminates almost all of the excess smoking-
related risk of death from lung cancer and COPD compared with never smokers.61,63 
When smoking ceases, the lung cancer death rate stops increasing steeply and re-
mains almost constant.64 Smokers with cancer who quit smoking improve their chance 
of survival, and decrease their chance of secondary cancer and of cancer recurrence;65 
smokers with COPD benefit from quitting regardless of previous heavy smoking or 
age.66
Finally, decreasing the number of smokers also protects nonsmokers from secondhand 
smoke, which causes in adults: lung cancer, coronary heart disease, strokes, and 
has reproductive effects in women; and in children: sudden infant death syndrome, 
low birth weight, impaired lung function, lower respiratory illness, and middle ear 
disease.52 Smoking cessation benefits virtually everyone, smoker and nonsmoker. 
Mortality in the near future and throughout the first half of the 21st century could be 
substantially reduced by current smokers giving up the habit.67 Widespread cessation 
of smoking in the UK has already approximately halved lung cancer mortality that 
would have been expected had former smokers continued to smoke.67 
In the US, smoking prevalence was 42% in 1965 and current smokers outnumbered 
former smokers three to one.68 In 2014, there were more former cigarette smokers 
(22%)13 than current smokers (18% or 40 million).52 Likewise, in the Netherlands, 
there were 29% of former cigarette smokers and 25% of current smokers in 2015.30 
Furthermore, in the US, two-thirds of adult smokers want to stop smoking, and 43% 
of smokers have made a quit attempt in the past year.52 The vast majority of smokers 
regret starting smoking: around 90% in Canada, the US, the UK, Australia,69 South 
Korea, and Thailand;70 80% in New Zealand; 71 and ‘only’ around 75% in Malaysia and 
China.70 There’s no other product with even a fraction of such customer disloyalty. 
Nicotine —one of tobacco’s components—is addictive and therefore central in con-
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tinuing smoking and in the difficulty of quitting.52 In addition, the tobacco industry 
has designed its cigarettes to precisely control nicotine delivery levels and provide 
nicotine doses sufficient to create and sustain addiction.72 All forms of tobacco have 
the potential to be addictive because they contain nicotine, but cigarettes are the 
most efficient for delivering nicotine into the body.73 Several individual factors interact 
to determine the level of addiction, including type of tobacco use (e.g. cigarettes, 
smokeless tobacco), duration of tobacco use, amount of tobacco use (i.e. number of 
cigarettes smoked per day), and genetic predisposition.74
Tobacco dependence is a chronic disease that often requires repeated intervention and 
multiple attempts to quit.75 Effective treatments exist, however, that can significantly 
increase rates of long-term abstinence from smoking. 
There are two types of treatments: counseling treatments and medications. 
1) Several pharmacologic treatments are available. Smokers are more frequently 
abstinent 6 months after stopping smoking when they used nicotine replace-
ment therapy (NRT) (18% alone, 32% when using a combination of patches and 
oral medication or inhaler), varenicline (28%), bupropion (19%) compared with 
placebo (11%).76 Cytisine is more effective than NRT and cheaper than other 
pharmacotherapies, and could offer a valid help to smokers who cannot afford 
pharmacotherapies, including in low- and middle-income countries. Unfortunately, 
so far it is only available in Eastern Europe.77
2) Individual, group, and telephone counseling are effective, and their effectiveness 
increases with treatment intensity. Two components of counseling are especially 
successful: practical counseling (problem solving/skills training), and social sup-
port.75 The landscape of tobacco cessation is evolving and new technologies 
provide new ways to deliver smoking cessation help: social media support, texts, 
smartphone applications. The advantage is that every smoker can find a solution 
that suits his/her needs and preferences. 
Combining counseling and medication is even more effective than using only one 
method.75 Other types of interventions reinforce the impact of those treatments:78 
advice from physician,79 self-help materials, mass media communications campaigns, 
Quit and Win challenges, and smoke-free places. Activities which activate our reward 
system (such as learning something new and exciting or being in a passionate love 
relationship)80 can help smokers who quit remain abstinent from smoking.81
Promoting smoking cessation activities also translates into quit attempts even among 
smokers not using cessation assistance, because such messages normalize quitting 
and reassure smokers that help is available should they need it.82
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I have shown (Chapters 2.1 and 4.1) that lung cancer incidence and mortality, as well as 
COPD mortality, are increasing among women, particularly in Europe. Women seem to 
be less successful at quitting smoking than men, although there are scant global data on 
this issue.73 Unless effective, comprehensive and sustained initiatives are implemented 
to increase cessation rates among women and to prevent smoking uptake among young 
women, the prevalence of female smoking in developed and developing countries is 
likely to rise to 20% by 2025.83 The tobacco industry has used female empowerment 
and beauty as their main themes to market cigarettes to women.3 The same powerful 
strategy can be used in anti-smoking ads, as demonstrated by the WHO campaign 
targeting women (figure 2), to dismantle the tobacco industry’s marketing strategy, 
deter women from smoking and encourage them to quit smoking.
Likewise, chapter 3.2 demonstrated that the smoking-attributable burden of cancer in 
the US is as large as in non-Hispanic Whites than in non-Hispanic Blacks. Therefore, 
anti-smoking campaigns should target, or at least include, Black people (figure 2). 
Of note, quitlines in the US —an evidence-based tobacco cessation service offering 
free counseling, accessible by calling a number— are available in Spanish, Mandarin, 
Cantonese, Korean, and Vietnamese to meet the needs of non-English speakers.
Tobacco control
While smoking cessation aims at decreasing the risk of smoking-related health prob-
lems among smokers and those exposed to secondhand smoke, tobacco control aims 
not only at making current smokers quit, but also to prevent people from taking-
up the habit in the first place. Primary prevention takes time to implement and the 
results are delayed.84 The greatest effect on reducing morbidity and mortality in the 
next 10–20 years will come from cessation by current smokers. In contrast, primary 
prevention will mainly reduce smoking-related diseases 20+ years from now. The two 
interventions are therefore complementary.
The decision to experiment with cigarettes, to become a regular smoker and to sustain 
the habit as many determinants, at individual, personal environment, and social and 
cultural environment level (figure 3). Therefore, the tobacco epidemic is being tackled 
in several ways. The WHO lists proven effective strategies to end this epidemic in the 
MPOWER measures:86
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1) Monitor use and prevention policies. The WHO encourages the use of standards 
and scientific and evidence-based protocols for tobacco surveys, as well as dis-
seminating their results. It also promotes monitoring of tobacco control policies 
and reporting of tobacco-related health outcomes. In 2012, 2.8 billion people in 54 
countries were covered by effective tobacco use surveillance.87
2) Protect people from tobacco smoke. Complete prohibition of smoking in all indoor 
environments is the only intervention that effectively protects people from the 
harm of secondhand smoke. Smoke-free environments also help smokers who 
want to quit. It reduces smoking prevalence and tobacco consumption among 
workers.86 So far, only 16% of the world population is covered by comprehensive 
smoke-free laws.35
3) Offer help to quit tobacco use (see page 244)
4) Warn about the dangers of tobacco. The extreme addictiveness of tobacco and 
the full range of health dangers have not been adequately exposed to the public. 
Furthermore, comprehensive warnings about the dangers of tobacco are critical to 
changing its image, especially among adolescents and young adults. 
Figure 2. Poster of the 2010 WHO World No Tobacco Day focused on Gender and to-
bacco, with an emphasis on marketing to women.
248 Chapter 5
5) Enforce bans on tobacco advertising, promotion and sponsorship. In spite of 
vehement denial from tobacco companies —which pretend to simply aiming at 
increasing their market share— tobacco marketing enrolls new customers. Some of 
the new consumers become addicted to tobacco (the younger the faster the addic-
tion)88 and turn into long-term smokers. Moreover, marketing normalizes tobacco 
use and presents it as no different from other consumer product. Finally, marketing 
strengthens the tobacco industry’s influence over the media, as well as sporting 
and entertainment businesses, through billions of dollars in annual spending on 
advertising, promotion and sponsorship.
6) Raise taxes on tobacco. Significant increases in tobacco taxes (to more than 75% 
of the retail price) encourage current tobacco users to stop using, prevent potential 
users from taking up tobacco use, and reduce consumption among those that 
continue to use, with the greatest impact on the young and the poor.89 Raising 
taxes on tobacco products is the most effective way to reduce tobacco use,90 yet 
it is the least widely implemented measure.91 Kulik92 argues that price increases 
should be coupled with strong efforts to provide free access to smoking cessation 
services to prevent further deterioration of the financial situation of poor smokers.
MPOWER is being implemented across the world. WHO estimates that 2.8 billion people 
in 103 countries are now covered by at least one MPOWER measure at the highest 
level.91 Overall, countries with higher levels of MPOWER measures experience greater 
decreases in current smoking prevalence.93
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Source: Adapted from “Towards a future without tobacco”85
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The WHO also conceived the world’s first treaty against tobacco, the Framework Con-
vention on Tobacco Control (FCTC),94 to steer global and country level action against 
the tobacco epidemic. It was unanimously adopted at the World Health Assembly in 
May 2003. The treaty, signed by 168 countries as of May 2016, provides practical 
policy interventions. It fosters a move from occasional surveys to surveillance sys-
tems, from information and education to changing social and cultural norms, a move 
from demand-side awareness to supply-side controls, and from isolated quit programs 
to a more integrated approach to health services.95
Which countries of the world are showing the way in tobacco control?
One would think that high-income countries would have stronger tobacco regulations, 
but as shown in Table 3, some low- and middle-income countries took the lead in some 
areas such as banning tobacco advertising, promotion and sponsorship. Interestingly, 
tobacco control level differs from one country to another within Europe, hence smoking 
prevalence varies greatly (from 13% in Sweden to 39% in Greece).98 Those variations 
will later translate in differences in tobacco-related cancer burden.1 In 2013, the UK, 
Ireland, Iceland, and Norway were the forerunners while Czech Republic, Cyprus, 
Germany and Austria had the weakest tobacco control.99 The leading countries had in 
common high tobacco prices, comprehensive smoke-free legislation, and comprehen-
sive tobacco ban. Through a directive, applicable in May 2016 to EU Member States,100 
the EU aims at raising the level of health protection of all its inhabitants. It is a step 
forward in tobacco control, and includes for instance:
- larger and mandatory health warnings on both cigarette packages and roll-your-
own (RYO) —a product increasingly popular in Europe–101 tobacco packs; 
- the ban of flavored cigarettes and RYO tobacco products (such as menthol in 
2020); 
- the ban of packages of less than 20 cigarettes (favored by youth, with low purchas-
ing power). 
- health warning on e-cigarettes and limits the size of e-cigarette tanks and their 
nicotine concentration. 
- combating illicit tobacco trade by increasing the traceability of cigarette packs. 
Member States are free to apply stronger regulations in their countries, such as plain 
cigarette packages (Table 3). 
There are strong antagonist forces opposing tobacco control. The goal of the tobacco 
industry, as any other for-profit company, is to sell tobacco with the least hindrance. 
It exploits multiple tactics and acts on several domains including scientific, political,102 
and economic.103 It engages into sophisticated pathways to influence policy using lob-
bying, the media, public relations, industry allies, and contributions to legislators.104 
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These efforts involve campaigns to neutralize clean indoor air legislation, minimize 
tax increases, and preserve the industry’s freedom to advertise and sell tobacco. The 
tobacco industry diverts attention from the health issues by focusing attention on the 
economic issues. For example, they use their employees to lobby against legislation 
with the excuse that it threatens their job security. At the same time, the tobacco 
industry also fuels problems as a way to fight economic constrains. For instance, it 
participates in smuggling as a way to counter tax hikes,105 and weakens the impact of 
tax increases with product discounts.106 
Twenty years ago, Barendregt et al.107 came to the conclusion that, from an economic 
point, smoking cessation would lead to increased health care costs (as smokers die 
prematurely, they save health care costs of older ages, as well as pensions distribu-
tion). The study was vigorously contested, as was a study sponsored by the tobacco 
industry arguably presenting the financial advantage for the Czech Republic to main-
tain its weak tobacco control.108 Overtime, more studies have shown that smoking 
is clearly an economic burden to societies: 120 billion euros were lost to tobacco 
smoking in France in 2010109 —taking into account the savings on pension funds, 33 
billion euros in the Netherlands,110 544 billion euros in 2009 in European Union,111 and 
289 billion dollars per year in the US in 2009–2012.52
Furthermore, growing tobacco contributes to people being undernourished by using 
agricultural land, water, and labor that could be used to produce food instead. Six of 
the top ten tobacco-producing countries had undernourishment rates between 5% 
and 27% in 2009.112 In addition, tobacco production requires heavy use of fertilizers, 
pesticides, and wood (200 000 hectares of forest are cleared to cure tobacco each 
Table 3. Leading countries for WHO MPOWER measures
MPOWER measure Leading countries
Monitor use and prevention 
policies
Tobacco use is monitored in 54 countries including most European countries, 
Australia, New Zealand, the USA, Canada, Japan, South Korea, Chile, Argentina, 
Uruguay, Egypt, India, Iran, Oman, Thailand, Malaysia…87 
Protect people from tobacco 
smoke 
Comprehensive smoke-free law covering all indoor public places and workplaces: 
Chile, Jamaica, Madagascar, Russian Federation, and Suriname91
Offer help to quit tobacco 
use 
Appropriate cessation services in Argentina, Belgium, Brunei Darussalam, Malta, 
Mexico91 and the Netherlands96
Warn about the dangers of 
tobacco
Thailand (picture warnings on 85% of both sides of packages), Uruguay (80%), 
Brunei, Canada and Nepal (75%)97
Australia has implemented standard (plain) packages. France, Ireland, and the UK 
are deploying them in 2016.
Enforce bans on tobacco 
advertising, promotion and 
sponsorship
Complete ban on all tobacco advertising, promotion and sponsorship: Kiribati, 
Nepal, Russian Federation, Suriname, United Arab Emirates, Uruguay, and Yemen91
Raise taxes on tobacco Taxes raised to >75% of retail price: Bangladesh, Bosnia and Herzegovina, Croatia, 
Kiribati, New Zealand, Romania, and Seychelles91
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year).113 Farm workers, especially child laborers, are at risk of nicotine toxicity, caused 
by handling tobacco leaves without protection during harvest and processing.114 Child 
labor is observed in all countries with family-operated tobacco farms, with children 
working full time or during non-school hours. In addition, more than 175 000 tons 
of cigarette butts —containing hazardous substances such as arsenic, lead and nico-
tine— are discarded annually.115 The FCTC also addresses the environmental damage 
of tobacco.
Based on the existence of those opposing forces (tobacco control vs. tobacco indus-
try), we can infer two scenarios:
1) The tobacco industry masters ways to obstruct tobacco control,106,116 and the 
imprint of the culture of smoking will remain for a long time in media (books and 
movies).117 The addictive component of tobacco can transform people who just 
want to try cigarettes into long-term users and later impede smoking cessation. So 
tobacco use will persist for centuries.
2) The experience of countries such as Australia, the UK, and the US, where male 
smoking prevalence has fallen from 70% post war to 15–20% today, provides 
living proof that targeted tobacco control strategies can work, albeit at a slow 
pace. Smoking prevalence among the population with the most acute knowledge 
of the health impact of smoking in the US —medical doctors— was as low as 2.5% 
in 2006-2007.118 It will take time, but smoking will eventually disappear.
Resistance for change exists but is surmountable. If additional effective measures are 
not adopted, there could be 1 billion smoking-related deaths in this century.119 The 
tobacco-related public health harms, in addition to the economic and environmental 
burdens, are serious enough to morally justify the end of tobacco use.
RECOMMEnDaTIOnS
Based on the conclusions of my studies and their limitations, several actions can be 
recommended to improve public health.
Improve monitoring of smoking prevalence in racial minorities
As the need for tobacco control policies which target high smoking prevalence racial 
groups continues (e.g. American Indians and Alaska Natives in the US),13 so does the 
need for monitoring their effectiveness. Clearly, more efforts are necessary to improve 
data collection of smoking prevalence in minorities, as well as country of birth, time 
since arrival in the country —as acculturation plays a role in smoking prevalence—120 
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and country of ancestors. Those efforts should comprise sample sizes large enough to 
allow reliable estimates.
Tobacco endgame
Tobacco is the only legal product that kills prematurely more than one out of two121 
of its users when used exactly as intended by manufacturers. The feat of the tobacco 
industry resides in marketing an addictive carcinogen as a lifestyle choice. ‘[T]he root 
cause of the smoking epidemic is also evident: the tobacco industry aggressively 
markets and promotes lethal and addictive products, and continues to recruit youth 
and young adults as new consumers of these products.’52 If any other consumption 
product, for example spinach, had been proven to be as deadly, it would have been 
long banned from production, distribution, marketing and consumption. 
What makes tobacco special and so challenging to eradicate is its addictive component 
—addiction to spinach is unheard of. Decreasing the nicotine contents of cigarettes to 
less-addictive (legally possible in the US since 2009 and under the control of the FDA) 
or non-addictive levels has been proposed.122 The idea is that fewer young people 
who experiment with cigarettes would become addicted adult smokers, and previously 
addicted smokers would find it easier to quit smoking. The few preliminary studies led 
to conflicting results. A meta-analysis showed that either gradually or immediately 
reducing nicotine contents would lead to minimal compensatory smoking (increased 
intensity or rate of smoking),123 while a randomized controlled trial showed an impact 
on cigarette consumption and puffing behaviour with intermediate and low levels of 
nicotine in cigarettes.124 This emphasizes the importance of using multiple behavioural 
and biologic measures to study the effect of reduced nicotine content cigarettes.
Stronger, new actions are needed to eliminate tobacco as a health, economic and en-
vironmental burden, on the medium term. Now, serious people are discussing ending 
tobacco as a public health problem. New Zealand, Scotland and Finland have officially 
established the goal of doing so by 2025, 2034, and 2040, respectively.125 It is called 
the “tobacco endgame” and aims at phasing out the use of tobacco. There are several 
potential strategies to achieve this goal:125 
1) further implement measures from the FCTC 
2) replace cigarettes with alternative products (harm reduction) 
3) deny tobacco sales to people born after a certain year (the tobacco-free generation 
proposal) 
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More FCTC
It is the strategy chosen by New Zealand, Scotland and Finland to reach the end of 
tobacco use in their countries over the next 10–25 years. Although tobacco control has 
been successful in decreasing tobacco use of the past half century, the first strategy 
advocating for ‘more of the same’, as recommended by the FCTC and MPOWER (more 
populations covered by measures, stronger measures, more measures adopted), 
is only a preliminary phase which creates a climate that facilitates the shrinking of 
tobacco use. All of those measures discourage rather than prohibit adult tobacco use. 
Even implemented fully, those measures may be insufficient to achieve an endgame 
but can set a stage where other initiatives become feasible.125 
Harm reduction
This strategy is not usually considered as an endgame strategy because the goal is to 
reduce rather than eliminate tobacco-related harm, by encouraging cigarette smokers 
to switch to less harmful nicotine products such as smokeless-tobacco and electronic 
cigarettes (e-cigarettes).
Over 300 million people around the world use smokeless tobacco products, the vast 
majority of whom live in South Asia.35 Those products cause cancers of the oral cavity, 
pancreas and esophagus.51 However, smokeless tobacco causes less pulmonary dis-
eases than cigarettes. Therefore, if smokers immediately and permanently switched 
to low nitrosamine —a cancer inducing substance— smokeless tobacco, such as snus 
(marketed in Sweden), their risk would be reduced.126 Yet, if smokers maintained a 
dual use (snus and cigarettes) —as currently promoted by the tobacco industry— there 
would be no health benefit at population level in a country like the US.127
A rapidly growing form of nicotine delivery product is e-cigarettes. E-cigarette use 
is anticipated to be much less harmful than smoking conventional cigarettes128 be-
cause it avoids the inhalation of most of toxic combustion products. The extent of 
the harm reduction has yet to be established,129 but what we know is that they are 
not harmless.130,131 There is a heated debate whether or not officials should promote 
e-cigarettes.131-133 
On the positive side, they can be seen as a means for smokers to decrease or substitute 
their cigarette consumption, or as temporary aid to smoking cessation. A Finnish study 
offered 48 participants unwilling to stop smoking cigarettes to use e-cigarettes. Six 
months after the end of the study, 21% of them had stopped cigarette smoking, 23% 
had cut their cigarette consumption at least by half, and the remaining participants 
smoked at least 50% more cigarettes,134 suggesting positive effects in light smokers. 
Other studies have been performed, and reported positive results.135-137 E-cigarettes 
rapidly evolve to offer a better experience to users, closer to smoking cigarettes. Thus, 
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randomized controlled trials with those new products are necessary (and under way). 
Most importantly, these studies have to compare the effectiveness of e-cigarettes for 
quitting against other measures, like NRT and counseling. 
On the negative side, they have the potential to renormalize cigarette use if they 
are permitted in venues where cigarettes are banned, they can appeal to nonsmok-
ers and former smokers, and they maintain nicotine addiction. Certainly, under no 
circumstance is nicotine a biological need —but in the 1950s, it was presumed to be 
an essential drug for calming and stimulating stressed people. Nicotine is a poison.138 
Encouraging the sale of nicotine products is supporting people buying a poison. In 
the US, a third of cigarette smokers also used e-cigarettes in 2013. More troublesome 
was the report of e-cigarette use among former smokers (5%) and even in never-
smokers (1%). Although smokers were most likely to use these products, almost 
a third of current e-cigarette users were nonsmokers, suggesting that e-cigarettes 
contribute to primary nicotine addiction and to renormalization of tobacco use.139 Also 
of concern were the results of a study among high school students in Los Angeles 
showing that those who had ever used e-cigarettes at baseline compared with nonus-
ers were more likely to report initiation of combustible tobacco use over the next 
year.140
Regardless of whether or not e-cigarettes are a gateway to conventional cigarette 
use, there is no reasons for minors to use a product for which the presumed public 
health benefit is harm reduction for adult smokers.141 Therefore, strict regulations are 
needed to forbid sales to minors, advertising directed to youth, flavoring, and use in 
smoke-free places; to tax e-cigarettes; to have them exclusively sold by licensed re-
tailers; and to require health warning on the product to ensure that e-cigarettes do not 
contribute to preventable chronic diseases. Nevertheless, controlling for e-cigarette 
ads on the internet will prove challenging, if at all possible.
Both smokeless tobacco and e-cigarettes are still addictive and harmful, but again, 
much less than cigarettes. As long as cigarettes are available for purchase, there 
is a potential for smokeless tobacco and e-cigarettes to be gateways to cigarettes 
(increasing the number of cigarette smokers) and to maintain nicotine addiction 
(getting nicotine when cigarette smoking is not permitted). Those harm reduction 
solutions are thus only appealing if cigarettes are banned. Another way to see this 
is that smokeless tobacco and e-cigarettes make cigarettes bans possible.142 After 
eliminating cigarettes, a second step can be to diminish the nicotine contents of the 
other tobacco products, so as to make them less addictive and attractive. Overtime, 
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there would be lower intake and lower dependence upon those better —but still not 
safe— alternatives.
Tobacco-free generation
Increasing the minimum legal sale age for tobacco products, as required by the FCTC, 
can be seen as an intermediate step to the proposal to the tobacco-free generation. 
For instance, the minimum smoking age in the Netherlands was raised from 16 to 18 
years only in 2014, 57 years after the first warning in the Health Council report —
which only warned of the danger in children.143 Nearly 9 out of 10 smokers experiment 
cigarettes under the age of 18, and 98% of smokers started before the age of 26 in 
the US.52 Furthermore, the vast majority of Americans who begin daily smoking during 
adolescence are addicted to nicotine by young adulthood.144 Therefore, preventing 
youth initiation may be the key to ending the tobacco epidemic. Nevertheless, there 
are two important drawbacks to the existing ‘underage’ restriction. 
1) It creates a rite-of-passage effect: underage people may think that by smoking 
they appear 18.145 This belief has been exploited by the tobacco industry’s mock 
tobacco control campaigns ‘Kids don’t smoke’. Prohibiting sales to minors does reduce 
cigarette consumption among them, but only to a certain extent does it reduce ciga-
rette initiation. Banning cigarettes makes them attractive to a fraction of teen specifi-
cally because cigarettes are outlawed. Therefore, renewed anti-smoking campaigns 
backed by behavioral science to address smoking initiation triggers in adolescents are 
needed. Teens are introduced to cigarettes by same-age peers or individuals of legal 
age and in the same circles (at school or siblings), when they are not directly bought 
from careless tobacco retailers. In an effort to overcome this loophole, some localities 
in the US have raised the age higher. In 2015, Hawaii became the first state to enact 
a law increasing the tobacco sales age to 21, followed by California in 2016. More 
than 125 localities, including New York City, have raised the tobacco sales age to 21.88 
According to a study by the Institute of Medicine of the National Academies using two 
established and complementary tobacco simulation models —SimSmoke and CISNET 
modeling— raising the minimum age of legal access to tobacco to 21 is predicted to 
result in a 12% decrease in the prevalence of tobacco use among today’s teenagers 
once they become adults —because some people will never start smoking— and later 
reduce smoking-related deaths by 10%.146 There is extensive public support (71%) 
for this ruling in the US, including among smokers (58%) and people aged 18-20 
(62%).147
2) But, it has an adverse signaling effect: if the government forbids access to tobacco 
for people under a certain age, then it implies that it is acceptable for people with legal 
age to buy it.145 Thus, the tobacco industry’s frequent claim is: ‘It’s a legal product’. 
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Yet this does not make tobacco a safe product. There is irony in the message sent to 
citizens: ’You can buy cigarettes, but don’t do it’. The paradox goes on when adults are 
able to buy cigarettes, but are strongly encouraged to stop using them (which would 
not prove so challenging if cigarettes were not addictive).
The tobacco-free generation proposal, by prohibiting the sale of tobacco to individu-
als born after a certain year, aims at overcoming the defects of rite-of-passage and 
misleading messages of current youth access laws. The proposition to ban people 
born after 2000 from smoking has for example been discussed at the Senate of the 
Provinces of Tasmania and Queensland, Australia, and in Singapore, but has not been 
adopted. With this measure, the impact on supply is gradual and obvious, but the 
impact on demand is also important. It sets the stage for new types of public health 
messages: ‘tobacco is something of the past’. Over time, the age gap between teenag-
ers and the last cohort of smokers steadily widens, facilitating a change of norms. 
Hence, enforcement becomes progressively easier: ‘the best law is one that so shapes 
social norms that it becomes self-enforcing’.148 Tobacco use will thereby gradually 
disappear. If the teenagers of today became the first tobacco free generation, the 
positive outcome on mortality rates would chiefly take place in the middle or second 
half of the 21st century. Secondhand and third-hand (smoke residue left in furniture, 
carpets, etc.) will also decrease gradually. 
The measure may seem to be drastic to some. However, the estimation of 450 million 
adults prematurely killed by smoking between 2000 and 2050149 calls for drastic ac-
tion, and there are precedents for the generational method. It was used to phase out 
opium smoking in Formosa (now known as the island of Taiwan) in 1900, and in British 
Ceylon in 1910. Within 35 years, opium use was eradicated.145 Additionally, despite of 
the economic consequences, 60 countries have already completely banned asbestos 
(only partial ban in the US) because of its deleterious health effects. It is therefore 
possible to do the same with tobacco.
Possible endgame implementation strategies can integrate ideas from the FCTC, harm 
reduction and the tobacco-free generation.
advancing tobacco control in low- and middle-income countries
Tobacco use in low- and middle-income countries (LMICs) is not new. Trade in tobacco 
and its products has expanded dramatically in the 1980s as result of a variety of 
bilateral, regional and international trade agreements that have significantly reduced 
trade barriers.150 Tobacco industries invested in those countries to increase their prof-
its.151,152 The ingredients for a tobacco epidemic are already in place: in 2000, eight 
out of ten smokers lived in developing countries.150 Over the past 15 years, smoking 
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prevalence only increased in LMIC (fi gure 4) and Croatia (a high-income country since 
2008). As a consequence, cigarette smoking was very strong in 2012 in Chile (32% 
prevalence in men and 26% in women), in Egypt (36% in men and 1% in women), 
and Indonesia (57% in men and 4% in women) for instance (fi gure 5).153 On average, 
50% of men and 9% of women smoke in LMICs, while the gender gap narrowed in 
high-income countries (being 35% and 22%, respectively).32 
In LMICs, greater attention is being given to the ubiquitous problem of poverty. 
Within the health sector, this focus translates into improving access to health services, 
and reducing the burden of communicable diseases. Indeed, risk factors for chronic 
disease, such as smoking and poor diet, are arguably seen as matters of individual 
lifestyle choice, and not the consequences of various circumstances that go beyond 
personal choice (fi gure 3), including lack of investment from governments. Neverthe-
less, there is an inextricable relationship between tobacco and poverty (fi gure 1). At 
the country-level, tobacco generates large productivity loss155 and healthcare cost, 
which undermine economic development in many countries.35 At the individual-level, 
tobacco spending adds directly to fi nancial stress. The WHO estimates that as much 
as 10% of household income can be spent on tobacco products, leaving less money 
for food, education, housing, and clothing.32 Disadvantaged populations (in countries 
from all income levels) sustain the habit because smoking can be seen as a means of 
coping with diffi  cult circumstances, as an “aff ordable” recreation, and as a response 
to stress and exclusion.26 
Figure 4. Where did smoking prevalence rise between 2000 (blue) and 2015 (orange)?154
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We can expect that, as economic development is achieved by low-income countries, 
they will transition into becoming middle-income countries. Henceforth, cigarettes will 
be marketed to more people and more people will be able to aff ord them. While smok-
ing prevalence is still very low in low-income countries (e.g. 5% in Sudan and Niger, 
and 4% in Ethiopia) (fi gure 5) it could increase to the level of middle-income countries 
—although smoking prevalence in middle-income country is very diverse— (e.g. 11% 
in Algeria and Kenya, 25% in Bolivia, and 30% in Indonesia).153 It is therefore critical 
to now establish and expand strong tobacco control where tobacco smoking is com-
mon, and educate the people on the harms of tobacco and ban tobacco marketing 
where tobacco smoking is rare.
The FCTC aims at implementing tobacco control in all countries, regardless of the 
smoking prevalence or the economic level. The FCTC has been integrated into the 
Sustainable Development Goals of the United Nations (17 goals directed to a sustain-
able development to meet by 2030 which aspire to human-rights-centered approaches 
to ensuring the health and wellbeing of all people). This gives an additional incentive 
for governments in LMICs to act on tobacco control. Several LMICs already lead the 
way in tobacco regulation (Table 3). Four LMICs have all MPOWER measures in place 
Figure 5: Over a billion people smoke worldwide
Circle size: number of smokers in 2012. Darker color: higher smoking prevalence
Source: WHO’s Global Health Observatory,159 as in154 
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at the highest level (Turkey, Uruguay, Panama and Iran), three more are only one step 
away from the highest level (Brazil, Argentina and Nepal). About 1.8 billion people 
—a third of all people living in LMICs— are now protected by at least one MPOWER 
measure at the highest level.91 For example, smoking prevalence monitoring —the 
first measure of MPOWER— is achieved by the GATS (Global Adult Tobacco Survey), in 
more than 25 LMICs with highest burden of tobacco use, including India, Indonesia, 
Nigeria, Philippines, Senegal, Thailand, and Viet Nam.
Yet, signing the FCTC is not sufficient. For instance, China ratified it in 2005 and 
smoking prevalence has been stable (53% of men and 2% of women) for the past five 
years.156 Annual tobacco-related deaths in China are projected to rise to two million 
by 2030, when the young adult smokers of the turn of century reach middle-age. 
Similarly, at current risk, India will have one million tobacco-related deaths during 
the 2010s, and the number will grow as population rise. At this pace, global annual 
tobacco-attributable deaths are predicted to reach ten million around 2030.149 The 
tobacco industry is constantly working at fighting tobacco control, directly in LMICs,157 
or using LMICs to challenge global tobacco control.158
Advances in tobacco control in LMICs —where most of today’s smokers live (figure 
5)— are urgently needed. In particular, vigilance is required to ensure that women in 
LMICs, especially in those with rapidly growing economies,160 do not begin to smoke in 
large numbers as women have done in some high-income countries.161
air pollution control
Avoiding cigarette smoking and secondhand smoke is a smart way to avoid smoking-
related cancers, COPD, and other smoking-related diseases. Yet it is not sufficient. 
Besides smoking, air pollution —both indoor and outdoor— is another common risk 
factor to lung cancer in many countries162,163 and COPD.164 Furthermore, air pollution 
also affects adults with respiratory symptoms in urban areas.165 
Some of the problematic air pollution pollutants are called fine particulate matter 
(PM2.5). These small particles can get past the body’s normal defenses and penetrate 
deep into the lungs. They are most abundant in LMICs in Africa and Asia166 (figure 
6), and come from both human and natural sources (such as wind filled with mineral 
dust from the Arabian and Saharan deserts). More than 80% of the world’s population 
breathe polluted air that exceeds the WHO’s recommended level of 10 micrograms per 
cubic meter of PM2.5.167
Outdoor air pollution is generated by transport, power generation, industrial activity 
(including farming), biomass burning, and domestic heating for example. Pollution 
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levels in western Europe and North America have generally declined since the late 20th 
century, but they are increasing in some rapidly industrializing countries, notably in 
Asia. 
Reducing the public health impacts of outdoor air pollution requires addressing the 
main sources of outdoor pollution. Although individuals can contribute to the reduction 
of outdoor air pollution, it also requires action by public authorities at the national, re-
gional and even international levels. For instance, while the final decision to commute 
by bicycle is left to individuals, the creation of infrastructures for bicycles is essential 
for the promotion of this fossil energy-free means of transportation.
Indoor air pollution includes biomass burning for cooking and heating, as well as 
heating of some oils used for cooking.168 Women and children can be at a particularly 
high risk of lung diseases from exposure to household air pollution.169 A wide range of 
interventions are available to reduce indoor air pollution and associated health effects. 
Interventions can be classified according to their target: 
1) interventions on the source of pollution: using alternative fuels (solar power, elec-
tricity, or biogas) and improved stoves 
2) interventions to the living environment: build chimneys, cooking windows, or 
smoke hoods
3) interventions to user behavior: keeping young children away from smoke 
Epidemiological studies are essential to monitor the impact of (indoor and outdoor) air 
pollution and monitor the effect of interventions. For example, for many years, Xuan-
wei, a farming town in western China, had one of the highest incidence rates of lung 
cancer in the world. Women were developing cancer at equal or higher rate than men, 
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although women rarely smoked. However, they used coal in open fire pits to cook, and 
coal again to heat their poorly ventilated houses. Lung cancer rates declined after the 
Chinese government offered a financial incentive to families building chimneys, and 
families started to use a portable stove they could carry outside.168 
So far, too many people in LMICs continue to lack access to affordable, life-saving 
clean energy systems. Several decades of research, national stove programs and 
international initiatives have yet to lead to a significant reduction in the population de-
pending on polluting fuels and technologies to meet their daily energy needs. Roughly 
the same number of people today cook with polluting energy systems as did 30 years 
ago. Population growth has outstripped incremental progress in increasing access 
to clean, modern energy systems.169 Access to affordable, reliable, sustainable and 
modern energy for all is now one of the Sustainable Development Goals. This ought to 
spur further action on reducing pollutant emissions.
5.2 COnCLuSIOnS anD fuTuRE RESEaRCH
Our work evaluated the smoking-related burden of cancer and COPD in several popu-
lations and subpopulations within a country, and their changes over time. We have 
shown that smoking-related cancer incidence rates are declining in most of studied 
populations —mainly high- and very high-income countries— among men, following 
longstanding reductions in smoking prevalence. In contrast, due to delayed declines in 
smoking prevalence among women, smoking-related cancer (particularly lung cancer) 
incidence rates were still increasing, except for some declines in few European popula-
tions. In many countries, COPD mortality rates declines, probably due to declines in 
smoking prevalence, as well as increasing wealth. In LMIC in Asia and Latin America, 
female COPD mortality rates were high and declining despite low smoking prevalence. 
We also expanded our analyses on the smoking-related burden of cancer in a high-
income country which was at the origin of mass production, marketing, and sales of 
tobacco: the US. Firstly, that the fraction of cancers deaths attributable to cigarette 
smoking can be large (29%), with fractions higher than 30% in Southern states and 
at low as 17% in Utah. Secondly, that the smoking-related burden of cancer is sub-
stantial in every racial/ethnic group (from 19% in Hispanics and non-Hispanic Asians, 
to around 28% in non-Hispanic Whites and non-Hispanic Blacks). 
On the one hand, our findings highlight the potential health gains in every population 
that can be achieved with a reduction or elimination of tobacco use. On the other 
hand, they show the long lag time for the effects of prevention (declines in smoking 
prevalence) to be reflected in population health. Those results stress the continuing 
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need for tobacco control and identify women (particularly in LMIC, where smoking 
prevalence is still low), Blacks and Whites, and Southern states populations in the US, 
as group which would particularly benefit from tobacco control.
However, the generalization of those conclusions to the global population are limited 
by the fact that we could only access data for some countries, most of them being 
high-income countries. Our studies in the US showed large disparities between racial/
ethnic groups, as well as geographic location, and we can speculate that the disparities 
are even larger at global level. This means that tobacco control has to be implemented 
at global level, as intended by the FCTC.
This work glances at what could be a tobacco-free world, from the cancer and COPD 
health perspectives. Despite its successes in the recent past, there is a need for a 
breakthrough in tobacco control. Most importantly, to put tobacco behind us, tobacco 
control has to be integrated at a very large scale that goes beyond public health and 
economic gains. It has to be addressed in a general context of human development.95 
The FTCT has been integrated in one of the health targets of the Sustainable Develop-
ment Goals: “Ensure healthy lives and promote well-being for all at all ages”. Tobacco 
control must also be considered as part of other Goals: ending poverty, achieve food 
security, promote sustainable economic growth, end child labor, promote safe working 
environments, sustainably manage forests, reduce corruption and bribery, develop 
accountable and transparent institutions at all levels through various pathways il-
lustrated in Figure 7. 
Future research agenda
There is substantial evidence on the negative health impact of tobacco, whether from 
first-hand or secondhand smoking, or smokeless tobacco use, in high-income coun-
tries. There is also a growing demonstration of the high economic cost of tobacco, 
at individual- and national-level. Finally, the ambivalent role of the tobacco industry 
(knowingly selling deadly products while pretending to be public health partners) and 
its constant interference in politics and economic and health policy has repeatedly 
been reported.102,151,170
Nevertheless, numerous questions related to tobacco remain —besides clinical re-
search to find life-saving cures— calling on a wide range of experts (table 4).
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CONTROL
LOBBYING
Restrict power of lobbies
Combat covert industry 
interference and undue 
influence
RESEARCH
Study health effects of tobacco 
and nicotine
Investigate social and genetic 
determinants of smoking and 
addiction
Explore new tools for smoking 
cessation
LAW ENFORCEMENT
Combat smuggling 
Fight corruption and bribery
Develop accountable and 
transparent institutions 
End child labor
Figure 7. Possible leverages for tobacco control.
Source: adapted from35 
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In this thesis, we have used population-based cancer registry data and national vital 
statistics to describe the large smoking-related burden of two non-communicable 
diseases, demonstrating the need for a broad alliance against tobacco, to end tobacco 
use in the twenty-first century.
Table 4. A sketch of future research on tobacco-related topics
Type of studies Subject / study question
Environmental studies What is the environmental burden of tobacco throughout its lifecycle at national and 
global level (from farming, to curing, to use, and to disposal)? 
Occupational studies How can the working conditions (safety) of farmers producing and transforming tobacco 
leaves be improved?
Laboratory studies Is nicotine the only addictive component in tobacco?
Behavioral studies How can behavior related to tobacco use be changed and the change sustained? 
How effective are e-cigarettes compared to existing smoking cessation tool?
Epidemiological 
studies
What is the prevalence of emerging tobacco products use (e-cigarettes, hookah, little 
cigars, etc.)? 
What is the health impact of e-cigarettes?
How do cancer incidence rates in two neighboring countries with different levels of 
tobacco control compare, using cancer registry data?
Can tobacco control implementation be detected in period-cohort analyses of cancer 
incidence, using cancer registry data?
What is the smoking-related cancer incidence in LMICs?
What would be the smoking-related global mortality in 2030, based on several tobacco 
control scenarios (different levels of MPOWER measures)?
Political studies How can the influence of lobbies be better regulated?
Business studies What is the tax/regulatory threshold for tobacco industries to make insufficient profit and 
give up selling deadly products?
New technologies Can we create a smartphone app which can make a difference in smoking initiation and 
smoking cessation?
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5.3 SuMMaRY
Prior to the nineteenth century, lung cancer was a rare disease. It took time, intel-
ligence, and fortitude to prove that cigarette smoking was responsible of the rapid 
increase in lung cancer deaths observed in high-income countries in Northern America 
and Europe during the first half of the twentieth century. During the second half of 
that century, more diseases would be causally linked to smoking, including eleven 
more cancer types, chronic obstructive respiratory disease (COPD), and cardiovascular 
diseases. Even sixty years after irrefutable evidence of the health harms of tobacco 
and the implementation of tobacco control policies leading to declines in smoking 
prevalence, the burden of smoking-related cancers and COPD remains colossal and 
underrated. Therefore, the international burden of the smoking-related cancers and 
COPD was assessed at the turn of the twenty-first century, with a special focus on 
Europe and the United States of America —a country which played a pivotal role in the 
dissemination of cigarettes throughout the world.
In Europe, smoking-related cancer incidence remains high as there is a lag time of 
several decades between smoking and disease diagnosis. Mass cigarette use followed 
the economic development of the continent: firstly, in northern and western Europe, 
secondly southern Europe, and thirdly in central and eastern Europe. Adoption of 
smoking by women lagged behind that of men by decades, and never reached the very 
high male smoking prevalence. Over the 1998–2007 period, lung cancer incidence —of 
which more than 80% of cases are due to smoking— declined or levelled off in men all 
over Europe (Chapter 2.1), following sharp declines in smoking prevalence since the 
1950s. In contrast, female lung cancer incidence increased in 19 countries over the 
same period. In other major smoking-related cancers (oral cavity and pharyngeal, la-
ryngeal, and esophageal), the effect of past smoking prevalence trends is less evident 
because of lower smoking-attributable fractions, concomitant trends of risk factors 
specific to those sites, or low number of cases. Over the 1998–2007 period, incidence 
rate of oral cavity and pharyngeal cancer only increased in few countries among men 
in some age groups (in the Czech Republic, Denmark, in Slovakia, UK, and Germany). 
Incidence also increased in some age groups in these countries among women, as 
well as in Ireland, Norway, and in the Netherlands. Laryngeal cancer incidence just 
increased among Bulgarian men, while the number of cases remained very low in 
European women. Finally, surges in esophageal cancer incidence among men were 
generally restricted to the northern half of Europe, whereas among women, increases 
appeared to occur in most countries in western, central and eastern Europe. 
Manufactured cigarettes are a product which has constantly evolved since their launch 
at the end of the nineteenth century, to attract and retain smokers. The changes 
in cigarette design and composition are reflected, with a lag time, in populations in 
changes in the distribution of lung cancer sub-types. While lung cancer incidence 
declined or remained stable over 1973–2002 among men in all of the eleven high-
income countries studied —except Spain— trends varied by subtype (chapter 2.2). 
Squamous cell carcinoma (SCC) has been the most frequently diagnosed subtype of 
lung cancer among men at the beginning of the study period. However, adenocarci-
noma (AdC) diagnoses surpassed SCC diagnoses among men in six countries starting 
around the 1990s. Contrary to the declines in SCC incidence, AdC incidence leveled 
off or even increased over time. In contrast, AdC was always the predominant subtype 
of lung cancer and continued to increase among women throughout the study period. 
Reasons for the shift of the lung cancer epidemic from SCC to AdC subtypes among 
men include: first, the rise of filtered, lower tar- and nicotine-containing cigarettes led 
smokers to inhale deeper into the lungs (to get the same dose of nicotine), replacing 
central tumors (often SCC) with peripheral tumors (often AdC); second, changes in 
the carcinogenic mix of cigarette smoke. Because women picked up the habit a few 
decades after men, when filtered/low-tar and low-nicotine cigarettes had swamped 
the market, and because women were targets for these new ‘light cigarettes’, AdC was 
always more frequent than SCC among them.
Each year, cancer is responsible for around 10 million disability-adjusted life years 
(DALYs) lost (as the combination of years lost due to premature death and years 
lived with decreased quality of life due to disabilities) in the US (chapter 3.1). The 
burden of cancer is equivalent among men and women –each losing 5 million DALYs to 
cancer. However, the fraction of this burden attributable to cigarette smoking is higher 
among men than among women (32% and 21%, respectively) (chapter 3.2). It also 
varies by race/ethnic group; it is higher among non-Hispanic Whites and non-Hispanic 
Blacks (around 28%) than among non-Hispanic Asians and Hispanics (19%). Those 
differences in the smoking-attributable fraction of the cancer burden emerge because 
of differences in current and past smoking prevalence between races/ethnicities and 
genders, reflecting variances in social norms, socioeconomic status, targeted tobacco 
marketing, and acculturation level among immigrants. The smoking-attributable frac-
tion shows the theoretical health gains if tobacco smoking was eliminated: from 10% 
of the cancer burden among non-Hispanic Asian women to 34% among non-Hispanic 
black men.
Besides gender and racial/ethnic differences, there are also geographic differences 
in the smoking-related cancer mortality the US (chapter 3.3). The national smoking-
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attributable fraction of cancer deaths is 29%, but is higher in Southern states: 
Kentucky (34%) —the highest fraction of all 51 states— Tennessee (33%), North 
Carolina (31%), South Carolina (30%), Georgia (29%), etc. This high mortality from 
smoking-related cancers is due to high smoking prevalence, likely reflecting weaker 
tobacco control policies and social norms made possible by the large economic influ-
ence of the tobacco industry in those tobacco-growing states. The fraction is also 
high in states with large poor and less educated populations, in the rest of the South 
(Louisiana, Alabama, and Mississippi), and in the Appalachian region (West Virginia). 
It is lowest in California (26%), where tobacco control is strong and large non-smoking 
Hispanic populations live, and in Utah (17%) where social norms (55% of people are 
Mormons) proscribe smoking. It is important to note that the effect of tobacco control 
on cancer deaths due to smoking are only visible on the long term, hence it is essential 
to implement it as soon as possible.
Using lung cancer mortality as a marker of past and current smoking exposure, in 
chapter 4.1, we investigated the effect of smoking on COPD mortality in 61 in high- 
and middle-income countries. It turned out that while lung cancer and COPD mortality 
where strongly correlated in high-income countries among women, they were only 
moderately correlated among men in both high- and middle-income countries. No 
correlation was found among women in middle-income countries. In fact, around 
2011–2013, lung cancer mortality rates were up to 10 times higher than COPD mortal-
ity rates in the majority of the countries, whereas in most of middle-income countries 
in Latin America and Asia the reverse was true. Also, while both lung cancer and COPD 
mortality were declining among men over the last 10 years (around 2002-2011), lung 
cancer mortality was increasing in about half of the countries and COPD was increasing 
in six European countries among women. Progress in the diagnosis and treatment 
of COPD symptoms (as opposed to limited progress in lung cancer treatment), as 
well as declines in poverty—a major risk factor for COPD— in the studied countries 
further mitigated the association between smoking (tracked by lung cancer mortality) 
and COPD mortality. In conclusion, while smoking had a major role in driving the 
COPD mortality rate in high-income countries, additional risk factors had to be also 
important to explain COPD mortality in middle-income countries.
We showed that the international burden of smoking-related cancer and COPD is large. 
Despite the global declines in smoking prevalence since the 1990s, the burden will 
continue to be large for some time due to the considerable lag time between smoking 
and ensuing cancer or COPD. In fact, lung cancer incidence and mortality are still 
increasing among women in most European populations. Furthermore, although the 
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mortality rate of smoking-related cancer and COPD mostly declined over 2002–2011, 
the number of deaths increased because of mere population growth and ageing. 
Since the definitive evidence of the link between smoking and numerous diseases 
starting in the mid-1950s, the very high male smoking prevalence has been halved 
in high-income countries. However, tobacco control and increased awareness of the 
harmful effects of tobacco had only limited bearing on female smoking prevalence, 
at least until the 1990s. Therefore, there is a continuing need for tobacco control. 
It should not take another sixty years to cut smoking prevalence by two in high-
income countries and among men in middle-income countries, and to prevent women 
in middle-income countries from picking up the deadly habit. If we want to eradicate 
tobacco-related diseases, tobacco control policies must be strengthened, harm-re-
duction solutions (smokeless tobacco and electronic-cigarettes) must be investigated 
for addicted smokers, and tobacco-free generation measures (i.e. ending the legal 
provision of tobacco to the generations that have not yet commenced consumption) 
should be undertaken. The damaging effects of tobacco go beyond their deleterious 
impact on health. Tobacco production triggers deforestation, and diverts land and 
water from food production; tobacco use causes economic losses for consumers and 
societies; and tobacco disposal produces toxic waste. A multidisciplinary approach is 
thus needed to strike tobacco at every stage, so that the harms of tobacco are put to 
an end in the twenty-first century.
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5.4 SaMEnvaTTIng
Vóór de negentiende eeuw was longkanker een zeldzame ziekte. Het kostte tijd, ver-
nuft en standvastigheid om te bewijzen dat het roken van sigaretten verantwoordelijk 
was voor de snelle stijging van longkanker sterfgevallen, waargenomen in de rijkere 
landen in Noord-Amerika en Europa in de eerste helft van de twintigste eeuw. In de 
tweede helft van die eeuw, bleken meer ziekten oorzakelijk verband te houden met 
roken, waaronder elf soorten kanker, chronische obstructieve luchtwegaandoeningen 
(COPD) en hart- en vaatziekten. Zelfs zestig jaar na onweerlegbaar bewijs van de 
gezondheidschade van tabak en steeds verdergaand tabaksbeleid leidde tot afname 
van het aantal rokers, blijft de last van roken gerelateerde kankers en COPD behoorlijk 
onderschat. Daarom is de internationale last van het roken gerelateerde kankers en 
COPD nog eens beoordeeld aan het begin van de 21ste eeuw, met een speciale focus 
op Europa en de Verenigde Staten van Amerika die zo’n cruciale rol hebben gespeeld 
in de verspreiding van sigaretten wereldwijd.
In Europa bleef de roken gerelateerde incidentie van kanker hoog, vanwege een 
decennia durend interval tussen het roken en de diagnose van de kankers. Massaal 
gebruik van sigaretten volgde de economische ontwikkeling van het continent: eerst 
in Noord- en West-Europa, vervolgens in Zuid-Europa, en gevolgd door Midden- en 
Oost-Europa. Het roken door vrouwen liep tientallen Jaren achter bij de mannen en 
bereikte nooit de hier en daar zeer hoge mannelijke rookprevalentie. In de periode 
1998-2007 is de longkanker incidentie bij mannen-waarvan meer dan 80% te wijten 
is aan roken- gedaald of afgevlakt in heel Europa (hoofdstuk 2.1), naar aanleiding 
van scherpe dalingen van het aantal rokers sinds de jaren 50. Daarentegen nam de 
longkanker incidentie bij vrouwen sterk toe in de 19 landen in dezelfde periode. Bij 
andere belangrijke roken gerelateerde kankers (mond- en keelholte, strottenhoofd 
en slokdarm) was het effect van het vroegere rookprevalentie trends minder evident, 
maar de toerekenbare fractie door het roken werd ook beinvloed door min of meer 
gelijktijdige invloeden van andere risicofactoren die specifiek zijn voor deze sites, 
maar ook het kleine aantal gevallen maakt dit niet mogelijk. Gedurende 1998-2007 
bleek de incidentie van kanker in de mond- en keelholte alleen maar te zijn toege-
nomen in Tsjechië, Denemarken, Slowakije, het Verenigd Koninkrijk en Duitsland. De 
incidentie was alleen toegenomen in sommige leeftijdsgroepen bij vrouwen in Ierland, 
Noorwegen, en in Nederland. De incidentie van strottenhoofdkanker was alleen toege-
nomen bij Bulgaarse mannen, terwijl het aantal gevallen zeer laag bleef bij Europese 
vrouwen. Forse stijgingen bij slokdarmkanker bij mannen bleven over het algemeen 
beperkt tot de noordelijke helft van Europa, terwijl dit bij vrouwen in de meeste landen 
van West-, Midden- en Oost-Europa ook het geval was.
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De industrieel vervaardigde sigaretten evolueerden voortdurend sinds de lancering 
eind Jaren ‘80 van de negentiende eeuw, om steeds nieuwe rokers te bedienen en 
te behouden. De veranderingen in sigaretontwerp en samenstelling bleken later uit 
veranderingen in de frequentie van longkanker subtypes. De meest vóórkomende sub-
types zijn plaveiselcelcarcinoom (SCC) en Adenocarcinoom (ADC) van de long. Terwijl 
de longkanker incidentie daalde of stabiel bleef in 1973-2002 bij mannen in alle elf 
rijke landen -behalve Spanje- varieerden de trends per subtype aanzienlijk (hoofdstuk 
2.2). SCC was het meest gediagnosticeerde subtype van longkanker bij mannen in het 
begin van de studie. Maar ADC diagnoses overtroffen SCC diagnoses bij mannen in 
zes landen rond 1990. In tegenstelling tot de daling van de SCC incidentie, vlakte de 
ADC incidentie af of steeg zelfs. Daarentegen was ADC altijd het overheersende sub-
type van longkanker bij vrouwen gedurende de studieperiode. Op grond van velerlei 
ander onderzoek zijn de meest aannemelijke redenen voor deze verschuiving van de 
longkanker-epidemie van SCC naar ADC: 
1. de opkomst van de gefilterde, lagere teer- en nicotine bevattende sigaretten leidde 
tot dieper inhaleren in de longen (om dezelfde dosis nicotine te krijgen), en tot 
vervanging van centrale door perifereer gelegen tumoren (vaak ADC); 
2. veranderingen in de kankerverwekkende mix van sigarettenrook. Omdat vrouwen 
de rookgewoonte een paar decennia na de mannen overnamen, toen gefilterd / 
laag teergehalte en lage-nicotine sigaretten de markt overspoelden, en 
3. omdat vrouwen de ideale doelgroep vormden voor deze nieuwe ‘light sigaretten’. Bij 
hen werd ADC dus altijd vaker aangetroffen dan SCC.
Per jaar is kanker in de VS verantwoordelijk voor ongeveer 10 miljoen disability-
adjusted life years (DALY’s) (als de combinatie van jaren verloren door vroegtijdige 
sterfte en jaren geleefd met een verminderde kwaliteit van leven als gevolg van 
een handicap) (hoofdstuk 3.1). De last van kanker is ongeveer gelijk bij mannen en 
vrouwen met elk 5.000.000 DALY’s. Het deel van deze last te wijten aan het roken 
van sigaretten is echter veel hoger bij mannen dan bij vrouwen (32% en 21%, res-
pectievelijk) (hoofdstuk 3.2). Het verschilt ook per etnische groep: hoger bij de niet-
Spaanse blanken en niet-Spaanse zwarten (ongeveer 28%) dan bij de niet-Spaanse 
Aziaten en Latijns-Amerikanen (19%). Deze verschillen ontstonden  als gevolg van 
verschillen in de vroegere (en huidige) rookprevalentie tussen deze etnische groepen 
als gevolg van verschillende sociale normen, sociaal-economische status, maar ook 
gerichte tabak marketing en acculturatie niveau onder allochtonen. De aan roken 
toerekenbare fractie toont de theoretische gezondheidswinst als het roken van tabak 
werd geëlimineerd (en zonder eventuele bijwerkingen hiervan): van 10% van de kan-
kerlast bij niet-Spaanse Aziatische vrouwen tot 34% bij niet-Spaanse zwarte mannen.
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Naast verschillen per geslacht en etnische groep bleek er ook aanzienlijke geografische 
variatie in de aan roken gerelateerde kankersterfte de VS (hoofdstuk 3.3). Nationaal 
bedraagt dit aandeel ongeveer 29%, maar bleek het beduidend hoger in zuidelijke 
staten, waar traditioneel veel tabak werd verbouwd: Kentucky (34%), Tennessee 
(33%), Noord-(31%) en Zuid Carolina (30%). Deze hoge sterfte aan roken gerela-
teerde kankers is te wijten aan een veel hogere prevalentie van roken, waarschijnlijk 
als gevolg van het minder strenge tabaksgebruikbeleid en heersende sociale normen 
voortvloeiend uit de grote sociale en economische invloed van de tabaksindustrie in 
deze staten. Maar de fractie bleek ook hoog in zuidelijke staten met een relatief grote 
arme, laag opgeleide bevolking (Louisiana, Alabama en Mississippi), en in de Ap-
palachen regio (West Virginia). Daarentegen was die lager in California (26%), waar 
de strengere bestrijding van het tabaksgebruik ook aansloeg op de aldaar sterk groei-
ende Spaanstalige bevolking, en het laagst in Utah (17%), waar sociale normen (55% 
Mormonen) traditioneel het roken verboden. Omdat het effect van tabaksgebruik op 
kankerdood door roken alleen op de lange termijn effect sorteert, is het essentieel zo 
spoedig mogelijk actie te nemen.
Met behulp van de sterfte aan longkanker als een ‘’marker’’ van het vroegere rook-
gedrag en ook de huidige roken blootstelling, onderzocht ik in hoofdstuk 4.1 het 
effect van roken op de sterfte aan chronisch long lijden (COPD) in 61 in hoge en 
midden-inkomens landen met enigszins betrouwbare doodsoorzakenstatistiek. Terwijl 
longkanker en COPD sterfte sterk gecorreleerd waren in de rijke landen, met name bij 
vrouwen, bleek dit verband minder sterk bij vrouwen in de midden-inkomens landen. 
In 2011-13 bleken de, longkanker sterftecijfers tot 10 keer hoger dan die van COPD 
in het merendeel van de landen, met uitzondering van de meeste midden-inkomens 
landen in Latijns-Amerika en Azië die het omgekeerde lieten zien. Terwijl tussen 2002 
en 2011) zowel de longkanker als de COPD sterfte daalde bij mannen, steeg de long-
kanker sterfte in de helft van de landen bij vrouwen, maar de COPD-sterfte alleen in 
zes Europese landen, waar ook grote toenames van het rookgedrag plaatsvonden. 
Vooruitgang in de diagnose en behandeling van COPD symptomen (in tegenstelling 
tot de beperkte vooruitgang in de behandeling van longkanker), evenals dalingen in 
armoede een belangrijke risicofactor voor COPD- in de bestudeerde landen verder 
beperkt het verband tussen roken (gevolgd door longkanker sterfte) en COPD sterfte. 
Tot slot, terwijl het roken een belangrijke invloed had op het COPD sterftecijfer in rijke 
landen, hadden bijkomende risicofactoren een belangrijk aandeel in de COPD sterfte 
in midden-inkomens landen.
Al met al lieten we zien dat de internationale last van roken gerelateerde kanker en 
COPD onverminderd groot is. Ondanks de globale afname van het aantal rokers sinds 
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de jaren 1990, zal de last nog enige tijd groot blijven als gevolg van de aanzienlijke 
tijdas tussen roken en de daaruit voortvloeiende kanker en/of COPD. In feite namen 
longkanker incidentie en sterfte zelfs nog steeds toe bij vrouwen in de meeste Eu-
ropese populaties. Hoewel het sterftecijfer aan roken gerelateerde kanker en COPD 
meestal afnam in de periode 2002-2011, steeg het aantal doden als gevolg van louter 
bevolkingsgroei en vergrijzing.
Aangezien het definitieve bewijs voor het verband tussen roken en tal van ziekten al 
in de Jaren ’50 zeer aannemelijk was, heeft de zeer hoge mannelijke prevalentie van 
roken van toen geleid tot de zeer ongunstige situatie in landen met hoge inkomens. 
Het blijft zeer verwonderlijk dat de bewustwording van de schadelijke effecten van 
tabak zo lang zo beperkt bleef bij vrouwen, vaak tot in de jaren ‘90. Het moet niet 
nog zestig jaar duren om de prevalentie van roken te halveren in rijke landen en 
bij mannen in het midden-inkomenslanden, noch om te voorkomen dat vrouwen in 
midden-inkomens landen de dodelijke gewoonte oppakken. Als we tabak gerelateerde 
ziekten willen uitroeien, moet bestrijding van het tabaksgebruik worden geintensi-
veerd, moet worden onderzocht of schadebeperkende oplossingen (rookloze tabak 
en elektronische sigaretten) waardevol zijn voor verslaafde rokers, en moet er naar 
tabak-vrije (jongere) generaties worden gestreefd (door beëindiging van de wettelijke 
erkenning van tabak aan die generaties). 
De schadelijke effecten van tabak gaan overigens verder dan hun schadelijke invloed 
op de gezondheid. Tabaksproductie draagt ook bij aan ontbossing en onttrekt land en 
water aan voedselproductie. Het gebruik van tabak is al met al in economisch opzicht 
schadelijk voor zowel consument als samenleving; en tabak produceert ook giftig 
afval. Een multidimensionele, -sectorale en -disciplinaire aanpak is dus nodig om het 
tabaksgebruik een slag toe te brengen in elke fase, opdat er nog in de 21ste eeuw een 
einde komt aan de schade van tabak.
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5.5 RéSuMé (fREnCH SuMMaRY)
Avant le XIXème siècle, le cancer du poumon était une maladie rare. Il aura fallu 
du temps, de la perspicacité et de la persévérance pour arriver à démontrer que le 
tabagisme était la cause de l’accroissement rapide du nombre de morts par cancer du 
poumon dans les pays à hauts revenus en Amérique du Nord et en Europe durant la 
première moitié du XXème siècle. Au cours de la seconde moitié du XXème siècle, on 
découvrira que le tabagisme est également responsable d’autres maladies, dont onze 
types de cancer, de la bronchopathie pulmonaire chronique obstructive (BPCO) et de 
certaines maladies cardiaques. Même soixante ans après la preuve irréfutable des 
effets délétères du tabac sur la santé et la mise en place de politiques de lutte contre 
le tabagisme ayant mené à une baisse de sa prévalence, le fardeau des cancers liés 
au tabac et de la BPCO reste colossal et sous-estimé. C’est pourquoi, j’ai souhaité 
évaluer le fardeau mondial des cancers liés au tabac et de la BPCO au tournant du 
XXème siècle, avec une attention particulière pour l’Europe et les Etats-Unis (un pays 
qui a joué un rôle fondamental dans la dissémination du tabagisme dans le monde).
En Europe, l’incidence des cancers liés au tabac reste élevée, car il faut plusieurs 
décennies après l’adoption de l’habitude de fumer pour que la maladie se développe 
et soit diagnostiquée. La consommation de masse des cigarettes est allée de pair avec 
le développement économique du continent : tout d’abord en Europe du Nord et de 
l’Ouest, ensuite au Sud, enfin en Europe centrale et de l’Est. Les femmes ont adopté 
la cigarette plusieurs décennies après les hommes, sans jamais atteindre leur niveau 
très élevé de consommation. Sur la période 1998-2007, l’incidence du cancer du pou-
mon (dont 80% des cas sont attribuables à la cigarette) a décliné ou s’est stabilisée 
chez les hommes dans toute l’Europe (chapitre 2.1), suite à une baisse drastique du 
tabagisme initiée dans les années 1950. Au contraire, sur la même période, l’incidence 
du cancer du poumon chez les femmes augmentait dans 19 pays. L’impact du taux 
de tabagisme sur l’incidence des décennies plus tard d’autres cancers fréquents liés 
au tabac (cancers de la cavité orale et du pharynx, du larynx et de l’œsophage) est 
moins évident pour plusieurs raisons. Premièrement, du fait du rôle secondaire de la 
cigarette dans ces cancers ; deuxièmement, des changements de prévalence d’autres 
facteurs de risques spécifiques pour ces maladies ; ou troisièmement, du faible nombre 
de cas. Sur la période 1998-2007, le taux d’incidence du cancer de la cavité orale et 
du pharynx n’a augmenté que dans quelques populations dans certaines classes d’âge 
chez les hommes : en République Tchèque, au Danemark, en Slovaquie, au Royaume-
Uni et en Allemagne. Le nombre de cas a également augmenté dans certaines classes 
d’âge chez les femmes dans ces pays, ainsi qu’en Irlande, en Norvège et aux Pays-
Bas. L’incidence du cancer du larynx a uniquement augmenté parmi les hommes en 
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Bulgarie, alors que le nombre de cas est resté très faible chez les femmes partout en 
Europe. Enfin, c’est seulement dans la moitié nord de l’Europe que le nombre de cas 
du cancer de l’œsophage chez les hommes a cru, alors que chez les femmes les cas ont 
augmenté dans la plupart des pays en Europe de l’Ouest, centrale et de l’Est.
Depuis leur lancement à la fin du XIXème siècle, les cigarettes manufacturées ont 
constamment évolué, afin d’attirer et de retenir les fumeurs. Les changements dans 
le design et la composition des cigarettes se sont traduits des années plus tard par 
des changements dans la fréquence des sous-types de cancer du poumon dans les 
populations. Les principaux sous-types sont les carcinomes épidermoïdes (CE) ou à 
cellules squameuses et les adénocarcinomes (AdC) du poumon. Alors que l’incidence 
du cancer du poumon a décliné ou est restée stable sur la période 1973-2002 chez les 
hommes dans les onze pays étudiés à hauts revenus (sauf en Espagne), les tendances 
ont varié par sous-type (chapitre 2.2). Les CE étaient les cancers du poumon le plus 
souvent diagnostiqués chez les hommes au début de l’étude. Pourtant, aux alentours 
des années 1990, les AdC devinrent le sous-type le plus fréquent. Alors que le nombre 
de cas de CE déclinait, le nombre d’AdC restait stable ou même augmentait au cours 
du temps. Au contraire, chez les femmes, les cas d’AdC ont prédominé sur toute la 
période d’étude et ont continuellement augmenté. Il existe plusieurs raisons pour 
expliquer le basculement du sous-type dominant du CE vers l’AdC chez les hommes. 
Tout d’abord, la mise sur le marché de cigarettes avec filtre et à plus faible teneur en 
goudron et en nicotine a incité les fumeurs à inspirer plus profondément (pour obtenir 
la même dose de nicotine). Comme la fumée s’insinuait plus loin dans les bronches, 
les tumeurs logées au centre des poumons (souvent des CE) ont été remplacées par 
des tumeurs à leur périphérie (souvent des AdC). Ensuite, avec le changement de la 
composition des cigarettes, le mélange des carcinogènes et leurs niveaux respectifs 
ont également changé. Comme les femmes ont adopté massivement la cigarette des 
décennies après les hommes, à un moment où ces cigarettes avec filtre et à teneur 
plus faible en goudron et en nicotine avaient inondé le marché, et qu’en outre, elles 
étaient la cible de campagnes de publicité pour ces cigarettes dites « légères », les 
AdC ont toujours été plus fréquemment diagnostiqués chez elles que les CE.
Chaque année, aux Etats-Unis, le cancer est responsable de la perte d’environ 10 
millions d’années de vie ajustées sur l’incapacité (AVAI) (chapitre 3.1). Les AVAI sont 
la combinaison du nombre d’années de vie perdues à cause d’une mort prématurée 
(c’est-à-dire avant l’espérance de vie) et du nombre d’années vécues avec une in-
capacité due à une pathologie ou un accident. Les AVAI mesurent le fardeau d’une 
maladie. Aux Etats-Unis, les hommes et les femmes perdent un nombre équivalent 
d’AVAI à cause du cancer — soit 5 millions d’AVAI chacun. Cependant, la fraction de 
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ces AVAI perdues attribuables à la cigarette est plus élevée chez les hommes (32%) 
que chez les femmes (21%) (chapitre 3.2). Cette fraction varie également suivant 
la race/l’ethnie : elle est plus élevée chez les Blancs non-hispaniques et les Noirs 
non-hispaniques (environ 28% du fardeau du cancer est dû à la cigarette) que chez 
les Asiatiques et les Hispaniques (19%). Ces écarts sont le résultat de différences dans 
la prévalence du tabagisme actuel et passé entre les races, les ethnies et les sexes. 
Les différences dans la prévalence du tabagisme sont elles-mêmes issues de varia-
tions dans les normes sociales (acceptabilité du tabagisme), du statut économique et 
social (il y a plus de fumeurs chez les pauvres et les personnes moins éduquées), les 
cibles du marketing des cigarettiers et du degré d’adoption du mode de vie américain 
par les migrants hispaniques. Ce calcul montre qu’on pourrait en théorie abaisser le 
fardeau du cancer de 10% chez les femmes asiatiques à 34% chez les hommes Noirs 
non-hispaniques en éliminant totalement les cigarettes.
Outre les différences entre les races, les ethnies et les sexes, il existe également des 
différences géographiques dans la mortalité due au tabac aux Etats-Unis (chapitre 
3.3). Au niveau national, 29% des décès par cancers peuvent être attribués à la 
cigarette, mais cette fraction est plus élevée dans les Etats du Sud : 34% au Kentucky 
(la fraction la plus haute parmi les 51 Etats), 33% au Tennessee, 31% en Caroline du 
Nord, 30% en Caroline du Sud, 29% en Géorgie, 28% en Virginie, etc. La prévalence 
élevée du tabagisme dans ces Etats du Sud explique la forte proportion des décès par 
cancer due à la cigarette. Cette forte prévalence résulte de politiques de lutte contre le 
tabac plus faibles et des normes sociales quant à l’acceptabilité du tabagisme dans les 
Etats du Sud, elles-mêmes rendues possibles par la puissante influence économique 
de l’industrie du tabac. En effet, 95% du tabac produit aux Etats-Unis provient de ces 
six Etats. Cependant, la fraction des décès par cancer due à la cigarette est égale-
ment élevée dans les Etats ayant de larges populations de personnes pauvres et peu 
éduquées dans le reste du Sud des Etats-Unis (Louisiane, Alabama et Mississippi) 
et dans la région des Appalaches (Virginie Occidentale). Au contraire, cette fraction 
est la plus faible en Californie (26%) où une politique vigoureuse de lutte contre le 
tabagisme est poursuivie depuis 25 ans et où vit une grande communauté hispanique 
(qui fume peu), et en Utah (17%) où des normes religieuses (55% des habitants sont 
Mormons) proscrivent la cigarette. Il faut souligner que les effets d’une politique de 
lutte du tabagisme sur la mortalité par cancer due au tabac s’observent à long terme 
et qu’il faut donc la mettre en place le plus rapidement possible.
En utilisant le taux de mortalité par cancer du poumon comme marqueur de l’exposition 
au tabac, j’ai examiné l’influence du tabagisme sur la mortalité par BPCO dans 61 
pays à hauts et moyens revenus (chapitre 4.1). Il ressort de cette analyse que si 
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l’association entre le tabac et la mortalité par BPCO est forte dans les pays à hauts 
revenus chez les femmes, l’association est modérée chez les hommes dans les pays 
à hauts et moyens revenus. En outre, aucune corrélation n’a été trouvée chez les 
femmes dans les pays à revenus moyens. Pour preuve, aux alentours de 2011-2013, 
le taux de mortalité par cancer du poumon était jusqu’à 10 fois plus élevé que celui 
par BPCO dans la majorité des pays, sauf dans la plupart des pays à revenus moyens 
en Amérique latine et en Asie, où l’inverse était observé. Par ailleurs, alors que les 
taux de mortalité du cancer du poumon et de la BPCO ont baissé sur les dix dernières 
années (aux environs de 2002-2011) chez les hommes, le taux de mortalité du cancer 
du poumon a augmenté dans la moitié des pays et celui de la BPCO dans six pays 
européens chez les femmes. Les progrès dans le diagnostic et le traitement de la BPCO 
(par opposition aux progrès limités dans le traitement du cancer du poumon), ainsi 
que le déclin de la pauvreté — un facteur de risque majeur de la BPCO — dans les pays 
étudiés, ont également atténué la relation entre le tabagisme (signalé par les décès 
par cancer du poumon) et les décès par BPCO. En conclusion, si le tabagisme joue un 
rôle majeur dans la mortalité par BPCO dans les pays à hauts revenus, des facteurs 
de risque supplémentaires sont également importants pour expliquer la mortalité par 
BPCO dans les pays à revenus moyens.
J’ai montré que le fardeau international des cancers liés au tabac et de la BPCO est 
gigantesque. En dépit de la baisse de la prévalence du tabagisme au niveau mondial 
depuis les années 1990, ce fardeau continuera à être colossal pendant longtemps à 
cause de la longue période de latence entre l’adoption de l’habitude de fumer et les 
cancers et les BPCO consécutifs. Au demeurant, l’incidence et la mortalité du cancer du 
poumon continuent d’augmenter chez les femmes dans la plupart des pays européens. 
De plus, malgré la baisse du taux de mortalité des cancers liés au tabagisme et de la 
BPCO sur la période 2002-2011, le nombre de morts a augmenté simplement à cause 
de l’accroissement et du vieillissement de la population.
Depuis la preuve indiscutable du lien entre le tabagisme et de nombreuses maladies 
à partir du milieu des années 1950, la très forte prévalence du tabagisme chez les 
hommes a été divisée par deux dans les pays à hauts revenus. En revanche, la lutte 
contre le tabagisme et l’augmentation de la prise de conscience des effets délétères 
du tabac sur la santé n’ont eu qu’un impact limité sur le tabagisme des femmes, au 
moins jusque dans les années 1990. C’est pourquoi, il y a un besoin continu de lutte 
contre le tabagisme. Il ne faudrait pas mettre encore soixante ans pour diminuer de 
moitié la prévalence du tabagisme chez les hommes et les femmes dans les pays à 
hauts revenus et chez les hommes dans les pays à revenus moyens, et pour empêcher 
les femmes habitant les pays à revenus moyens d’adopter la cigarette. Si nous voulons 
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éradiquer les maladies liées au tabac, les politiques de lutte contre le tabac doivent 
être renforcées, les solutions de substitution comportant moins de risque pour la santé 
(tabac sans combustion et cigarette électronique) doivent être examinées pour les 
fumeurs dépendants et, enfin, des mesures pour une génération sans tabac (c’est-
à-dire l’interdiction de la vente du tabac aux générations qui n’ont pas commencé 
à fumer) doivent être adoptées. Les effets dévastateurs du tabac vont au-delà des 
risques pour la santé. La production de tabac engendre des déforestations et détourne 
les terres arables et l’eau de la production de nourriture ; le tabac génère des pertes 
économiques pour ses consommateurs et la société ; et les déchets des cigarettes sont 
toxiques. Une approche multidisciplinaire est donc nécessaire pour combattre le tabac 
à chaque étape de la vie du produit, afin que les méfaits du tabac cessent au cours du 
XXIème siècle.
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